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Health research  with  developing  countries  has  been part of the  European Commission's research 
agenda for  almost  15  years. 
It is  currently  part  of the  specific  RTD  Programme  in  the  field  of  Cooperation  with  Third 
Countries  and  International  Organizations  (INCO):  activity  II  of the  Framework  Programme  IV 
(1994-1998)  (see  annex). 
This  document introduces  research projects  on  bacterial and  viral  diseases  together  with  projects 
on  non-communicable  diseases.  It combines  summaries  of completed  contracts  for  STD3  and  a 
catalogue  of ongoing  and  new  contracts  of STD3  (Science  &  Technology  for  Development)  and 
!NCO-Developing Countries  1st and  2nd call for proposals.  Other volumes  of this  documentation 
deal  with  research on health  systems  and  parasitic  diseases. 
The  research  agenda  is  focused  on  the  frequently  occurring  and  enduring  health  problems  of 
developing  countries.  The  systematic  application  of modem  biological  and  clinical  research  to 
these problems is  in the best tradition of medical research and has resulted in many achievements. 
Improving health conditions in developing countries through application of science and technology 
is  recognised  as  an  integral  component of development policy. 
Address: 
European  Commission 
Health research  with Developing  Countries 
DG XIJJB-4 
Rue  de  la Loi,  200 
1049  Brussels 
Belgium 
Tel:  +32.2.295.62.82 
Fax:  +32.2.296.62.52 
E-mail:  michel.pletschette@dg12.cec.be 
R.  Gerold 
Director 8 
The INCO-DC Workprogramme 
Sector Health 
The  selection  of  research  areas  is  based  on  existing  and  newly  identified 
health  needs  in  DC's  and  on  the  capacity  to  cope  with  these  needs  through 
research.  The  tools  and  the  systems  developed  for  the  control  of  health 
problems in  Europe are not always directly applicable in  DC's.  Specific aspects 
of health care policy,  of health care delivery, and the natural history of diseases 
require  approaches  adapted  to  DC's.  Adequate  and  timely  ethical  clearance 
should  be  obtained  whenever appropriate. 
Research on the tools for prevention and the fight against the predominant 
diseases 
Vaccines 
Vaccines  are  cost-effective  tools for  disease  control.  Research  on  vaccines  in 
the programme should be concentrated on  selection, evaluation and delivery of 
antigens,  with  the  objective  of  designing  vaccines  applicable  for  DC's.  For 
vaccines against diseases with a significant impact in  Europe,  emphasis will  be 
on  aspects  specific  to  DC's.  With  regard  to  the  evaluation  of  antigens, 
emphasis will  be  put  on  immunological  mechanisms underlying  experimentally 
induced  protection.  Research  on  the  non  targeted  effects of vaccines will  also 
be  taken  into  consideration. 
Drugs 
Emphasis will be put on targeted drug design and targeted drug delivery, based 
on  the  fundamental  understanding  of  biological  functions  of  pathogens  and  of 
disease  mechanisms.  Research  on  drugs,  including  bioactive  natural  com-
pounds  is  eligible  when  focused  on  drugs  for  predominant  diseases  in  DC's 
when  non-toxic efficient treatments  are  unavailable. 
Diagnostic products 
This research  should make an  initial distinction between  1) the development of 
diagnostic products as research tools, or 2) the development of diagnostic tools 
for  routine  health  care.  Application  of  high  technology  approaches  to  design 
robust  and  simple  diagnostic  tools  for  routine  health  care  will  be  given  due 
attention.  The  relevance  for  practical  case  management  of  the  read-out  of 
routine  diagnostic tools  should  be  adequately addressed. 
For  each  project  concerning  the  design  and  the  development  of  vaccines, 
drugs  and/or  diagnostics  products,  the  feasibility  of  introducing  affordable 
products envisaged  should  be  pre-evaluated. Research on the biology of the diseases 
Biology 
The  understanding  of the  processes  and  biological  interactions  is  a source of 
new  techniques  and  tools  for  the  control  of  disease.  Research  on  genome 
structure  and  regulation  of  gene  expression  is  eligible  if  it  supports  the 
investigation of defined biological  mechanisms aiming at the control  of disease 
causing  pathogens.  Metabolic  pathways  that  differ  between  the  human  host 
and  the  pathogen  may  be  addressed  as  a  source  for  targeted  interventions. 
Immunological  studies  should  concentrate  on  the  biological  function  of  anti-
genic  molecules  and  the  mechanisms  leading  to  protection  against  disease. 
Studies  on  the  genetics  of  vectors  are  supported  as  tools  that  allow  under-
standing of the physiological processes of the vectors,  and  vectorial  interaction 
with  the  pathogenic  agent  and  the  host.  Studies  of  intervention  based  on 
vectorial  biology are  eligible  provided that monitoring  is  envisaged on  a longer 
term  and  on  a sustainable  basis. 
Pre-clinical models 
A model  may  be  used for different purposes.  Where a model  is  proposed as  a 
screen  in  a  development  process,  the  relevance  of  the  particular  model  for 
human  disease  has  to  be  established.  In  vitro  and  in  vivo  models  for  human 
disease  will  be  the  subject  of  studies  aimed  at  refinement,  replacement  and 
reduction  of  animal  experimentation. 
Complementary areas bridging science and application 
The programme will  contribute to  improved coordination and to better research 
methodology in fields of growing interest and for which only a limited number of 
international  links  are  currently  established,  linking  EU  scientists  to  their 
colleagues  in  DC's.  The  modalities for implementation  of this  research  will  be 
concerted  actions  for  topics  not  addressed  under  1.3.1,  1.3.2  and  1.3.3. 
Opportunities  to  combine  research  with  existing  initiatives  or  future  develop-
ment  initiatives  of  the  EU  and  of  Member  States  in  these  fields  will  be 
exploited.  These  topics  are: 
Relevance and methodology of health interventions 
A large  number of problems and  of  important bottlenecks have been  identified 
for  the  evaluation  of  specific  tools  and  of  methods  for  the  interventions  in 
health  in  the  field.  Apart from  technical  aspects such  as  unequivocal  contribu-
tion  of  morbidity  and  mortality  of  the  health  problem  under  study,  there  are 
issues of  strategy,  of ethics and  relevance to be  covered.  Studies and  tests of 
interventions  have  to  be  integrated  into  the  existing  health  systems  and  the 
process  of  this  integration  can  consequently  form  part  of  the  research.  The 
9 10 
research workers' responsibility for the results of their intervention research and 
for the  continuation  of the  health  services  depending  on  these  studies  should 
be adequately addressed.  In order to be eligible for support under this heading, 
the  health  problem  for which  an  intervention  is  planned  should  be  relevant  in 
epidemiological  terms  as  well  as  in  terms  of  the  needs  expressed  by  the 
community  in  which  it  is  studied.  Innovative  methods  on  the  interventions  on 
health  problems  will  be  supported  for  evaluation  in  the  field.  The  planning  of 
interventions  should  take  account  of  ongoing  activities  in  appropriate  geo-
graphical  areas  and  concentrate  preferably  on  those  fields  where  significant 
investments have already been  made,  or are  planned,  so  that optimum  use  is 
l'nade  of existing  capacities. The  European  Commission  and  support 
for Virology/Bacteriology 
Non Communicable Diseases  Research 
* Geographical  distribution 
* Context The  portfolio  of  projects  under  the  research  area  of  microbial  and  non-
communicable  diseases  is  necessarily  wide  and  somewhat  dispersed  over  many 
topics  (figure  1  ). 
However the major health issues are covered with a substantial and coherent effort 
developed  over  the  active  period  the  STD  programme  and  more  and  more 
successfully linked  with  the  INCO-DC  exercise. 
Such  is the case with  cholera research  where innovative epidemiology is  linked to 
innovative vaccine research but also tuberculosis research where molecular epide-
miology is bridging to operational research on control programme management. 
Collaboration in other diarrhoeal projects has led to new important findings such as 
the  role  of Cryptosporidium  in  the  research  of children  diarrhoea. 
The programme is,  with a relatively small number of projects, contributing substan-
tially to the  development of tuberculosis subunit vaccines but also to  the  develop-
ment  of  efficient  vaccination  against  the  major  courses  of  death  in  children  in 
developing countries:  namely acute  respiratory  infections. 
Based  on  long-term capitalization  with  partners  in  The  Philippines,  a new vaccine 
against  pneumococcal  disease  is  now  under  clinical  development  while  other 
research  in  Guinea-Bissau, Bangladesh and  Sudan is likely to improve vaccination 
against measles. 
STD/INCO  HIV research  looking  at the  differences  of  progression  of the  disease, 
the mortality associated with the HIV-2 type and the issues linked to its association 
with  tuberculosis  has  been  among  the  most  productive  in  the  field.  Based  on 
numerous new partnerships emerging,  a major effort is  now with  the  development 
of research  into the  biology of HIV  subtypes  and  variants. 
Other  pathogens  are  not  forgotten,  hemorrhagic  fever  research  has  been  repre-
senting  a great part of the  European  effort  in  the  domain. 
There  are  a few  projects  on  non-communicable  diseases  showing  well  also  the 
limits of the definition  in  the  current classification.  Scorpion  and  snake envenoma-
tion  can  represent  an  important cause  of mortality  in  many developing  countries, 
hence the  important research  effort on  the  molecular biology of  the  diseases. 
Other problems  like  metabolic and  blood  disorders are  somewhat  underrepresen-
ted  in  relation  to  the  long-standing  burden  of  diseases  they  represent,  but  the 
results  are  substantial. 
Over  the  years,  the  size  of  projects  have  increased  and  the  number  somewhat 
reduced  but the exercise as  such  appears well  consolidated and  remains a strong 
asset  in  the  field  of  international  health  research. 
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STD3 
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TS3*CT920122 
TS3*CT930238 
TS3*CT930241 
TS3*CT930231 
IC18*CT960050 
IC18*CT96011 0 
IC18*CT960114 
IC18*CT970216 
IC18*CT970246 
IC18*CT970255 
Studies on  maternal and neonatal morbidity due to sexually 
transmitted diseases 
A longitudinal epidemiological study of HIV-2 infection in 
Guinea-Bissau: transmission, disease development, 
immunology and prevention 
Role of placenta in transmission of HIV infection from mother 
to child 
Studies of the epidemiology of HIV infection and other 
sexually transmitted diseases in  Mwanza region, Tanzania 
Intervention study of sexually transmitted diseases and HIV 
infection among female prostitutes in Abidjan,  Ivory Coast 
The well-women clinic: studies on women's reproductive 
health 
Appropriateness of diagnostic ultrasound at district hospital 
level 
A study on the role of H  IV-1  genotypes on the epidemiology 
of HIV in Tanzania and Uganda 
Study of HIV-1  variability in  Cameroon and Gabon. 
Implications for vaccine and antiviral intervention strategies 
Multicenter study on factors determining differential spread of 
HIV infection in African towns 
Virological and molecular characteristics of HIV strains in 
Africa: the impact of genetic subtypes on the pathogenesis 
and prognosis of HIV infection 
Study of HIV-1  variability in  Cameroon and Gabon. 
Implications for vaccine and antiviral intervention strategies 
Development of a HIV candidate vaccine for phase I and II 
clinical trials in  China 
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STUDIES ON  MATERNAL AND  NEONATAL MORBIDITY DUE  TO  SEXUALLY TRANS-
MITTED  DISEASES 
Period: 
Co-ordinator: 
Objectives 
January 1,  1992 - December 31,  1993 
INSTITUUT VOOR TROPISCHE GENEESKUNDE, DEPT OF 
MICROBIOLOGY, Antwerpen, Belgium (M.  LAGA) 
The  overall  aim  was  to  assess  interventions to  reduce  complications  in  mother and  child 
due  to  sexually transmitted  diseases.  Specific objectives were: 
•  To  determine risk factors to  pre-term delivery (PD) and post-partum endometritis (PPE); 
•  To  validate  different diagnostic approaches for the  management  of  gonorrhoea  during 
pregnancy; 
•  To  assess the cost-effectiveness of an  intervention programme against gonorrhoea and 
syphilis to  reduce  perinatal  complications; 
•  To  determine  risk factors  for syphilis  in  pregnant women; 
•  To  determine the  incidence,  microbial  aetiology,  risk factors,  and  clinical  and  histologic 
features  of  PPE; 
•  To assess the influence of gonococcal outer membrane proteins on  pregnancy outcome 
in  women  with  gonococcal  infection  during  pregnancy; 
•  To  develop diagnostic criteria and  assess the  responses to  treatment for PPE. 
Activities 
*  Interventions against gonorrhoea in  pregnancy:  gonorrhoea detection and  Treatment in 
pregnancy  was  assessed.  The  effect  of  the  intervention  was  estimated  by  comparing 
the  incidence of adverse  pregnancy outcome  in  both  the study and  the  control  group, 
including  prematurity,  low birth  weight,  chorioamnionitis,  and  postpartum  endometritis. 
*  Studies  on  syphilis:  the  impact  screening  and  treatment  of  syphilis  during  pregnancy 
was evaluated by comparing the incidence of prematurity, stillbirth,  low birth weight, and 
congenital  syphilis  in  children  from  women  with  and  without syphilis during  pregnancy. 
*  Studies on  PPE:  in  a case control  design,  patients with  clinical signs and  symptoms of 
post-partum infection and controls will be studied in  order to assess risk factors and the 
aetiology of  post-partum  infections,  and  to  develop case  management strategies. 
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Results 
For  the  intervention  study  on  gonorrhoea  in  pregnancy a total  of 2.383  pregnant women 
were  recruited from  two antenatal clinics in  Nairobi.  Patients in  the intervention group (N= 
1  060)  were  screened  and  treated  for  STDs,  the  non-intervention  group  (N=1  323) 
received  routine  antenatal  care.  Women  were  followed  up  at  delivery,  2  and  6  weeks 
postpartum. Of these women  6°/o  had chlamydia infection,  5.1 °/o  gonorrhoea,  5.6°/o  syphilis 
and  16.2°/o  were  infected  with  HIV.  For  chlamydia  infection  and  gonorrhoea  risk  factors 
were age  less than  20 years (p<0.01  OR  2.5)  and  not having a fixed  sex partner (p<0.01 
OR  2.1 ).  3  or  more  partners  during  lifetime  was  a  risk  factor  for  contracting  chlamydia 
infection,  syphilis  or HIV infection  but  not for gonorrhea. 
During  pregnancy  no  clinical  signs  or  symptoms  (lower  abdominal  pain,  dysuria,  foul 
smelling  discharge,  colored  cervical  swab,  ectopia)  were  correlated  with  gonorrhoea  or 
chlamydia  infection.  Two  weeks  after  delivery  chlamydia · infection  was  found  to  be 
associated  with  ectopia (p<0.3  OR  2.2). 
There  was  no  difference  in  pregnancy  outcome  (gestational  age  at  delivery,  birth  weight, 
PPE and ophthalmia neonatorum between patients of the intervention and non-intervention 
group.  The  main  reasons were: 
~  The  high  incidence  of  gonorrhoea  and  chlamydia  infection,  14.8o/o  and  17°/o  per year 
respectively  bringing  the  infection  levels  after  intervention,  almost  back  to  pre-
intervention  levels two  weeks  after delivery; 
~  The  high  loss  to  follow-up  (56.6o/o)  in  the  intervention  group. 
Thirteen  percent of  women  developed  post-partum  endometritis (PPE).  A history of  lower 
abdominal pain  (p<0.0001) and foul  smelling lochia (p<0.0001) were associated with  PPE. 
Having  a  Caesarean  section  (p<0005  OR  3.1 ),  gonorrhoea  (p<O.OOOO  OR  2.9)  and  no 
fixed  partner (p<0.002 OR  1  .8)  were  risk factors. There was no significant association with 
chlamydia  infection. 
1  0.9o/o  of  newborns  developed  ophthalmia  neonatorum  (ON).  Having  a  mother with  PPE 
(p<0.005  OR  2.3)  was  a risk  factor,  as  was  gonorrhoea  (p<0.0001  OR  2.6)  or chlamydia 
infection (p<0.001  OR 2.6)  in the mother.  Reintroducing ON  prophylaxis with tetracycline in 
Pumwani  Maternity Hospital  could  prevent 825  cases  of  ON  per year. 
For the study on  syphilis and pregnancy outcome,  12 296 pregnant women were screened 
when  presenting for delivery at  Pumwani  Maternity Hospital  in  Nairobi.  More  than  one  in 
two patients delivering in  Pumwani Maternity Hospital were not screened for syphilis during 
pregnancy  (53.5°/o). 
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A total  of  1  156 women  and  their newborns were enrolled  in  the study.  Of these 840 had 
no  syphilis  during  pregnancy;  140  women  were  treated;  176  women  had  serological 
evidence  of  recently  acquired  syphilis  but  were  not  treated  during  pregnancy.  Age, 
belonging to a ethnic group who does not practice circumcision, not having a fixed partner, 
number of previous pregnancies and abortions were not associated with syphilis. However, 
19.4o/o  of women  who  were  seropositive for  T.  pallidium were  infected with  HIV. 
The incidence of perinatal mortatity was  1 .3°/o  in  the control group. Among women  treated 
for  syphilis,  the  incidence  was  3.6o/o  and  among  the  untreated  women  7.2°/o.  The 
incidences  of  low  birth  weight  were  1  0.0°/o,  14.4o/o  and  16.8°/o  respectively  in  controls, 
treated and  untreated women.  In  the multivariate analysis perinatal death was significantly 
associated  with  syphilis  (0R=6.7; 95o/o  C.l.  2.2-20.8). Treatment reduced the  incidence of 
perinatal  mortality,  although  treated  women  still  had  a  higher  risk  for  perinatal  mortality 
(0R=3.8, 95°/o C.l.  1.0-15.0). Assuming a prevalence of syphilis among pregnant women of 
6.5°/o  in  Nairobi,  it  is  estimated  that  2  cases  of  perinatal  mortality  per  1000  births  at 
Pumwani Hospital could be prevented if all antenatal clinical attenders were screened and 
treated  for syphilis during their first visit to  the  antenatal  clinic. 
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A  LONGITUDINAL  EPIDEMIOLOGICAL  STUDY  OF  HIV-2  INFECTION  IN  GUINEA-
BISSAU: TRANSMISSION, DISEASE DEVELOPMENT, IMMUNOLOGY AND PREVENTION 
Period: 
Co-ordinator: 
Objectives 
April  1, 1992 - June 30,  1996 
STATENS SERUM  INSTITUT,  DEPT. OF EPIDEMIOLOGY RESEARCH, 
Copenhagen, Denmark (P. AABY) 
Improve the understanding of HIV-2 infection and promote its prevention, through studying: 
•  The  impact of  HIV-2  infection  on  mortality. 
•  The  risk  factors  for  and  the  probability  of  disease  development  in  HIV-2  infected 
individuals,  including  immunological  parameters. 
•  The  risk factors for HIV-2  positivity in  people over 50  years  of age. 
•  The rate  of transmission of HIV-2 from  mother to child/foetus,  and  its possible risk and 
co-factors. 
•  The  role  of other sexually transmitted  diseases (STD)  in  the transmission  of  HIV-2. 
•  The  socio-cultural  context  which  influences  popular  understanding  of AIDS  and  AIDS 
information. 
•  The  social  implications of  an  increase  in  the  number of AIDS  cases. 
Activities 
*  Coordinate  the  only  two  community  cohorts  of  HIV-2  infected  individuals  in  urban 
Bissau  and  in  a rural  area. 
*  Annual  surveys to  follow  mortality  in  cohorts examined for HIV  infection. 
*  Detailed interviews with people over 50 years of age have been performed in  an  urban 
area of  Bissau. 
*  A study of the  mortality of children  born  to  HIV-2  infected  mothers. 
*  Analyses of immunological parameters,  including T-lymphocyte subsets,  neopterin,  and 
beta-2-microglobulin,  viral  load  and  co-infections,  including  HTLV. 
*  Develop an  ELISA for antibodies to  H.  ducreyi. 
*  Analyze  risk factors for concordance for HIV-infection  in  couples. 
*  Initiate prospective community study of the  interaction between  tuberculosis and  HIV-2 
and  HIV-1. 
Results 
In  1990-93 in  the  cohort of  671  persons  of  50+  years  of age  a  HIV-2  seroprevalence  of 
14.1 o/o was found while that of HIV-1  was only 0.1 o/o. The main risk factors for infection were 
younger age group and ethnic group. The more behavioral factors varied between men and 
women.  For  men,  factors  like  early  sexual  experience  and  having  been  in  the  colonial 
Portuguese  army  were  significantly  associated  with  HIV-2.  For  women,  travelling  was  a 
significant  risk  factor,  as  was  a  history  of  blood  transfusion  and  a  history  of  preparing 
monkey  meat.  In  a  similar  analysis  of  risk  factors  for  HTLV  seropositivity  in  the  same 
population, HTLV was associated with being bitten by a monkey,  scarifications, commercial 
sex, and age of sexual debut. The association with sexual risk factors was much stronger for 
women than for men and women had a three times higher prevalence than the men. 
The  overall  prevalence  of  HIV-2  did  not  increase  significantly over the  study period  from 
1987 to 1996. While the incidence was 1 per 100 person-years-at-risk (pyr) during 1987-89, 
it appears to have declined in recent years being only 0.3 per 100 pyr in the period 1989-93. 
More  rectfnt  data  from  1995-96  suggest  that  the  HIV-2  prevalence  is  in  fact  declining. 
However,  this  is  unlikely to  be  due  to  the  efficacy  of  preventive  activities  as  HIV-1  has 
increased strongly during the period  1992-95 from virtually zero to 2.5°/o.  In contrast to the 
much  publicized  results  from  Senegal,  we  have  found  no  evidence  that  HIV-2  provides 
protection  against  HIV-1  infection. 
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Using  data  from  rural  Guinea-Bissau,  we  have  conducted  an  analysis  to  see  whether 
transmission  is  related to  viral  load.  The major risk factor for women  being seropositive if 
married to a seropositive man  was the age of the woman  being over 40.  The proviral load 
did not have a significant effect in  this analysis.  In  both cohort studies in  Bissau,  we  have 
also found a surprisingly high incidence of HIV-2 infection among women over 40-45 years 
of age.  In  urban Bissau,  HIV-2 infection was five times higher than for young women even 
though  younger  women  certainly  have  more  sexual  contacts.  This  suggests  that  age-
related  susceptibility may play an  important role  in  the  HIV-2  epidemic. An  analysis of the 
prevalence of HTLV among people over 50 years of age in  Bandim,  Bissau,  indicates that 
the  pattern  of  increased age-related susceptibility for women  may also apply for  HTLV. 
For  the  oldest  cohort  in  Bissau,  we  have  carried  out  a  survival  analysis  of  the  9-year 
follow-up  of  HIV-2  infected  and  uninfected  adults.  Mortality  was  only  two  times  higher 
among  HIV-2  infected individuals, the difference was most marked among younger people 
under 40-50 years of age.  For people over 50,  there was a minimal difference in  mortality 
related  to  HIV-seropositivity.  HIV-2  infected  individuals  who  were  living  with  a  HIV-2 
infected spouse had significantly higher mortality than  HIV-2  infected individuals who were 
living  with  a spouse  who  was  not  infected. 
In  both  cohorts  of HIV-2  infected  individuals we  have found  no  sign  of  strain  differences 
between young and old individuals and between AIDS cases and asymptomatic cases. Only 
strain A appears to be  present in  Guinea-Bissau. Hence,  it is  unlikely that strain difference 
can explain the variable outcome of HIV-2 infection. In a cohort of HlV-2 infected individuals 
from  a rural  area of Bissau where pro-viral levels had  been determined, we have shown a 
very  strong  association  between  pro-viral  level  and  the  mortality during the  following  3-4 
years. There is no trend to increasing load with age. The interaction with HTLV infection has 
been examined. There is no sign of amplification of HIV-2 pro-viral load by HTLV. 
The immunological samples collected in  1988, 1990 and 1992 from H  IV-2 infected individu-
als  and  controls  have  shown  very  small  changes  in  T-cell  subsets  over the  4  years  of 
observation. There was no association between T-lymphocyte values and the risk of dying 
during the follow-up period.  T-lymphocyte values were significantly different for individuals 
who  were  concordantly infected  with  their spouse compared  to  HIV-2  infected  individuals 
who  were  living  with  an  uninfected  spouse.  Syphilis  antibodies  have  been  measured  on 
samples previously collected  in  Bissau  and the  rural  area.  Data suggest that syphilis may 
suppress CD4 T-cells and could thus contribute to progression of HIV-2 related infection. It 
has not been feasible to examine the H.  ducreyi antibodies on filter paper blood samples. 
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ROLE  OF  PLACENTA  IN  TRANSMISSION  OF  HIV  INFECTION  FROM  MOTHER  TO 
CHILD 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1992 - October 31 , 1994 
DANISH CANCER SOCIETY,  DEPT. OF VIRUS AND CANCER 
Aarhus,  Denmark (P.  EBBESEN) 
The  general  purpose  is  to  study the  role  of the  placenta  in  vertical  transmission  of HIV. 
•  Human  placental  cell  types will  be  characterised with  respect to  presence of CD4 and 
HIV.  Limited  studies will  be  done  with  baboon  placenta.  Immunohistochemical  studies 
will  be  done. 
•  Placental  thophoblast cells  will  be  isolated  and  cultured.  These  will  be  analysed  with 
FACscan  with  respect to cell  types,  presence of CD4  and  HIV. 
Activities 
HIV  infected  labouring  women  admitted  in  a  busy  maternity  hospital  in  Nairobi  will  be 
enrolled  in  the study.  Placenta's will  be collected and the neonates will  be followed till the 
age  of  3 to  6 months to  determine  the  vertical  transmission  rate,  using  PCR  techniques 
(Institute  of Tropical  Medicine, Antwerp,  Belgium). 
At  the  Institute  of  Primate  Research,  Nairobi,  cryostat  placental  sections  will  be  charac-
terised with respect to CD4 and HIV/SIV using immunohistochemical studies. Placental cell 
isolation  and  FACs  analysis  will  also  be  done  as  well  as  in  situ hybridisation  and  PCR 
studies. 
The  Department of Virus and Cancer,  Danish Cancer Society, Aarhus,  Denmark, will  study 
placental  cells  with  monoclonal  antibodies  developed  by  the  department  and  in  situ 
hybridisation  with  the  probes  produced  by  the  department.  An  ELISA test for trophoblast 
interferons will be developed and used for determining concentrations in  maternal and fetal 
blood. 
Histological  studies on  fixed  placental  material  will  be  done at the  Department of Human 
Pathology,  University of  Nairobi. 
Expected outcome 
~  Improvement of  our understanding  of the  mechanisms  of mother-to-child  transmission 
of HIV and  the  placental  cell  types  involved  in  transmission. 
~  Establishing the  role  of interferon  in  the  vertical  transmission  of HIV. 
~  Better  understanding  of  the  role  of  placental  inflammation  in  vertical  transmission  of 
HIV. 
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Results 
A total  of  274  placentae  and  maternal/cord  blood  samples  were  collected.  Of these  128 
samples  were  ELISA+  and  98  ELISA-.  The  PCR  was  done  on  57  blood  samples  from 
babies collected during follow up and 7 were found to be  positive with  at least one primer 
par.  This  represents  an  apparent transmission  rate  of  12°/o. 
A data base on  maternal history/risk factors and placental status is set up  in two institutes 
(IPR  and  Danish  Cancer  Institute).  The  FAGS-analysis  done  on  169  maternal  samples 
showed  a  low  CD4/CD8  ratio  in  124.  An  intact  syncytiotrophoblast  was  present  in  all 
placentae.  Cytotrophoblast  cells  were  rare.  Cells  staining  for  CD4  were  present  in  the 
villus  axis within  placental  mesenchyma and  endothelial  lining  of blood.  Presence  of HIV 
proteins was  very rare  (17°/o).  Maternal/fetal  barrier was  intact. 
All  cord sera were tested for alpha interferon and  16o/o had high  levels.  It was evident that 
HIV  infection  could  occur  without  provoking  an  enhancement  of  placental  and  fetal 
interferon  response.  More  detailed  studies  were  done  in  17  positive  and  22  control 
samples.  None  of  the  maternal  samples  had  detectable  rheumatoid  factor  and  were 
negative for HBV core antigen or HCV but malaria was the predominant parasitic infection. 
In  the  216  placentae  studied  chorioamnionitis,  funistitis  and  villitis  was  present  in  92,  34 
and  16  respectively.  Malarial  pigments were  present  in  1  0 placentae. 
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STUDIES  OF  THE  EPIDEMIOLOGY  OF  HIV  INFECTION  AND  OTHER  SEXUALLY 
TRANSMITTED  DISEASES IN  MWANZA REGION,  TANZANIA 
Period: 
Co-ordinator: 
Objectives 
December 1,  1992 - November 30,  1995 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
EPIDEMIOLOGY AND POPULATION SCIENCES 
London,  United Kingdom (R.  HAYES) 
•  To  measure  the  impact  of  an  intensive  control  programme  for  sexually  transmitted 
diseases (STDs)  on  the incidence and  prevalence of STDs over a two year period  in  a 
large  rural  population. 
•  To  identify  risk  factors  for  HIV  infection  and  other  STDs  through  case-control  studies 
conducted  at  baseline  and  after  two  years,  and  to  quantify  the  effects  of  these  risk 
factors. 
•  To  investigate  the  aetiologies  associated  with  genital  ulcer  syndrome  (GUS)  in  this 
region  through  studies  at  an  STD  clinic;  to  estimate the  percentage  of GUS  cases  at 
this clinic associated  with  each  aetiology. 
•  To  estimate  the  incidence  of  asymptomatic  carriage  of  chancroid  in  selected  urban 
groups  at  high  risk  of  HIV  and  other  STDs;  to  evaluate  the  field  performance  of  a 
serological test for  H.  ducreyi. 
Activities 
This  research  project  complemented  the  "Mwanza  Region  HIV/STD  Intervention  Pro-
gramme",  funded  by  the  AIDS  Task  Force  of  the  EC  (DG  VIII)  and  the  UK  Overseas 
Development Administration,  which  aimed  to  measure  the  impact  of  improved  treatment 
services for STDs on  HIV incidence in the general population of rural  Mwanza. This project 
comprised  the  following  activities: 
*  More  accurate  documentation  of  the  impact  of  the  intervention  on  STDs,  through 
syphilis and  H.  ducreyi serology on  all  12.000 adults in the main cohort at baseline and 
after two  years. 
*  Regular  follow-up  every  three  months  of  a  sub-cohort  of  1.200  men  to  record  the 
incidence of STDs  and  related  treatment-seeking  behavior. 
*  Annual  surveys of  STDs among  100 women  attending antenatal  clinics  (ANC)  in  each 
of the twelve  study communities. 
*  Case-control  studies  of  risk factors  for  HIV infection  and  other STDs.  Cases detected 
from  main  cohort  surveys  at  baseline  and  two-year  follow-up,  with  controls  sampled 
from  the entire  study cohort. 
*  Etiological  studies  in  GUS  patients presenting to  the  STD  clinic  in  Mwanza town. 
*  Intensive  studies  of  commercial  sex  workers  and  STD  patients  in  a  search  for 
asymptomatic carriers of  H.  ducreyi. 
*  Field  evaluation  of  serological  tests  for  H.  ducreyi,  including  serial  testing  of  GUS 
patients  at  the  STD  clinic. 
Results 
=>  After  two  years,  the  prevalence  of  active  syphilis  (APR  +/RPHA+)  was  S.Oo/o  in  the 
intervention (I) and 7.0o/o in the comparison (C) communities, a significant reduction of about 
30o/o  (P  = 0.02).  Seroconversion  for  syphilis  (TPHA)  was  also  30o/o  lower  in  the  I 
communities, but this difference was not significant.  In males, the prevalence of sympto-
matic urethritis was about 50°/o lower in the I communities (P=0.056). These effects help to 
explain the 40o/o reduction in HIV incidence achieved by the intervention programme. 
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=>  In  the  male  sub-cohort,  incidences  per  100  person-years  were  as  follows:  reported 
genital  discharge  syndrome  (GDS):  9°/o  (I)  and  14°/o  (C);  reported  GUS:  1.4o/o  (I)  and 
2.1 °/o  (C). About 30o/o  of men  reported  more than one partner per quarter, and reported 
condom  use was low  (<5o/o  of men).  Many men  did not seek treatment at government 
health  units,  but  more  did  so  in  I communities,  where  the  improved  services  were  in 
place. 
=>  Data  from  the  ANC  surveys  showed  very  high  prevalences  of  reproductive  tract 
infections (RTis) among pregnant women. At the follow-up survey,  prevalences were:  T. 
vagina/is  24°/o,  N.  gonorrhoea  1.7o/o,  C.  trachomatis  5.2°/o,  active  syphilis  10.5o/o  and 
42o/o  of women had at least one RTI. There were no significant differences between the 
I and  C communities,  presumably because most infections are asymptomatic or poorly 
symptomatic,  and  are  therefore  not  covered  by  syndromic  treatment  services.  Other 
strategies  will  be  needed  to  reduce  the  burden  of  RTis  in  these  women.  Data  from 
these  studies  were  used  to  develop  a  "risk  score"  to  predict  cervical  infection  from 
simple questions on social and behavioral factors, and this was shown to perform better 
than  clinical  approaches to  diagnosis. 
=>  Among 154 consecutive patients presenting with GUS at the STD clinic, prevalences of 
pathogens  were:  20o/o  H.  ducreyi (by  PCR:  30o/o  of  these  were  culture-positive);  39o/o 
were  positive on  syphilis serology but few  were confirmed  by  dark-ground microscopy 
(5°/o);  13°/o  HSV2  (antigen  ELISA);  1  °/o  LGV  in  males  (antigen  ELISA).  There  was  no 
identifiable pathogen  in  40o/o  of cases. 
=> A cohort of 40 CSWs were followed monthly for 6 months, but no cases of symptomatic 
or  asymptomatic  H.  ducreyi  were  observed.  STD  incidence  in  this  cohort,  already 
enrolled in  an  HIV/STD intervention programme,  was very low.  100 patients presenting 
to  the  STD  clinic  without GUS  were  also  studied,  with  the  detection  of H.  ducreyi by 
PCR  in  1/50  males  and  2/50  females,  none  of  whom  developed  ulceration  subse-
quently. Asyrnptomatic carriage may play a role  in  the transmission of this agent in  this 
population. 
=> The serological test for  H.  ducreyi is being  modified and  improved,  and will  be  applied 
to sera from  the  Mwanza studies  in  due course. 
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INTERVENTION  STUDY  OF  SEXUALLY  TRANSMITTED  DISEASES  AND  HIV  INFEC-
TION  AMONG  FEMALE  PROSTITUTES IN  ABIDJAN, IVORY COAST 
Period: 
Co-ordinator: 
Objectives 
January 1, 1994- December 31,  1996 
INSTITUUT VOOR TROPISCHE GENEESKUNDE, DEPT OF 
MICROBIOLOGY, Antwerpen, Belgium (M.  LAGA) 
•  To  define effective strategies to prevent HIV infection  in  high risk populations which  are 
simple,  independent of sophisticated laboratory infrastructure and generalizable to large 
populations. 
•  To  collect  data  on  attitudes  and  behavior  related  to  STD  and  HIV  infection  among 
prostitute  populations  in  Abidjan,  including  sexual  practices,  preventive  behavior  and 
health  seeking  behavior. 
•  To determine the prevalence of STD and infection with HIV-1  and HIV-2, and associated 
risk factors  in  this  population. 
•  To  evaluate  3 different  interventions  aimed  at  reducing  HIV  and  STD  incidence  rates 
among a group of women  followed  prospectively. The goal  is to  determine the  efficacy 
for preventing  HIV and  STD,  the  feasibility and  the  cost of the  interventions. 
Activities 
Based  on  the  knowledge  that  interventions  consisting  of  condom  promotion  and  regular 
STD  screening  and  treatment  can  have  a  considerable  impact  on  HIV  incidence,  the 
question  remains  whether  simpler,  less  sophisticated  STD  interventions  independent  of 
laboratory infrastructure will  have the  same  impact on  HIV  incidence. 
The  project  will  evaluate  different  levels  of  STD  interventions  among  a group  of  female 
prostitutes  in  Abidjan.  Initially,  a cross  sectional  survey  will  be  performed  to  collect  data 
about attitudes and  behavior related to  STD  and  HIV infection, to determine prevalence of 
STD  and  HIV and to validate the diagnostic accuracy of different algorithms. A subsample 
of  HIV  negative  women  will  then  be  enrolled  in  a  prospective  study.  They  will  be 
randomized to one of the three STD  interventions.  Condom  promotion and  distribution will 
be  performed for all  women  similarly. 
Women  will  be followed  up  monthly for a total  duration of minimum 2 years.  Every month 
condom  use  will  be  monitored  and  STD  will  be  treated  according  to  the  2  different 
algorithms or the  gold  standard  laboratory approach. 
The  prevalence  of  STD  will  be  monitored  after one  and  two  years  intervention  in  the  3 
groups. The incidence of HIV will  be monitored on a 6 monthly basis and will be compared 
in  the  3 intervention  groups  over a period  of 2 years. 
The  cumulative  incidence  rate  of  HIV  over  a  2  year  period  will  be  the  final  outcome 
measure,  and will  be  compared  in  the 3 groups after controlling for confounding variables 
such  as  sexual  exposure. 
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Expected outcome 
~The  definition  of  more  effective  strategies to  prevent  HIV  infection  in  high  risk female 
populations based on  condom promotion and STD control. These strategies should not 
only be  effective  in  controlling  HIV and  STD,  but also  be  independent of sophisticated 
laboratory infrastructure, simple and generalizable to larger populations. These strategies 
will be useful not only for Cote d'lvoire but also for the rest of the developing world. 
~  In  addition  this  project  should  contribute  to  strengthening  the  research  capability  of 
members of the  lvorian  National AIDS  Control  programme,  as well  as scientists at the 
"lnstitut National  de  Sante  Publique"  in  Cote d'lvoire. 
Results 
A baseline  study  on  HIV  infection  and  sexually  transmitted  diseases  was  conducted  on 
483  commercial  sex  workers.  Of  these  23°/o  had  a  genital  ulceration.  Gonorrhoea  was 
found in 34.5°/o of women, chlamydia! infection in  1  0°/o,  trichomonas infection in 24.5°/o and 
syphilis  in  22o/o.  The  overall  prevalence  of HIV  infection  was  88°/o,  50o/o  of women  were 
infected with  HIV-1,  2o/o  with  HIV-2  and  36°/o  were  dually reactive. 
Before the  start of the  intervention consisting of condom  promotion,  health education and 
management of STDs the incidence of HIV infection was 23 per 100 women-years. During 
the  intervention  this incidence dropped to 3 per 1  00  women-years. 
By  the  end  of  1995,  1201  women  were  enrolled  in  the  study.  Among  the  HIV  infected 
women  (24°/o  HIV-1,  26o/o  dually  seroreactive,  5o/o  HIV-2)  shedding  of  the  virus  was 
associated with  HIV-1  infection, immunosuppression and presence of gonorrhoea, chlamy-
dia!  infection  or genital  ulceration. 
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THE  WELL-WOMEN  CLINIC:  STUDIES ON  WOMEN'S  REPRODUCTIVE  HEALTH 
Period: 
Co-ordinator: 
Objectives 
January 1, 1994- December 31, 1995 
UNIVERSITY OF GENT,  DEPT OF OBSTETRICS AND 
GYNAECOLOGY, Gent, Belgium (M. TEMMERMAN) 
•  To  study the  prevalence rates of reproductive tract infections (RTI),  sexually transmitted 
diseases  (STD)  and  cervical  cancer  in  women  attending  a  family  planning  clinic  in 
Nairobi,  Kenya. 
•  To validate diagnostic criteria and  risk markers in the management of STD and cervical 
cancer in  family  planning  clinic  attenders. 
•  To  develop training  programmes to  upgrade the  staff  in  a family  planning  clinic  in  the 
management of STD/RTI. 
•  To  carry out qualitative research  into the health seeking and  health  providing behaviour 
in  an  urban  family  planning  clinic. 
•  To  determine  clinical  and  subclinical  risk  markers  for  human  papilloma  virus  infection 
(HPV),  in  order to  identify women  at  high  risk  for cervical  lesions. 
•  To  compare  existing  diagnostic  techniques  for  the  clearly  detection  of  cervix  cancer 
(Papanicolaou  screening) with  recently developed  new screening techniques  (cervicog-
raphy). 
•  To  examine  the  feasibility  of  an  integrated  programme  addressing  women's  health 
issues. 
•  To  identify cost-effective means of integrating STD  prevention and  control  programmes 
into  more  comprehensive  services. 
Activities 
The  site  selected  for  this  intervention  is  a  busy  planning  clinic  in  Nairobi  with  50  to  80 
attendants  per  day.  A substantial  proportion  of  these  women  present  with  signs  and/or 
other  symptoms  related  to  STD  or  RTI.  Many  primary  health  care  facilities,  including 
maternal-child  health  and  family  planning  clinics,  do  not  adequately  address  RTI  in 
women.  STD  clinics,  on  the  other  hand,  are  often  overloaded  and  not  woman-friendly. 
Recognition  of these  issues  argues for incorporating  STD  concerns  not  a comprehensive 
program  of  reproductive  health  services  rather  than  addressing  them  in  a  separate, 
potentially  stigmatizing  manner  that  emphasizes  their  sexual  acquisition.  In  addition, 
cancer  of  the  cervix  is  also  very  common  in  Kenya,  accounting  for  high  morbidity  and 
mortality  rates.  National  screening  programmes  for  early detection  of  cervical  cancer are 
hardly  implemented  due  to  the  lack  of  adequate  cytology  facilities,  the  lack  of  properly 
trained  staff and  quality control. 
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The  findings  of  these  studies  allow  the  development  and  implementation  of  simple 
interventions targeting STD,  RTI  and cervical  lesions in  a comprehensive way contributing 
to the  improvement of  reproductive  health  of women  in  the developing world. 
The  initial  phase  of  the  WWC  Supermarket  Project  was  the  realisation  of  an 
STD/RTI/HIV/cervical  dysplasia  prevalence  study.  In  order to  measure  the  magnitude  of 
the  problem  in  a  population  of  family  planning  clinic  attenders,  over  500  consecutive 
women attending for family planning purposes were assessed for the presence of STD/RTI 
and  cervical  cancer.  The  STD  prevalences were as  expected for African  urban  standards 
in  low risk populations (C.  Trachomatis 4°/o,  N.  Gonorrhoeae 2°/o,  syphillis 2°/o,  HIV-1  10°/o) 
but  striking  was  the  high  rate  of  cervical  precancerous  lesions.  Twelve  percent of these 
women  had cervical epithelial dysplasia (CIN)  of whom  6°/o  CIN  II  (moderate dysplasia) or 
CIN  Ill  (severe dysplasia). 
During  the  second  phase  (1995)  more attention  was  given  to: 
*  Study the  interactions between  CIN  and  HIV. 
*  To  expand  the training  component. 
*  To establish a referral site for follow-up and management of precancerous lesions of the 
cervix. 
*  To  the  dissemination  of the  results. 
*  To  assess  the  syndromic approach for detecting  STD/RTI  in  this  group. 
*  To  explore  the  possibilities  of  networking  with  other  regional  and  international  organi-
zations  in  the  area of  reproductive  health. 
Based  on  the  results  of  the  first  survey,  a  second  study  was  initiated  in  1995.  The 
objectives  were  to  evaluate  "risk  scores"  to  predict  cervical  infections  and  to  develop 
strategies  to  reduce  the  transmissions  of  STD  and  HIV  including  information,  education 
and  communication,  HIV  testing  and  counselling  and  the  control  of  sexually  transmitted 
infections (STI). The study was conducted to determine the impact,  relevance,  access and 
obstacles to these  interventions  in  women  considered to  be  at low risk. 
A new questionnaire has been developed. Again  530 women  were enroled and  examined 
at  FPAK  Ribiero clinic.  The  results of the  second  phase  indicate that: 
*  Scoring  systems  based  on  historical  data  and  clinical  findings  may  assist  in  the 
management of women considered to be  at low risk for STI.  Sensitivity measures may 
be  improved  with  the  identification  of  other  predictor variables  and/or the  addition  of 
simple diagnostic testing. 
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*  The  prevalence  of  cervical  dysplasia  and  aggressive  H  PV  serotype  are  substantial. 
Family  planning  clinics  in  developing  countries  provide  an  important  opportunity  to 
implement programmes  for the  detection  and  management of cervical  malignancies. 
*  Intervention  strategies  need  to  be  targeted  to  women  in  the  general  population  who 
remain  highly  vulnerable  to  HIV/STD  infections  despite  access  to  information,  con-
doms  and  STI  treatment.  Programmes  at  family  planning  clinics  may  provide  an 
excellent  opportunity  to  increase  awareness  of  vulnerability  and  implement  novel 
interventions. 
Conclusions and recommendations 
~  The  project  management  structure  has  been  set  up  well  and  seems  to  function 
satisfactory. 
~  Overall,  the  WWC  project  prevalence  study  has  progressed  well.  Thanks  to  the 
dedication  of  the  participants  and  the  overwhelming  clients'  response,  data  collection 
was  much  easier  than  anticipated.  The  prevalence  of  CIN  was  alarmingly  high  and 
needs further consideration. 
~  There is a need for integrated services within existing FP clinics. This was evidenced by 
the  frequency  of  STI  complaints.  The  especially high  prevalence  of  CIN  and  HIV  also 
serves to  accentuate the  need for routine  pap  smear or other methods  of examination 
of the  cervix  in  this  population. 
~Strengthening  screening  facilities  without  proper  treatment  and  intervention  being 
considered as  unethical, a substantial amount of time and  effort has been  spent to find 
proper,  safe,  accessible  and  affordable  treatment  facilities  for  patients  identified  with 
CIN  lesions.  As  the  public  sector  in  Nairobi  was  not  able  to  care  for  these  women, 
arrangements  were  made  with  KMWA  members  working  privately  to  treat  these 
patients.  Additional  mechanisms  to  ensure  the  intervention  will  be  explored.  KMWA 
hopes  to  avail  the  colposcopy  and  CIN  treatment  facilities  to  the  general  public  at  a 
small  fee.  It  is  known  that  the  Kenyatta  National  Hospital  (KNH)  - the  only  public 
facility  offering  colposcopy  services  - is  already  overwhelmed  with  cases.  Due  to 
logistic  problems and  constant  breakdown  this  facility  is  unavailable  most  of  the  time. 
This  leads  to  long  waiting  time  and  possible  progression  of  CIN  in  many cases.  The 
KMWA facility would serve to provide this very much needed service on top of ofloading 
some  of the  KNH  clients. 
~  Additional  training  and  supervision  in  the  field  of  colopsocopy,  cytology  and  manage-
ment  of  STD/RTI  and  cervical  lesions  will  be  required.  The  remaining  budget  of  this 
contract  (1 0°/o)  will  be  used to  send  one  of the  senior KMWA members who  has  been 
exposed  to  training  to  a  higher  level  course  in  Europe  to  be  better  prepared  for 
organizing  training  courses  in  Nairobi  for  Kenya  and  for East-Africa. 
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~  To  avoid  duplication  of  efforts,  networking  with  other  groups  working  in  the  area  of 
reproductive  health  has to  be  enforced. 
~  Research  experience  gained  from  this  project  will  be  useful  for  KMWA  in  formulating 
other  research  proposals  and  implementing  other  research  programmes.  The  KMWA 
WWC  lab  is  also foreseen  to  serve  as  a training  lab  for updating  cyto technicians  on 
cervical cancer screening techniques. The lab would also be a centre for quality control 
which  is  lacking  in  most  laboratories  offering  cervical  cancer  screening  services  in 
Nairobi.  KMWA  has  trained  and  experienced  cyto  pathologists  able  to  offer  technical 
assistance  in  this  respect. 
Partners 
University of Gent 
University Hospital 
Dept. of Obstetrics and Gynaecology 
De  Pintelaan 185 
9000 Gent 
Belgium 
Kenyan Medical Women's Association 
P.O.  Box 49877 
Nairobi 
Kenya 
Diagnostisch Centrum SSDZ 
P.O.  Box 5010 
2600 GA Delft 
The Netherlands 
M. Temmerman 
Tel: +32/9/240.37.83 
Fax:  +3219/346.79.55 
E-mail: marleen.temmerman@ rug.ac.be 
A.  Kapila 
Tel:  +25/4/256.08.13 
W.  Quint 
Tel:  +31/1/560.30.50 
Fax: +31/15/2604550 
E-mail: infoddl@ddl.nl 
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A STUDY ON  THE  ROLE OF HIV-1  GENOTYPES ON  THE EPIDEMIOLOGY OF HIV IN 
TANZANIA AND UGANDA 
Period: 
Co-ordinator: 
Objectives 
November 1, 1996-October 31,  1999 
UNIVERSITY OF MUNICH, DEPARTMENT OF TROPICAL 
MEDICINE, Munich, Germany (M.  HOELSCHER) 
•  Retrospective  study  (  1988-1995)  to  determine  the  different  subtypes  present  in  the 
regions,  to  identify  their  geographical  distribution  and  possible  alterations  of  the 
proportions  in  different population  groups over the  observation  period. 
•  Consistenc y check,  whether the current distribution  of subtypes  in  AIDS  patients  in  a 
specific region  is comparable to  the distribution of subtypes  in  this  region  seven  years 
ago  (at the  approximate time  of infection.) 
Activities 
*  1.200 Tanzanian  and  900  Ugandan serum  samples are tested  by V3-serotyping  ELISA 
by the African  partners. 
*  1  0°/o  of  the  samples  will  be  reanalysed  as  control  group  by  LMU  by  V3-serotyping 
ELISA. 
*  Approx.  20°/o  of the 2100  samples will  be  untypable  by  V3-loop  ELISA.  These  will  be 
referred  to  Europe and  will  by analysed  by HMA (SMH)  and  sequencing  (LMU). 
*  Consistency  check  whether the  subtype  distribution  of  1  00  AIDS  patients  of the  year 
1995 is  comparable  with  the  distribution  of 1  00 AIDS  of the year. 
Expected outcome 
=> The distribution of subtypes in  different geographical regions and  in  different population 
groups. 
=>A probable change of predominance of subtypes over the years, which gives an  insight 
into  differences  in  transmission  efficacy. 
=>  Detection  of new strains from  other parts of Africa to  the  Mbeya  Region. 
=>  Detection  of new variants. 
=>  Essential  information  for the  preparation  of vaccine campaigns  in  this  region. 
=>  Differences  between  the  distribution  of subtypes  at the  time  of conversion  (5-7  years 
ago) and the present distribution. This could reveal possible differences in pathogenicity 
in  the  different strains. 
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Partners 
LMU/Department of Tropical Medicine 
and infectious Diseases 
Section International Medicine and Public 
Health 
Leopoldstr. 5 
80799 Munich 
Germany 
LMU/Max-v-Pettenkofer-lnstitut 
Pettenkofer-str. 9a 
80336 Munich 
Germany 
Imperial College of Medicine at St. Mary's 
Pread Street 
London W2 1  PG 
United Kingdom 
Mbeya Regional AIDS Control Programme 
P.O.  BOX 259 
Mbeya 
Tanzania 
District Medical Office 
P.O.  Box 217 
Fort Portal 
Uganda 
M. Hoelscher/F.  v.  Sonnenburg 
Tel:  +49/89/21.80.38.30 
Fax: +49/89/33.60.38 
E-mail: hoelscher@ lrz.uni-muenchen.de 
L. Gurtler 
Tel:  +49/89/51.60.52.73 
Fax: +49/89/51.60.52.74 
R.  Cheingsong-Popov/J. Weber 
Tel:  +44/171n25.15.39 
Fax: +44/171 /725.66.45 
L.  Mkwera 
Tel:  +255/65.25.  77 
Fax: +255/65.42.06 
G. Kabagambe-Rugamba 
Tel:  +256/48.32.27.40 
Fax: +256/48.32.27  .43 
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STUDY  OF  HIV-1  VARIABILITY  IN  CAMEROON  AND  GABON.  IMPLICATIONS  FOR 
VACCINE AND ANTIVIRAL INTERVENTION STRATEGIES 
Period: 
Co-ordinator: 
Overall aim 
April 1  , 1998 - September 30, 2000 
INSTITUTE OF TROPICAL MEDICINE 
Antwerp, Belgium (G. VAN  DER GROEN) 
•  To  study the biological function  of antigenic epitopes inducing broad cross-neutralizing 
antibodies,  and the role  they play against infection  and/or progression to disease. 
•  To  monitor anti-HIV drug susceptibility and viral  load of genetically diverse primary HIV 
strains circulating  in  Cameroon and  Gabon. 
Objectives 
•  To  provide  a  surveillance  system  for  newly  emerging  and  naturally  occurring  recom-
binant HIV-1  strains in  Cameroon and Gabon. 
•  To  classify sera from  H  IV  infected  individuals according to their capacity to  neutralize 
primary isolates representing  different genetic clades. 
•  To  characterize broadly neutralizing antibodies and epitopes in  individuals infected with 
HIV-1  of  different  genetic  subtypes,  and  evaluate  the  role  they  play  in  disease 
protection. 
•  To  investigate the susceptibility of HIV-1  strains belonging to different genetic clades, to 
both  existing  and  experimental  anti-HIV  compounds  and  to  provide  a  surveillance 
system  for  emerging  strains  of  HIV-1  with  naturally  occurring  mutations  conferring 
antiviral  drug resistance. 
•  To  optimize the quantification of HIV RNA in  plasma of patients infected with  different 
types,  subtypes and  recombinant subtypes of HIV. 
Activities 
*  Both  heteroduplex mobility assay (HMA)  on  PCR  amplified fragments  generated from 
HIV RNA in  serum or plasma of HIV infected individuals and V3-peptide ELISA will  be 
used to monitor the prevalence of different genetic subtypes of HIV-1. 
*  HMA  on  both  gag  and  env fragments  of  the  same  isolate  will  allow  to  study  the 
prevalence of recombinant viruses. 
*  Susceptibility  of  the  different  subtypes  and  the  natural  recombinant  viruses  towards 
various HIV inhibitors will  be  determined. 
*  Neutralizing  antibody  patterns  in  sera  of  individuals  infected  with  all  subtypes  (A-H) 
within  group M and representatives of group 0  to their homologous and heterologous 
primary isolates will  be  documented  using a  peripheral  blood  mononuclear cell  based 
neutralization assay. 
*  Neutralization data will  be analyzed  by a  multivariate (spectral  mapping) analysis. 
*  Chimeric  viruses  consisting  of  neutralization  sensitive  and  insensitive  primary  HIV-1 
strains  will  be  constructed  in  order to  characterize  the  epitopes  playing  a  role  in  the 
neutralization  process. 
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Expected outcome 
=>  Making available to developing countries a simple economical serologic test to  monitor 
circulating  HIV-1  subtypes. 
=>  Since  only  a  limited  number  of  key  isolates  are  required  to  document  the  broad 
cross-clade  neutralization capacity of a particular serum,  we  hope  in  future  to  be  able 
to monitor the efficacy of HIV-1  vaccines inducing high-titer cross-neutralizing antibodies 
in  an  economic way. 
=>To  enable  some  research  centres  in  Cameroon  and  Gabon  to  solve  some  of  their 
specific problems,  such  as the impact of the extreme high  genetic variability of HIV on 
anti-HIV drug  susceptibility as  well  as  on  the characterization  of conserved  neutraliza-
tion epitopes; discovery of new,  not yet identified HIV subtypes and recombinant viruses 
naturally  occurring;  development  of  antiviral  drugs  efficient  against  the  predominant 
HIV-1  subtypes circulating  in  developing countries. 
Partners 
Institute of Tropical Medicine 
Nationalestraat 155 
2000 Antwerpen 
Belgium 
ORSTOM 
Laboratoire de retrovirus 
Avenue Agropolis 911 
P.O.  Box 5045 
34032 Montpellier 
France 
Centre for the Study and Control of 
Communicable Diseases 
Faculty of Medicine and Biomedical Sciences 
P.O.  Box 8445 
Melen street 
Yaounde 
Cameroon 
TIBOTEC NV 
Drie Eikenstraat 661 
2650 Edegem 
Belgium 
VIRGO NV 
Central Virological Laboratory 
Drie Eikenstraat 661 
2650 Edegem 
Belgium 
G. VanDer Groen 
Tel:  +3213/2476.319 
Fax: +3213/2476.333 
E-mail: cmaeckelbergh@ microb 
E.  Delaporte 
Tel:  +33/4/6761.7558 
Fax:  +33/4/6754. 7800 
E-mail: delaport@orstom.orstom.fr 
P.  Ndumbe 
Tel:  +23/7/315.1 04/206.496 
Fax:  +23/7/315.178 
M.P. de Bethune 
Tel:  +3213/8250.208 
Fax: +32/3/8250.615 
E-mail: marie-pierre.de.bethune @tibotec. uia.ac.be 
R.  Pauwels 
Tel:  +32/3/8255.015 
Fax: +32/3/8250.615 
E-mail: rudi.pauwels. @virco.uia.ac.be 
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MULTICENTER STUDY ON  FACTORS DETERMINING DIFFERENTIAL SPREAD OF HIV 
INFECTION  IN  AFRICAN TOWNS 
Period: 
Co-ordinator: 
Objectives 
December 1  , 1996 - January 30,  1998 
PRINCE LEOPOLD INSTITUTE OF TROPICAL MEDICINE, 
DIVISION OF MICROBIOLOGY 
Antwerp, Belgium (M.  LAGA I A.  BUVE) 
•  To  improve our understanding of the factors that determine the extent of the spread of 
HIV  infection  in  populations  in  sub-Saharan  Africa  where  the  predominant  mode  of 
transmission  is  heterosexual contact.  in  view of better targeted  interventions to  reduce 
new H  IV  infections. 
Specific objectives 
•  To  compare  the  distributions  of  likely  population  risk  factors  for  the  spread  of  H  IV 
infection,  in  four large cities  in  sub-Saharan Africa. 
+  To  establish  with  policy  makers the  results  of the  study and  the  likey effectiveness of 
different intervention  approaches. 
Data analysis and report writing 
*  In  each  of the  sites  data analyses will  be  carried  out  immediately following  entry  nad 
cleaning  of the  data.  Descriptive analyses at a population  level  will  provide  insights in 
the distribution of suspected risk factors.  Multivariate analyses will identify individual risk 
factors  for HIV  infection  in  each  of the  sites. 
*  Comparative data analyses will be carried out in  Europe.  Comparisions will be  made of 
the distributions of sustpeced risk factors (mainly sexual behaviour characteristics,  STD 
prevalence,  circumcision)  between  study sites. 
*  As well as these standard statistical analyses simulation modelling exercices will enable 
us to  assess whether results from  the study are consistent with documented spread  of 
HIV  infection  in  the different sites. 
Discussion of study results with policy makers 
As soon as the first results of the comparative data analysis are available, a workshop will 
be  organized  in  each  site to which  policy makers  involved  in  AIDS  control  are  invited.  In 
this  workshop  the  results  of  the  research  will  be  discussed  and  recommendations  for 
interventions will  be  formulated. 
Partners 
Prince Leopold Institute of Tropical Medicine 
Division of Microbiology 
Nationalestraat 155 
2000 Antwerpen 
Belgium 
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M.  Laga/A. Buve 
Tel:  +32/3/247.63.16 
Fax:  +32/3/247.63.33 
E-mail: abuve@ microbiol.itg Contract number IC18*CT960114 
Programme National de Lutte contre le SIDA 
P.O.  Box 04 378 
Cotonou 
Benin 
lnstitut de Fromation et de Recherche 
Laboratoire Population et Sante 
P.O.  Box 1556 Yaounde 
Cameroon 
Centre Hospitalier Universitaire 
Laboratoire d'Hematologie et d'lmmunologie 
P.O.  Box 155 
Yaounde 
Cameroon 
Tropical Diseases Research Centre 
P.O.  Box 71769 
Nkana Road 
Ndola 
Zambie 
INSEAM 
Unite 88 
Hopital National de Saint-Maurice 
14 rue du Val  d'Osne 
94415 Saint-Maurice 
France 
London School of Hygiene and Tropical 
Medicine 
Dept. of Epidemiology and Pop. Sc 
Keppel Street 
WC1 E 7HT London 
United Kingdom 
University of Nairobi 
Dept. of Community Health 
Kenyatta National Hospital 
P.O.  Box 19676 
Nairobi 
Kenya 
The Population Council 
The Chancery building 
Valley Road 
P.O.  Box 17643 
Nairobi 
Kenya 
Ministry of Health 
National AIDS/STD Control Programme 
SCU - STD Control Unit 
P.O.  Box 20781 
Nairobi 
Kenya 
N.  Davo 
Tel:  +229/31.54.88 
Fax: +229/30.42.08 
EvinaAkam 
Tel:  +237/22.24.71 
Fax: +237  /22.67.93 
L.Zekeng 
Tel:  +237/20.71.85 
Fax: +237/23.02.96 
T.  Sukwa 
Tel:  +260/2/61.44.87 
Fax: +260/2/61.44.87 
B.Auvert 
Tel:  +33/1/45.18.38.70 
Fax: +33/1 /45.18.38.89 
E-mail: robinson@citi2.fr 
L. Williams 
Tel:  +44/171/927.22.43 
Fax: +44/171 /436.42.30 
E-mail: r.hayes@lshtm.ac.uk 
J. Wang'ombe K. 
Tel:  +254/2n2.46.39 
Fax: +254/2n2.46.39 
A. Ajayi 
Tel:  +254/2n1.34.80 
Fax: +254/2n1.34.  79 
M.  Kahindo 
Tel:  +254/2/72.  78.09 
Fax: +254/2/71.38.24 
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VIROLOGICAL AND MOLECULAR CHARACTERISTICS OF HIV1  STRAINS IN AFRICA. 
THE  IMPACT OF HIV GENETIC SUBTYPES ON  THE  PATHOGENESIS AND PROGNO-
SIS  OF  HIV INFECTION 
Period:  September 1997 - September 2000 
Co-ordinator:  ORSTOM RETROVIRUS 
Montpellier, France (E.  DELAPORTE) 
Objectives 
General objective 
To analyse the impact of specific genetic subtypes on the natural history of HIV-1  infection. 
Specific objective 
•  To  identify  the  genetic  subtype  circulating  in  three  existing  cohorts  of  HIV  infected 
patients  in  Senegal,  Cameroon  and  Guinea-Bissau;  to  study  virological  and  antigenic 
characteristics  related  to  the  genotype. 
•  To  identify  risk  factors  associated  to  specific  genotypes  and  to  assess  clinical, 
immunological  and  virological  parameters  as  well  as  survival  over  3  years  period  in 
HIV-1  infected  patients according to  genotypes. 
Activities 
This project consists on  two  parts: 
First,  a  transversal  study  among  ongoing  cohorts  of  HIV  infected  patients  in  Senegal, 
Cameroon  and  Guinea-Bissau  will  allow  to  determine  the  prevalence  of  the  different 
genotypes  circulating  in  this  populations  and  to  characterize  their  virological  properties. 
Both  heteroduplex mobility assay (HMA) and V3  peptide serology will be  used to diagnose 
the  different  genetic  groups  and  subtypes  of  HIV-1.  An  algorithm  will  be  developed  to 
simplify  the  genetic  subtyping  of  HIV-1.  The  biological  phenotype  will  be  analyzed  and 
correlated with  the genetic sequence of the V3  loop.  Risk factors associated to genotypes 
will  be  analyzed. 
Secondly,  the  possibility  to  perform  a  follow-up  of  HIV-infected  patients  in  Senegal, 
Guinea-Bissau and  Cameroon allows us  to  initiate a prospective study in  order to  assess 
clinical,  immunological  and  virological  parameters  as  well  as  survivial  over a three  year 
period.  The  biological  phenotype  will  be  determined  every  6  months  and  correlated  with 
CD4  counts and  clinical  parameters.  Several  clinical,  serological,  virological  and  immuno-
logical  parameters  will  be  studied  in  order  to  see  if  certain  genotypes  have  a  different 
pathogenesis and  prognosis for  HIV disease development. 
Expected outcome 
The  potential  benefits of the  proposed  projects are  multiple.  A better clinical  care  of HIV 
infected  patients  is  offered  through  a  standardized  approach  and  with  the  possibility  to 
treat infections due  to  the  immune-depression. 
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The  development  of  a  new,  simple  and  rapid  strategy  to  monitor  the  relative 
prevalence  of  the  different  genetic  subtypes  of  H  IV-1  strains.  Such  data  are 
important for the development of future  HIV vaccines.  Information will  be  provided 
on  differences in disease development, prognosis and  risk factors accroding to the 
genetic subtypes.  Such  data are expected to  be  important for the  management of 
HIV  infected  patients. 
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STUDY  OF  HIV-1  VARIABILITY  IN  CAMEROON  AND  GABON.  IMPLICATIONS  FOR 
VACCINE AND ANTIVIRAL INTERVENTION STRATEGIES 
Period: 
Co-ordinator: 
Overall aim 
April 1  , 1998 - September 30, 2000 
INSTITUTE OF TROPICAL MEDICINE 
Antwerp, Belgium (G.  VAN  DER GROEN) 
•  To  study the biological  function  of antigenic epitopes inducing broad  cross-neutralising 
antibodies,  and the role  they play against infection  and/or progression to disease. 
•  To  monitor anti-HIV drug susceptibility and viral load of genetically diverse primary HIV 
strains circulating  in  Cameroon and  Gabon. 
Objectives 
•  To  provide  a  surveillance  system  for  newly  emerging  and  naturally  occurring  recom-
binant HIV-1  strains in  Cameroon and Gabon. 
•  To  classify sera from  HIV infected  individuals according to their capacity to  neutralise 
primary isolates  representing  different genetic clades. 
•  To  characterize broadly neutralising antibodies and epitopes in  individuals infected with 
HIV-1  of different genetic subtypes, and evaluate the role they play in disease protection. 
•  To  investigate the susceptibility of HIV-1  strains belonging to different genetic clades, to 
both  existing  and  experimental  anti-HIV  compounds  and  to  provide  a  surveillance 
system  for  emerging  strains  of  HIV-1  with  naturally  occurring  mutations  conferring 
antiviral  drug  resistance. 
•  To  optimize the quantification of HIV RNA in  plasma of patients infected with  different 
types,  subtypes and  recombinant subtypes of HIV. 
Activities 
The  study  design  will  be  as  follows:  both  heteroduplex  mobility  assay  (HMA)  on  PCR 
amplified  fragments  generated  from  HIV  RNA  in  serum  or  plasma  of  HIV  infected 
individuals  and  V3-peptide  ELISA  will  be  used  to  monitor  the  prevalence  of  different 
genetic subtypes of H  IV-1 . HMA on  both  gag and  env fragments of the same isolate will 
allow  to  study  the  prevalence  of  recombinant  viruses.  Susceptibility  of  the  different 
subtypes  and  the  natural  recombinant  viruses  towards  various  HIV  inhibitors  will  be 
determined.  Neutralizing antibody patterns in  sera of individuals infected with all subtypes 
(A-H)  within  group  M  and  representatives  of group 0  to  their homologous and  heterolo-
gous primary isolates will be documented using a peripheral blood mononuclear cell based 
neutralisation  assay.  Neutralisation  data  will  be  analyzed  by  a  multivariate  (spectral 
mapping)  analysis.  Chimeric viruses  consisting  of neutralisation  sensitive  and  insensitive 
primary  HIV-1  strains  will  be constructed  in  order to  characterize  the  epitopes  playing  a 
role  in  the neutralisation process.  Human monoclonal antibodies with cross-clade neutrali-
sation capacity will  be  generated. 
Consecutive isolates and sera of long term, slow and rapid progressors will be analyzed in a 
time paired sequential manner in autologous and heterologous neutralisation experiments, in 
order to monitor the role of neutralisation antibodies in the progression of the infection. 
Expected outcome 
Making  available  to  developing  countries  a  simple  economical  serologic  test  to  monitor 
circulating  HIV-1  subtypes. 
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These  data are  essential  for the  development of future  HIV vaccines,  as well  as for the 
development of  efficient anti-HIV drugs;  multivariate  analysis  of HIV-1  neutralisation  data 
will  allow  to  monitor  the  efficacy  of  HIV-1  vaccines  inducing  high-titre  cross-neutralising 
antibodies,  in  an  economic way,  since only a limited  number of key  isolates are  required 
to  document the  broad  cross-clade  neutralisation capacity of a particular serum.  This will 
also  facilitate  the  selection  as  well  as  the  design  of antigens  to  be  incorporated  into  a 
suitable  HIV-1  vaccine  preparation;  to  enable  some  research  centres  in  Cameroon  and 
Gabon to  solve some of their specific problems,  such  as the  impact of the extreme  high 
genetic variability of H  IV on  anti-H IV drug susceptibility as well as on  the characterization 
of conserved neutralisation epitopes; discovery of new,  not yet identified HIV subtypes and 
recombinant viruses naturally occurring development of antiviral drugs efficient against the 
predominant HIV-1  subtypes circulating  in  developing countries;  strengthening the alliance 
with  research  centres  in  Cameroon  and  Gabon  and  leading  centres  in  Europe,  with 
expertise on  HIV variability studies  in  Africa and  on  studying the anti-HIV drug  activity. 
The probability of the realisation of the planned objectives is high, since both the overseas 
laboratories  as  well  as  the  research  centres  in  Europe,  have  already  an  ongoing 
collaboration  and  are  active  in  the  field  of HIV/AIDS since  many years. 
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DEVELOPMENT  OF  A  HIV  CANDIDATE  VACCINE  FOR  PHASE  I  AND  II  CLINICAL 
TRIALS IN  CHINA 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1997 - October 31 , 2000 
INSTITUTE OF MEDICAL MICROBIOLOGY, 
UNIVERSITY OF REGENSBURG, 
Regensburg, Germany (R. WAGNER) 
•  To  create  a basis  for testing  HIV  candidate  vaccines  in  clinical  phase  1/2 trials 
•  To  develop  a novel  HIV-candidate vaccine  on  the  basis  of  regional  virus  strains 
•  To assess the safety,  immunogenicity and efficacy of the proposed candidate vaccine in 
a relevant  primate  model 
Activities 
*  Careful  monitoring  of  the  epidemic  situation  in  a  given  population  is  one  of  the 
important issues  in  preparing clinical  phase  1/2  trials.  Due  to  the  very  recent  outbreak 
of  the  HIV  epidemy  in  the  rural  population  in  the  Dehong  prefecture  of  Yunnan,  the 
variability  of  the  virus  in  this  area  seems  to  be  still  restricted  to  a  HIV-1  B
1-Thai 
subtype.  However,  the  antigenic  drift  will  be  carefully  monitored  by  the  Chinese 
Academy  of  Preventive  Medicine  (CAPM)  and  the  Health  and  Epidemic  prevention 
stations (HEPS)  assisted by the Institute of Medical Microbiology and Hygiene (RIMMH, 
Germany). 
*  In  order  to  optimize  the  chances  of  a  successful  vaccine,  recombinant  virus-like 
particles  and  a  corresponding  DNA  vaccine  will  be  constructed  based  on  a  careful 
molecular  characterization  of  prevalent  B 
1-(Thai)  and  C-clade  H  IV  strains  of  the 
endemic areas  in  China  (CAPM). 
*  The  long  term  safety,  immunogenicity  and  toxicity  of  the  different  antigen  delivery 
systems  will  be  analyzed  in  rhesus  macaques  in  collaboration  with  the  Biomedical 
Primate  Research  Center  (BPRC,  The  Netherlands)  and  the  Institute  of  Molecular 
Biology  (1MB,  Kunming,  China). 
*  The  efficacy  of  the  induced  immune  responses  after  heterologous  challenge  of  the 
immunized  monkeys  with  a pathogenic  SHIV  chimera  will  be  determined. 
*  After  having  demonstrated  the  safety  and  efficacy  of  the  antigens  in  the  proposed 
animal  model  and  in  case  of a favourable  epidemiological  situation,  clinical  phase  1/2 
trials  will  be  prepared. 
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Expected outcome 
It is expected, that this project will lead to a close collaboration between the European and 
Chinese partners in  the area of epidemiology and vaccine development.  Furthermore, this 
study will  contribute  to  the  molecular characterization  of the  prevalent  B
1
- and  C-clade 
HIV strains from  South-East Asia,  which  will  be  subsequently utilized for the construction 
of an  innovative VLP and  DNA based antigen-delivery system. A systematic evaluation of 
these  candidate  vaccines  with  respect  to  their  safety,  immunogenicity  and  efficacy  is 
considered  to  be  an  essential  prerequisite  in  order  to  proceed  to  further  clinical  trial 
phases. 
Partners 
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THE  APPLICATION  OF  DNA  FINGERPRINTING  TO  THE  PATHOGENESIS  OF  HIV-
RELATED TUBERCULOSIS IN  AFRICA 
Period: 
Co-ordinator: 
Objectives 
August 1,  1992 - July 31,  1995 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPT.  OF CLINICAL SCIENCES, London,  United Kingdom (P. 
GODFREY-FAUSSETT) 
The  study  aimed  to  determine  to  what  extent  the  development  of  TB  in  HIV  infected 
patients  in  Africa  is  due to  reinfection  rather than  relapse  or reactivation. 
Achievements 
*  Establishment of molecular epidemiology in Zambia and transfer of molecular, computer 
and  epidemiological  skills. 
*  Baseline studies on variability of DNA fingerprint patterns within and between patients in 
a high  prevalence  region. 
*  Prospective study of the molecular epidemiology of TB in  a relatively closed community 
with  high  prevalence  of  H  IV. 
*  Contribution  to  control  programme  activities of  reference  laboratory and  Lusaka  notifi-
cation  register. 
*  Support to teaching  within  UNZA medical  school. 
*  Regional  interest in  possibilities of  molecular epidemiology enhanced. 
*  Extension  granted  to  develop new directions. 
Results 
==>  Around  2000  isolates  have  now been  typed  and  around  1500 stored  on  a Gelcompar 
database.  The  Molecular  Biology  Unit  is  funded  until  1999  by  DFID,  the  Goldfields 
Mining Company,  and  with  support from  the  EU  Concerted actions on  genetic markers 
for  the  epidemiology  of  tuberculosis  and  molecular  epidemiology  and  control  of 
tuberculosis  (BMH1-CT93-1614 and  BMH4-CT97-2102). 
==>  There  is  enough  genetic diversity within  a high  prevalence community to  be  useful for 
epidemiological  studies. 
==>  Multiple isolates from  most individuals have identical fingerprints. This finding  underlies 
almost all  attempts to  use  fingerprinting  as  an  epidemiological  tool  in  Africa. 
==>Community  based  studies  will  be  necessary  to  answer  the  question  of  reactivation 
versus  recent  infection.  The  definition  of  the  community  will  be  vital.  The  closer  one 
comes  to  a  closed  community,  the  more  informative  the  study  will  be.  Lusaka  is 
therefore a bad choice for such studies; not only is the population much too big to allow 
complete  coverage  of  the  community,  but  also  there  is  considerable  movement  of 
infected  patients  into and  out of the _city. 
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::::}  Studies in  the South African  Gold  Mining  industry show that much  Tb  is due to  recent 
transmission  whether  subjects  are  also  infected  with  HIV  or not.  Whether  the  same 
conclusion  will  be  found  in  a more general  population  remains  open. 
Most  recurrences  are  due  to  persistence  of  the  original  strain,  but  it  is  difficult  to 
document a cure  in  many individuals before their recurrence.  The  original  strategy for 
detecting recurrences was  inadequate and the  numbers of sets of isolates available for 
fingerprinting  remains  small. 
::::}  The  Department of Pathology and  Microbiology of the  University Teaching  Hospital has 
now included a Unit of Molecular Biology as part of the institution's structure. Staff have 
been  recruited  and  space made available.  Continuing interest and collaboration should 
follow. 
::::}  Equipment and consumables have been provided to the Chest Disease Laboratory and 
a collaborative arrangement with the British Public Health Laboratory Services has been 
established with  a two-way exchange of staff and  materials. 
::::}  Computerisation of the COL,  is continuing to work well  and  has improved the accuracy 
of the clerical  work and  provided  rapid  feedback on  quality assurance to  the technical 
staff and  on  results to  clinicians. 
::::}  Other studies that have shared  ZAMBART resources  include: 
1.  Paediatric tuberculosis:  diagnosis and  case  definition. 
2.  Infectivity of HIV positive and  negative TB  cases,  compared to community controls. 
3.  Epidemiology of bovine TB. 
Training 
An  important goal  of the  project  has  been  to  involve Zambian  staff at  every  level  of the 
work and  provide capacity strengthening to  promote future  collaborative  projects. 
Molecular Biology 
Four  Zambian  staff  and  one  expatriate,  employed  on  a  local  contract,  have  formed  the 
laboratory  team.  Training  in  molecular  biology,  particularly  fingerprinting  and  polymerase 
chain  reaction  techniques  has  been  given  in  both  London  and  Bilthoven.  Computer-
assisted analysis of fingerprints,  which  has been  being developed with  the  EU  Concerted 
Action  on  Genetic  Markers  (BMH1-CT93-1614),  has  also  been  taught  both  in  Bilthoven 
and  at  a workshop  in  Johannesburg.  Marian  Bruce,  a Scottish  molecular biologist,  spent 
two  years  working  in  the  laboratory  and  was  a  key  to  the  successful  training  of  the 
Zambian  staff.  Dr.  Munthali  has  subsequently  moved  in  to  histopathology  but  hopes  to 
continue to  use  molecular tools to  enhance studies of TB  and  HIV from  autopsy material. 
One of the graduate technicians, Grace Mbulo (nee Kalenge), took a year out from the lab 
to complete an  MPH degree with the University of Zambia. Her dissertation was developed 
in  collaboration  with  the  project  and  focuses  on  transmission  of  TB  in  the  Lusaka 
community - a continuing area of interest for the project. She has now returned to the lab 
and  is  continuing  with  fingerprinting  and  PCR  work.  Both  Dr.  Munthali  and  Mrs.  Mbulo 
spent  attachments  with  Dr.  Stuart Wilson  at  the  London  School  of  Hygiene  and  Tropical 
Medicine. 
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The other graduate technician, Catherine Mee joined the lab in late 1994. Following on-site 
training,  she  has  been  responsible  for  most  of  the  South  African  fingerprinting.  Since 
September 1996 she has been  attending the Masters course in Applied Molecular Biology 
of  Infectious Diseases at the  London  School.  She and  Dr.  Godfrey-Faussett attended  the 
workshop organised by the RIVM,  Bilthoven in Johannesburg to become more familiar with 
Gelcompar software  and  the  global  database of fingerprints  now available from  RIVM. 
Bupe Kambashi was the first technician to join the team and continues as a central part of 
the  team.  He  has  spent  six  weeks  on  an  attachment  to  RIVM,  working  with  Dick  Van 
Soolingen  and  Jan van  Embden's groups. 
Training has also been  provided  in  Zambia by visits from  various European centres.  Petra 
de  Haas  from  Bilthoven,  Stuart  Wilson  from  London,  Francis  Drobniewski  from  London 
have all spent time working with the team in the lab.  Stewart Cole, from  Paris,  also visited 
the  lab  and  lectured  on  molecular mechanisms of drug  resistance. 
The  result  of the  training  is  that the  lab  is  now competent to  produce  and  analyse  DNA 
fingerprints  from  M.  tuberculosis without external  supervision.  If  additional  techniques are 
to  be  introduced further specific training  will  be  needed. 
An  indicator of  the  success of the  laboratory is  that the  University Teaching  Hospital  has 
agreed  to  include  Molecular  Biology  as  one  of  the  Units  within  the  Department  of 
Pathology and Microbiology. This means that there is a formal commitment to provide staff 
and  career development for them  within  the  administrative framework of the  hospital. 
Data processing 
In  addition  to  the  training  in  computer-assisted  handling  of  fingerprints  (see  above),  we 
have concentrated on training staff in  general aspects of data processing. The project runs 
its  own  mini-course  on  Epi-lnfo  software.  The  first  courses  were  organised  and  run  by 
Maria Quigley from  the Tropical  Health  Epidemiology Unit of the  London  School  but more 
recently  in-house  courses  have  been  organised  for  project  staff.  It  is  hoped  to  extend 
these courses and make them available to medical students embarking on their community 
medicine projects and to postgraduate students attending the MPH  and  MMed courses  in 
Lusaka.  Epi-info is  used for most of the data storage  in  the  project (with the exception of 
the preventive therapy trial which used dbaseiV for storage and epi-info for data handling). 
Databases now include Tb  isolates stored,  fingerprints,  paediatric TB patients,  Lusaka TB 
notifications,  samples  processed  at  Chest  Diseases  Laboratory. 
Staff seconded to the project by the Ministry of Health and the Teaching Hospital Board of 
Management have  been  trained  on-site and  the  project  has  also funded  training  in  data-
processing at the  National  Institute of Public Administration. This diploma course is  run  in 
the  evenings  but  has  been  very  popular  with  the  data-processing  staff  (Given  Kashina, 
Ovy  Moonga,  Nasilele  Muchola and  Sylvia  Soko). 
Once  again,  the  Ministry of  Health  and  the  hospital  have  shown  their commitment to the 
future  of  the  data  processing  team  by  providing  staff  and  office  space,  which  they  have 
made  secure  for the  computers. 
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Epidemiology 
The project has promoted general training  in  epidemiology and research methodology and 
was  partly  responsible  for  securing  scholarships  for  Dr.  Nanthalile  Mugala  (who  was 
working  for  the  preventive  therapy  study),  Dr.  Lamios  Munthali  (see  above)  and  Mr.  P. 
Nyanga  (one  of  the  senior  clinical  officers  in  the  TB  programme)  to  attend  the  Royal 
Tropical  Institute  in  Antwerp.  These scholarships were funded  from  the  Belgian  Coopera-
tion and are an  example of the catalytic effect of an  integrated research project on training 
in  Zambia. 
Dr.  Godfrey-Faussett  attended  the  Short  Course  on  Advanced  epidemiological  methods 
run  by the  Epidemiology Department of the  London  School. 
Action research 
As  an  addendum  to  the  original  contract,  we  received  funds  for  Dr.  Alwyn  Mwinga (who 
runs  the  preventive  therapy  study)  and  Dr.  Godfrey-Faussett  to  have  a  workshop  in 
Amsterdam with  Dr.  Marteen van  Cleef,  Dr.  Peter Lever and  Dr.  Leon  Bijlmakers from  the 
Royal tropical  Institute. The ZAMBART Urban Tuberculosis Project was drafted, developed 
further in  Lusaka  in  discussion with  the  Ministry of Health  and  has  now  been  funded  by 
I  NCO-DC. 
Cochrane Collaboration 
Both  Dr.  Mwinga  and  Dr.  Godfrey-Faussett  attended  workshops  on  methodologies  for 
systematic  reviews  organised  by the  Cochrane Collaboration. 
Partners 
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CHARACTERIZATION OF MYCOBACTERIA FROM  HIV ENDEMIC AREA (TANZANIA) 
Period: 
Co-ordinator: 
Objectives 
March 1  , 1992 - February 28,  1995 
STATENS SERUMINSTITUT, MYCOBACTERIA DEPARTMENT, 
Copenhagen, Denmark (A.B. ANDERSEN) 
To  characterize  and  compare  mycobacteria  isolated  from  H  IV  positive  and  H  IV  negative 
patients.  The  strains  were  to  be  characterized  with  respect  to  species  and  strain 
distribution and  drug  susceptibility profiles.  The information and experience obtained  was 
expected to  contribute to  improved understanding of the following topics: 
•  Are there differences between mycobacteria infecting HIV positive patients compared to 
HIV negative individuals? 
•  How may the phenotype (including drug susceptibility) of mycobacteria be correlated to 
the  genotype as assessed  by RFLP analyses? 
•  How do the Tanzanian mycobacteria compare to mycobacteria isolated in  other parts of 
the world? 
During  the  project  period  the  participating  laboratories  should  develop  close  links  to 
facilitate  scientific  collaboration  and  transfer  of  technology  especially  within  the  field  of 
improved  laboratory diagnostic methods. 
Progress towards objectives 
A total of 400 samples were collected at the Central TB laboratory in  Dar es Salaam from 
patients admitted to the Muhimbili Medical Centre through a 7  -month period from late 1992 
to the beginning of 1993. Clinical  recordings are available for almost 80o/o  of these.  Most 
of  the  samples  originate  from  the  Dar  es  Salaam  area  and  they  all  represent  newly 
diagnosed  cases.  History  of  previous  TB  - if  known  - was  recorded  together  with 
information  on  HIV  status,  sex,  age,  and  drug  regimen.  The  information  obtained  was 
entered  in  an  anonymized  data  base  at  SSI  in  Copenhagen  together  with  the  data 
regarding  the  microbiological  strain  characteristics. 
During  the  same  time  period  a  similar  data  base  was  established  containing  data 
regarding  all  bacteriologically verified  new TB cases  in  Denmark during  1992. 
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Results 
The  risk  of  infection  with  a particular clone  of M.  tuberculosis as  assessed  by  genotype 
analyses  or phenotype  analyses appeared  not to  be  influenced  by the  HIV status  of the 
host. 
The genetic diversity of the Tanzanian  isolates was high,  both  in the  HIV positive and  the 
HIV  negative population. 
A fairly  high  frequency  of  strains  carrying  only  one  (8°/o)  or a few  copies  of  the  186110 
fragment were  observed  in  the Tanzanian  isolates.  In  our Danish  collection  we  have only 
observed  such  strains  imported  by  immigrants.  The  occurrence  of  a sin'gle  or low  (up  to 
five)  186110  elements  per  chromosome  correlated  to  the  phenotypic  appearance  of  the 
Asian  subtype. 
No correlation of RFLP to  resistance to any of the traditional anti TB drugs was observed. 
In both the studies in Tanzania and  in the analyses of strains collected  in  Greenland there 
was  a  clear  correlation  between  geographic  origin  of  the  samples  and  genetically 
relatedness  of the  bacterial  isolates. 
Improved diagnostic methods 
Identification of mycobacteria by monoclonal antibodies 
At KIT a simple enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies 
(MAbs)  for  the  identification  of  cultured  mycobacteria  belonging  to  the  Mycobacterium 
tuberculosis complex,  M.  avium complex,  M.  kansasii and  M.  fortuitum  was  established. 
This  method  may represent  a useful  and  cost-effective  alternative to  traditional  microbio-
logical  typing  methods.  Results  of  microbiological  identification  were  compared  with  the 
ELISA identification. 
RFLP on non-cultivable samples or on clinical samples 
The  RFLP  in  its  present format  is  dependent on  the  availability of  pure  cultures/colonies 
in  order  to  obtain  enough  DNA  for  a  Southern  blot.  In  this  project  and  also  in  other 
situations  it  would  be  preferable  if  the  technique  could  be  adapted  to  a  PCR  based 
method. Thereby it  would  be  possible to analyze old,  dead cultures.  It would  also reduce 
the  time  needed for each  sample,  which  in  turn  would  make the method more applicable 
to  clinical  use. 
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Spoligotyping (fingerprint PCR) 
The  group  at  KIT  collaborated  with  Dr.  J.D.A.  Van  Embden  and  his  group  on  the 
development of the spoligotyping of M.  tuberculosis strains (Kamerbeek et al.,  submitted). 
Spoligotyping is based on  the DNA polymorphism at a unique locus in  the  M.  tuberculosis 
chromosome. The locus contains multiple 36 base pair Direct Repeats (DRs),  interspersed 
by  non-repetitive  spacer  sequences,  34-41  base  pairs  in  length.  Since  the  DRs  are 
extremely  well  conserved  among  M.  tuberculosis  strains,  each  DR  copy  is  a target  for 
PCR. Two  DR primers were chosen, which permitted in vitro amplification of the whole DR 
region,  including  the  interspersed  spacers.  The  typing  method  relies  on  determining  the 
presence or absence  of spacers  in  the  in  vitro amplified  DNA by  hybridisation to  multiple 
synthetic spacer oligonucleotides,  which  are  covalently bound  to  a filter. 
58 Contract number TS3*CT910034 
Partners 
Statens Seruminstitut 
Artillerivej 5 
Copenhagen 2300 S 
Denmark 
Central TB Laboratory 
National Institute for Medical Research 
P.O.  Box 3436 
Dar-es-Salaam 
Tanzania 
N.H. Swellengrebel Laboratory of Tropical 
Hygiene 
Royal Tropical Institute 
Meibergdreef 39 
Amsterdam  11 050 AZ 
The Netherlands 
National Institute of Public Health and 
Environmental Protection 
A.  van Leeuwenhoeklaan 9 
Bilthoven 3720 BA 
The Netherlands 
A.B. Andersen 
Tel:  +45/32/68.37.31 
Fax: +45/32/68.38.  71 
I.M. Mtoni 
A.  Kolk 
Tel:  +31/20/568.87.11 
Fax: +31/20/668.45.79 
E-mail: bo@mail.support.nl 
J. van Embden 
Tel:  +31/30/74.21.13 
Fax: +31/30/29.29.57 
E-mail: jda.van.embden@ rivm.nl 
59 Contract number TS3*CT930254 
DETRIMENTAL EFFECTS OF TB ON  NATURAL HISTORY OF  HIV INFECTION:  VIRAL 
LOAD, IMMUNE  FUNCTION  AND APOPTOSIS 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994 - December 31,  1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPT OF CLINICAL SCIENCES 
London,  United Kingdom (H.  DOCKRELL) 
Using  clinical  material  from  patients  infected  with  both  M.  tuberculosis and  HIV,  we  aim 
to: 
Measure HIV viral  load with  immune function,  including CD4 counts,  lymphocyte prolifera-
tion  in  response  to  nitrogen  and  recall  antigens,  cytotoxicity  mediated  by  CD4  T  cells, 
cytokine  production  and T cell  susceptibility to  apoptosis. 
Activities 
*  A functional  immunology laboratory has  been  established  at the  Institute de Higiene e 
Medicina  Tropical,  allowing  lymphocyte  proliferation  assays  and  ELISA  assays  for 
cytokines  to  be  performed.  Over  140  patients  with  tuberculosis  and  with/without  HIV 
infection  have  now been  recruited  to the study. 
*  Two  PhD  students  are  being  trained  through  this  project  in  Birmingham  and  in  the 
Gambia.  Over twelve exchange visits to learn new techniques and to discuss progress 
have  been  made between  the  partners to  date. 
Results 
In  London,  live  M.  bovis BCG  has  been  shown  to  activate  more  DCB+T  cells than  dead 
BCG,  or PPD,  and  these  DCB+  T cells can  act as cytolytic effector cells. 
In Birmingham, a range of techniques for assessing apoptosis within cells in suspension or 
within tissues,  have been  established.  Lymph  node sections from tuberculous granulomas 
contained  a  greater  number  of  apoptotic  cells  than  those  from  reactive  lymph  nodes, 
showing that apoptosis is a prominent feature of tuberculosis lesions in  immunocompetent 
subjects. 
In  Lisbon,  lymphocyte  proliferation  tests  showed  decreased  responses  to  mycobacterial 
antigens  in  patients  with  tuberculosis  compared  to  controls.  Of  the  antigens  tested,  the 
strongest  IFN-y  cytokine  responses  were  induced  by  a  short  term  culture  filtrate  of 
M.  tuberculosis. 
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In the Gambia, follow up studies on  patients with tuberculosis alone have been carried out 
before  and  after two  months  of anti-tuberculosis during therapy.  Apoptosis,  as  measured 
by  the  ethidium  bromide  method,  induced  by  PPD,  was  greater in  patients with  dual  TB 
and  HIV  infections  than  in  those  with  TB  alone,  and  was  primarily  occurring  within  the 
CD4+  T  cell  subpopulation.  Cytotoxicity  assays  have  shown  depressed  responses  in 
patients with  tuberculosis compared  to  controls,  with  no  recovery of CTL function  at two 
months. 
Techniques  for  the  measurement  of  HIV-1  and  HIV-2  proviral  load  in  peripheral  blood 
mononuclear cells  have  now been  established,  and assays for plasma RNA Load  will  be 
functional  in  the  near future.  Recruitment of patients with  dual  tuberculosis  and  HIV-1  or 
HIV-2  infections  is  continuing;  samples  are  being  collected  before  anti-tuberculosis  drug 
therapy,  and  after two months of treatment,  and stored  for quantitation of viral  load. 
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TUBERCULOSIS CONTROL IN  AN  URBAN AREA WITH  HIGH  TBIHIV PREVALENCE 
Period: 
Co-ordinator: 
Objectives 
October 1, 1996- September 30,  1999 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
London,  United Kingdom (J.  PORTER) 
+  To  develop capacity for action  research  in  support of urban TB control. 
+ To  develop and evaluate interventions,  through  action  research. 
+  To  assess and document the pros and cons of different methodologies used. 
Activities 
*  To  provide training opportunities and technical support to those involved in TB control in 
the area of action  research. 
*  To  quantify the transition  coefficients used  in  the  Piot model  in  Lusaka  Urban  District. 
*  To  identify  and  explore  service,  patient  and  community  factors  that  determine  these 
coefficients. 
*  To  validate data collected  routinely by the  national TB control  programme. 
*  To  investigate ways to rationalise and assure quality in the use of laboratory services at 
both  reference and  peripheral  health facilities. 
*  To document the practical advantages and disadvantages of the different methodologies 
used  in  the  action  research  and  to  disseminate  these  for  use  by  TB  control  pro-
grammes in  other countries. 
Expected outcome 
~To  enhance the understanding of participatory research as applied to urban TB control. 
~  National or regional  conference for dissemination of results. 
~Workshops involving TB  programme  managers,  health  care  providers,  representatives 
of target groups for the  reformulation  of sustainable TB recommendations. 
~Workshops and  meetings with  policy makers. 
~  Scientific articles written  up  and published. 
~Manuals written  on  TB  control  to  identify and  prioritise the problem. 
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A  COMPREHENSIVE  INVESTIGATION  OF  ADVANCED  METHODS  IN  MOLECULAR 
BIOLOGY FOR  THE  DETECTION  OF  M.  TUBERCULOSIS AND  M.  LEPRAE 
Period: 
Co-ordinator: 
Objectives 
April 1992 - April 1995 
KONINKLIJK INSTITUUT VOOR DE TROPEN,  DEPT OF 
BIOMEDICAL RESEARCH 
Amsterdam, The Netherlands (A.H.J. KOLK) 
Comparison  of the  results  of conventional  and  novel  molecular technology for: 
•  The  detection. of  tuberculosis  and  leprosy patients. 
•  The  monitoring  of mycobacterial viability  in  tuberculosis and  leprosy patients. 
•  The  determination  of  M.  tuberculosis  infection  among  household  contacts  of  newly 
diagnosed tuberculosis patients  in  a prospective study. 
Activities 
Tuberculosis patients, household contacts and controls were sampled in Thailand,  Portugal 
and  The  Netherlands.  Microscopy,  culture  and  typing  were  performed  according  to 
standard procedures. Leprosy patients will be sampled from  outpatients clinics in Thailand. 
Clinical,  bacteriological  and  histopathological  assessment  of  the  newly  diagnosed  un-
treated  patients  were  done  according  to  standard  methods.  PCR  for the  detection  of  M. 
tuberculosis  DNA  and  M.  leprae  DNA  were  performed  as  previously  described.  PCR 
methodology for the  detection  of  amplified  DNA  and  RNA were  optimized  in  Amsterdam 
and  introduced  in  Bangkok and  Porto. 
Results 
ad  1  Scientists  and  technicians  from  Thailand  and  Portugal  were  trained  in  the  PCR 
technique  and  subsequently they  introduced  the  PCR  technique  in  their  own  laboratory. 
The  PCR  was further improved with  regard  to  quality control,  prevention of contamination 
and  detection  of  inhibitors.  In  addition  simple  methods  were  developed  for  detection, 
identification  and  quantification  of the  amplified  DNA both  for  M.  leprae and  M.  tubercu-
losis.  We  investigated  the  use  of  different clinical  specimens  for their applicability  in  the 
PCR.  We  found  that  (in  the  order  of  effectiveness)  spontaneous  sputum,  induced 
sputum,  throat swabs  and  nose  swabs  can  be  used  for the  detection  of  M.  tuberculosis 
using  the  PCR  technique.  M.  tuberculosis  was  only  detectable  in  the  nose  and  throat 
swabs  from  patients  with  clearly  ZN-positive  pulmonary TB  and  in  some  contacts  of TB 
patients. 
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We  have developed a cough  filter to simplify sampling of suspected  infectious pulmonary 
TB  patients which  may be  used  in  mass screening  programmes. 
We  have  developed  a  colorimetric  method  for  the  rapid  detection  and  identification  of 
amplified  M.  leprae  DNA  from  skin  biopsies  and  M.  tuberculosis  DNA  from  sputum 
samples.  We  also  designed  a  colorimetric  assay  based  on  streptavidin-coated  beads  or 
plates to  detect biotinylated  PCR  products with  a digoxiginin-labelled  detector probe.  We 
have  demonstrated that  PCR  is  a useful  technique for the  rapid  diagnosis of  pulmonary 
and  extra-pulmonary tuberculosis.  In  all  three  laboratories  a large  number of samples  of 
both  pulmonary and  extrapulmonary origin  were tested  in  PCR.  With  pulmonary samples, 
the  sensitivity of the  PCR  compared  with  culture  varied  from  96o/o  - 78o/o,  the  specificity 
from  90o/o  - 76o/o.  For the extrapulmonary samples the sensitivity varied from  1  OOo/o  - 44o/o, 
and  from  88o/o  - 83o/o  for the  specificity. 
PCR amplification of the 531-b fragment of the M.  leprae gene in fresh biopsy and slit skin 
smear specimens was evaluated for its usefulness in the detection of M.  leprae in patients 
in  Thailand.  Compared with  other diagnostic procedures,  PCR  showed a clear advantage 
in terms of sensitivity and specificity over both  microscopic examination of slit skin smears 
and  serologic detection,  especially in  paucibacillary patients. 
We  have  further  improved  and  standardized  the  NASBA  for  the  detection  of  the  M. 
tuberculosis complex in  clinical specimens. The NASBA had a similar sensitivity to culture 
when  applied  to  specimens  derived  from  20  pulmonary tuberculosis  patients.  The  sensi-
tivity of  NASBA was  lower than  culture  when  testing  extrapulmonary samples. 
All  58  control  specimens from  patients with  other diseases were  negative  in  NASBA and 
culture. 
ad  2  We  have  shown  that  PCR  can  be  used  for  the  follow-up  of  patients  during 
anti-tuberculous  treatment.  Since  PCR  detects  DNA,  it  can  detect  both  dead  and  alive 
bacteria provided the DNA is still  intact. This enables one to confirm a clinical diagnosis of 
tuberculosis  when  microscopy  is  negative.  All  three  laboratories found  the  same  results, 
suggesting that persisting  PCR  positivity,  more than 4 months after the start of treatment, 
should  raise  the question  of non-compliance or drug-resistance. 
We  have shown that NASBA for the detection of RNA can  be  used to assess the viability 
of mycobacteria in  vitro as well as  in  vivo.  Both  PCR and NASBA were evaluated for their 
potential  to  help  monitor bacterial  clearance  in  leprosy  patients  during  chemotherapeutic 
treatment. The results on  skin samples (smears and  biopsies) collected during the course 
of  chemotherapy  showed  that  the  number  of  PCR  or  NASBA  positive  cases  of  both 
multicabillary and  paucibacillary types decreased  sequentially. 
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The  morphology  of  the  mycobacteria  in  skin  biopsies  as  indicator  for  viability  was 
compared with the  NASBA-signals: the  presence of solidly stained mycobateria resulted  in 
strong  positive  NASBA signals,  while  fragmented  or granular  stained  M.  leprae  bacteria 
showed  a  variable  range  of  NASBA  signals,  including  negative  results.  No  relation 
between  the  NASBA results  and  the  bacterial  load  could  be  found. 
The  wide  range  of  NASBA  signals  observed  within  each  bacterial  index  (BI)  group 
reflected  most likely the  number of viable cells present,  rather than  both  dead  and  viable 
bacteria. Apparently,  the  presence of 168 rRNA in  skin  biopsies  of  leprosy patients  might 
be  indicative for the  efficacy of  therapy  of  leprosy patients. 
ad 3 Households contacts were studied in  Bangkok,  Porto and Amsterdam. A positive nose 
swab  could  arise from  inhaling aerosol  droplets containing  M.  tuberculosis from  the  index 
case and does not necessarily mean that the individual has an  active infection. Laboratory 
experiments  in  the  KIT  have  shown  that  mycobacteria  are  detectable  in  the  nose  of 
contaminated  individuals  (laboratory  workers  that  worked  with  heat  killed  M.  bovis BCG) 
for only a short time (3- 5 days).  In Amsterdam the household contacts were traced by the 
Municipal Health Centre. The samples from these contacts were collected at least 2 weeks 
after  the  index  patients  were  diagnosed  and  had  started  treatment.  The  relatively  long 
interval  between  start  of  treatment  and  sample  collection  in  household  contacts  may  be 
one  of the  reasons  why all  other nose swabs from  these contacts were  negative in  PCR. 
In  Porto and  Bangkok contacts and  patients were  tested  at the  same time;  there  was  no 
delay  between  the  diagnosis  of the  index  case  and  taking  the  induced  sputum  from  the 
household  contact. 
In  Porto  52o/o  of  the  27 household  contacts  had  PCR-positive  induced  sputum  samples, 
two  proved  to  be  TB  patients  since  both  microscopy  and  culture  were  positive.  One 
PCR-positive  contact  was  later  diagnosed  as  a  TB  patient  based  on  additional  clinical 
grounds. The other positive contacts were  not further investigated. At the TB  Division  15 of 
111  contacts  were  positive  in  PCR.  None  of  these  individuals was  treated  for TB. 
All  participants agreed that much  was  gained from  the project both  individually and  by the 
local  laboratory where the  PCR  is  now done.  Given  current cost constraints  in  the  health 
system,  it is unlikely that most laboratories will  be able to do both nucleic acid amplification 
and  culture  routinely all  samples.  Each  diagnostic centre will  have to  evaluate for its own 
patient population and  economic situation both  cost effectiveness and cost benefits of the 
available  diagnostic techniques. 
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MUCOSAL IMMUNITY AND  LEPROSY 
Period: 
Co-ordinator: 
Objectives 
November 1, 1992-April 30, 1995 
UNIVERSITY OF LONDON/INST. OF OPHTHALMOLOGY 
London,  United Kingdom (I.A.  CREE) 
The  primary aim  was  to  develop  and  use  a mucosal  challenge test to  compare  mucosal 
immunity  to  M.  leprae  with  evidence  of  infection  in  an  endemic  area  with  a  good 
MOT-based  control  programme.  The  aims  were  further defined  in  the  original  1991  grant 
application  as  follows: 
+  To  develop  a  mucosal  challenge  test  for  investigation  of  mucosal  cell-mediated  and 
humoral  immune  responses  to  M.  leprae. 
+ To  determine  which  mycobacterial  antigens  are  involved  in  the  mucosal  immune 
response  and  whether they might be  associated  with  protection  against  leprosy. 
+  To  investigate  the  suitability  of  modified  antigen  and  DNA  detection  methods  for  the 
early diagnosis of  leprosy. 
Activities 
To  accomplish  our aims,  we  had  first  to  establish  a mucosal  challenge  test  and  confirm 
that the mucosal immune response to  M.  leprae was  specific and  long-lasting. The  results 
of the challenge test development showed that an  anamnestic mucosal  immune  response 
occurs in  individuals exposed to  leprosy as  long as  1  0 years post-exposure.  No  response 
was  observed  in  those living  in  a non-endemic country and with  no  history of travel to  an 
endemic country. 
Having  shown  the  feasibility  and  safety  of  the  mucosal  challenge  test,  we  went  on  to 
survey  groups  of  leprosy  patients,  contacts  and  the  general  population  for  both  their 
salivary lgA response  to  M.  leprae (MLigA)  and  nasal  PCR  positivity. 
Results 
A total  of 304 subjects were  enrolled in  the first study:  PCR  and  mucosal  challenge tests 
were  performed  in  204  of  these  individuals.  MLigA  was  present  before  and/or  after 
challenge in  66% of treated patients, 76°/o of leprosy workers and 72% of healthy contacts. 
This  is  similar  to  previous  studies  in  Bangladesh  and  Fiji  which  predate  MDT  control 
programmes  (Cree  et  al.,  1988).  However,  only  33°/o  of  local  control  subjects  with  no 
known  exposure  to  leprosy  were  MLigA+  in  contrast  with  earlier  studies  showing  74o/o 
positivity among  local  controls  in  an  area  without  good  leprosy control. 
There  was  evidence  of  continuing  transmission  of  M.  leprae  in  both  household  contacts 
(2°/o  PCR+)  and  local  controls  (5o/o  PCR+).  PCR+  subjects were  either MLigA positive  or 
negative.  In  a  subsequent  follow-up  study,  nasal  swabs  were  taken  from  97  of  those 
studied in the first series: of three PCR+ individuals followed up after one year,  all became 
negative,  while  of  the  remaining  94 PCR- individuals  retested,  2 became  positive.  A total 
of 112 subjects were  retested with  the  mucosal challenge test:  22 converted from  positive 
to  negative  and  12 from  negative to  positive. 
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In  addition,  saliva  samples  were  tested  for  the  presence  of  ML-IgM  and  lgM  and  lgA 
anti-LAM,  and  total  lgA.  Serum  samples  were  tested  for  lgG,  lgM  and  lgA anti-whole  M 
leprae,  anti-LAM  and  anti-PGL  1 (BSA glyconjugate).  The  results  are  still  being  analyzed, 
but appear to  support the  PCR  and  MLigA data. 
Outcome 
The implications of these results should provoke some debate. Sub-clinical transmission of 
M.  leprae  explains  the  current  lack  of  effect  of  MDT  control  programmes  on  incidence 
despite the sustained drop in  prevalence of active disease. Despite this, there is a general 
reduction  in  general  population  immunity.  This  suggests  that  relaxation  of  MDT  control 
would lead to a recrudescence of disease as the non-immune population became infected. 
However,  partly  as  a  result  of  this  project,  we  can  now  detect  clusters  of  infection. 
Prophylactic  antibiotic  therapy  of all  individuals  in  these  clusters  would  reduce  transmis-
sion,  perhaps  to  the  point  where  eradication  rather  than  elimination  of  leprosy  became 
feasible. 
Final  analyse are  now being  performed. 
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IMMUNOLOGICAL AND MOLECULAR ANALYSIS OF LYMPHOCYTES AND ANTIGENS 
INVOLVED IN  LEPROSY (NEURITIC) LESIONS 
Period: 
Co-ordinator: 
Objectives 
April  1, 1993-March 31,  1996 
RIJKSUNIVERSITEIT LEIDEN,  DEPT. OF IMMUNOHEMATOLOGY 
& BLOOD BANK, Leiden, The Netherlands (T.  OTTENHOF) 
The objective of this project is to gain novel and  practical insights into the pathogenesis of 
leprosy lesions,  particularly leprosy nerve  lesions,  in  order to  be  able to: 
•  design specific and effective measures to prevent and treat nerve damage in  leprosy as 
well  as  to 
+  identify  antigens  that  may  be  useful  for  the  early  detection  of  neuritis  or  neuritis-
susceptible  individuals. 
Activities 
Protective  immunity against  Mycobacteria is  dependent on  T lymphocytes.  T cells  recog-
nize mycobacterial antigens as peptides bound to  major histocompatibility complex (MHC) 
molecules  on  the  surface  of  antigen  presenting  cells.  T  cells  can  exert  many  different 
effector  functions,  sometimes  resulting  in  immunopathology  as  seen  in  granulomatous 
leprosy  lesions  with  high  local  cell  mediated  immune  reactions.  Leprosy  predominantly 
affects  skin  and  nerves.  Irreversible  damage  to  nerves  is  the  most  severe  clinical 
complication of the disease and occurs particularly during reversal  reactions. This study of 
immunopathology of leprosy may lead to measures to control and prevent nerve reactions. 
The local immune response in  leprosy skin and nerve lesions will be studied, including the 
potential  involvement of autoantigens. 
This  project will  investigate  lymphocytes and  M.  leprae antigens that  may  be  involved  in 
acute  leprosy lesions,  using  a variety of  molecular and  cellular techniques. 
*  To  isolate and  clone  lesion  infiltrating T cells from  (diagnostic)  skin  and  nerve biopsies 
from  acute  leprosy  lesions and  to  characterize these T cells  with  regard  to  specificity, 
(antigen/MHC),  phenotype  (also TCR  usage)  and  function  (cytokine  release,  cytotoxic-
ity). 
*  To  isolate DNA clones from a Xgt11  M.  leprae expression library with  sera from  leprosy 
patients  with  acute  (nerve)  reactions,  and  to  analyze  whether  such  antigens  are 
associated with  neuritis by comparing them with recombinant antigens detected by sera 
from  other  leprosy  patients'  groups.  These  antigens  will  also  be  analyzed  for  T  cell 
stimulation. 
*  To  study whether these same sera directly recognize neural autoantigens (Western blot 
of peripheral nerves; a Schwann cell  gene library will be constructed) and whether such 
antigens are  also seen  by  autoreactive cells. 
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Expected outcome 
=>  Isolation  of  T  cells  from  leprosy  (neuritis)  lesions  and  defining  them  with  respect  to 
antigen  specificity,  function  and  membrane phenotype. 
=>  Several  M.  leprae or auto-antigens  will  be  molecularly and  immunologically character-
ized.  From both  1) and 2)  it may be  possible to identify antigens and/or T cells that are 
specifically associated  with  leprosy (neuritis)  lesions. 
Results 
T cells  have  been  isolated  from  several  nerve  biopsies  from  leprosy  patients  in  reversal 
reaction as well as from skin biopsies. All  biopsies were taken strictly for routine diagnostic 
purposes and  only a portion  of the  material  was  used  for research  purposes. 
A small  piece  (3-6  mm)  of the  radiocutaneous  or sural  nerve  was  dissected,  peripheral 
blood  lymphocytes  removed  and  freed  of surrounding  fibrous  tissue.  Tissue  lymphocytes 
were isolated over a Ficoll  gradient.  Preliminary analyses show the presence of Mycobac-
terium leprae reactive T cells  in  nerve biopsies under limiting dilution conditions.  Differen-
tial  expression of a number of adhesion molecules as well as T cell  receptor determinants 
has  been  observed  among  nerve  infiltrating  T  lymphocytes  as  compared  to  peripheral 
blood  derived  lymphocytes. 
From  some  biopsies,  Schwann  cells  could  be  cultured  using  a  newly designed  protocol. 
These  cells  are  currently  under  study  with  regard  to  (i)  their  capacity  to  act  as 
non-professional antigen  presenting cells in  leprosy reactions,  and  (ii)  their recognition  by 
sera from  reactional  leprosy cases  which  have  been  followed  longitudinally. 
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DNA  TYPING  OF  M.  TUBERCULOSIS:  EPIDEMIOLOGY  AND  EVALUATION  OF 
CHEMOTHERAPY 
Period: 
Co-ordinator: 
Objectives 
April  1  , 1993 - September 30,  1995 
NAT.  INST. OF PUBLIC HEALTH AND ENV.  PROT.,  UNIT 
MOLECULAR BIOLOGY 
Bilthoven, The Netherlands (J.  VAN  EMBDEN) 
The  objectives of this study were: 
•  To  develop  and  implement a highly  reproducible  DNA fingerprint typing  system  for  M. 
tuberculosis and  a system  for computer-assisted  analysis. 
•  The  establishment  of  a  database  of  DNA  types  of  hundreds  of  strains  from  Africa, 
Pakistan  and  the  Netherlands for future  epidemiological  purposes. 
•  To  determine whether unsuccessful chemotherapy of tuberculosis is  due to  inadequate 
therapy or by  reinfection  by  different  M.  tuberculosis strains. 
•  To  transfer  the  DNA  technology  for  molecular  diagnosis  of  tuberculosis  and  DNA 
fingerprinting  to Antwerp  and  Karachi. 
In  Bilthoven a robust and reproducible method has been developed to differentiate isolates 
of  M.  tuberculosis  which  allow  interlaboratory  comparison.  For  this  purpose  a  robust 
protocol  for  186110  fingerprinting  has  been  developed  and  this  protocol  has  been  used 
successfully by the three partners in  this project.  DNA fingerprints (generated  in  Bilthoven 
Antwerp and  Karachi) from  M.  tuberculosis isolated in Africa, Asia and Europe showed that 
transmission  within  and  among  countries  can  be  traced  using  this  method,  without  the 
need to carry out the experiments in  a single  laboratory. This now opens the prospect for 
a global  epidemiology of tuberculosis. This may be  of particular use as  an  early warming 
system  to trace the  dissemination  of  multiple drug-resistant M.  tuberculosis. 
By  18611 0  fingerprinting  many  M.  tuberculosis  strains  we  have  been  able  to  define 
genotypic  groups  ("clades")  of  M.  tuberculosis,  which  are  also  related  when  using  other 
independent  other  genetic  markers.  The  prevalence  of  these  genotypes  differs  strongly 
from  country to country and  the  genotyping  may be  useful  in  tracing  the  global  dissemi-
nation  of  M.  tuberculosis. 
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Strain typing of M.  tuberculosis isolated during chemotherapy disclosed that fingerprinting 
is a powerful method to monitor the efficacy of drug treatment by being able to distinguish 
between  reinfection  and  breakdown  from  a  previously  acquired  infection.  In  Bilthoven  a 
PCR-based  method  was  developed  to  simultaneously  detect  and  type  M.  tuberculosis 
complex bacteria  in  clinical  specimens,  which  also can  be  used  to  detect M.  bovis BCG 
from  diseased vaccinees. 
Much  of  the  technology  developed  in  Bilthoven  has  been  transferred  to  Antwerp  and 
Karachi,  by exchange of  researchers and  meetings. The  DNA typing  methods have been 
described  in  standard  protocols,  which  have  either been  published  or are  available  as  a 
protocol from  the  RIVM. 
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RAPID  DETECTION OF MULTIDRUG-RESISTANT MYCOBACTERIA 
Period: 
Co-ordinator: 
Objectives 
January 1,  1994 - December 31,  1995 
INSTITUT PASTEUR PARIS, UNITE DE GENETIQUE 
MOLECULAIRE BACTERIENNE, Paris, France (S.  COLE) 
Long term  &  general  goals: 
+  Elucidation of the molecular bases of drug-resistance in  Mycobacterium  tuberculosis. 
+  Development of rapid  methods for detection of drug resistance. 
Specific goals: 
•  Development  of  a  standard  protocol  for  performing  polymerase  chain  reaction-single 
stranded  conformation  polymorphism  (PCR-SSCP)  analysis  of genes  associated  with 
resistance  to  isoniazid,  rifampicin  and  streptomycin.  Prospective  study of drug  resist-
ance in  which the results obtained by PCR-SSCP were compared with those obtained 
by the proportion  method. 
+  Elucidation of the molecular basis of pyrazinamide and ethambutol  resistance. 
+  Implementation of molecular detection strategies in  clinical  and  reference  laboratories. 
Results 
The aim  of this  project was to study the  genes of  Mycobacterium  tuberculosis encoding 
the  targets  of  front-line  anti-tuberculous  drugs,  to  elucidate  the  molecular  basis  of 
drug-resistance,  and  to  use  the  genotypic  information  obtained  for  the  development  of 
rapid  molecular tests capable of predicting  phenotype.  Considerable progress was  made 
towards understanding the resistance mechanisms to fluoroquinolones and ethambutol and 
further insight into the well-established mechanism of resistance to isoniazid was obtained. 
Resistance  to  isoniazid,  rifampicin  and  streptomycin  results  from  alterations  to  key 
chromosomal  genes  and  can  be  readily  detected  by  means  of  DNA  sequencing  or 
PCR-SSCP analysis of selected  mutational  hotspots. A standardised  PCR-SSCP protocol 
for the detection of isoniazid,  rifampicin,  and  streptomycin  resistance was developed and 
optimised. A blind, prospective, longitudinal study was then conducted in  which the results 
obtained  by  PCR-SSCP  of  cultured  samples  of  M.  tuberculosis,  from  ±1 00  specimens 
obtained  from  recent  tuberculosis  cases,  were  compared  with  the  drug  susceptibility 
patterns  established  by  the  generally  accepted  reference  technique,  the  proportion 
method. 
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In  the  case  of  rifampicin,  excellent  sensitivity  and  specificity  were  observed,  and  the 
results  were  concordant  for  99o/o  of  the  samples.  Furthermore,  identical  results  were 
obtained  by  a  second-generation  molecular  test  for  drug  susceptibility  employing  solid-
phase  reverse  hybridization.  For  87°/o  of the strains,  good  agreement was  seen  between 
the  isoniazid  resistance  profiles predicted  by  PCR-SSCP and  those  determined  microbio-
logically.  The  difference  between  the  two  data-sets  can  probably  be  explained  by  the 
existence of an  additional  minor resistance  mechanism that has  not yet been  uncovered. 
Testing  for  resistance  to  streptomycin  proved  to  be  less  reliable  by  PCR-SSCP  since  a 
significant proportion of resistant isolates was not detected. These were probably resistant 
to  low  levels  of the  drug  (4  mg/ but  30  mg/ml)  and,  again  the  corresponding  resistance 
mechanism  has  not yet been  discovered. 
In  summary,  the  molecular methods  developed  and  evaluated  during  this  project  proved 
robust,  reliable and,  above all, considerably quicker as they allow resistance patterns to be 
determined in  2 days. This compares very favourably with the two-four weeks required for 
conventional  microbiological  procedures. 
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APPROACHES  TO  THE  DIAGNOSIS  OF  ACTIVE  TUBERCULOSIS  BASED  ON  THE 
DETECTION  OF  SPECIFIC  MYCOBACTERIAL COMPONENTS  IN  THE  URINE 
Period: 
Co-ordinator: 
Objectives 
April 1, 1994- March 31, 1996 
UNIVERSITY OF BERGEN, CENTRE FOR INTERNATIONAL HEALTH 
Bergen, Norway (B.  BJORVATN) 
•  To  identify  specific  mycobacterial  components  in  the  urine  of  patients  suffering  from 
tuberculosis. 
+  To  develop an  efficient,  rapid  and  cheap  test for the  detection  of  such  components. 
•  To investigate the practical utility of this test for the diagnosis of tuberculosis under field 
conditions. 
Activities 
*  To  produce the  mycobacterial  liposaccharide lipoarabinomannen (LAM),  and  to  synthe-
size  glycolipids  carrying  the  terminal  trisaccharide  3-0  methylated  Rhap  and  couple 
those  glycolipids to  carrier proteins. 
*  In  preparation for an  appropriate test,  to produce monoclonal and  polyclonal antibodies 
against the above components,  and to study their respective specificity and  prevalence 
among  representative  mycobacterial  isolates. 
*  To  optimize  methods  for  urinary  concentration,  and  to  establish  a  highly  efficient 
immunological  technique  for  studies  on  the  (likely)  urinary  excretion  of  such  compo-
nents,  both  in  relevant  animal  models  and  in  different  groups  of  patients  with 
mycobacterial  disease,  in  particular tuberculosis. 
*  To evaluate the practical utility of the designed assay both  in advanced laboratories and 
in  the  field  setting. 
*  To  provide  adequate training  of young  scientists,  both  in  Europe  and  in  Ethiopia. 
Expected outcome 
Our  research  will  hopefully  result  in  the  development  of  a  reliable,  non-invasive,  simple 
and  cheap  assay for mycobacterial  disease,  in  particular tuberculosis.  This would  imply a 
novel  and  significant contribution  to  the  diagnosis,  and  thereby control  of such  diseases. 
Summary 
Lipoarabinomannan  (LAM)  is  a  major cell  wall  component  common  to  all  mycobacterial 
species and  offers highly interesting possibilities for diagnostic approaches.  For the  last 2 
years  our  network  has  explored  the  idea  that  LAM  excretion  into  the  tissues  of  infected 
individuals may ultimately become detectable in  the  urine.  If so,  efficient detection of  LAM 
in  the  urine  provides  a  novel  approach  to  the  specific  diagnosis  in  patients  with  active 
mycobacterial  disease.  The  results  so  far are  highly encouraging. 
Our main  findings  may  be  summarised as  follows: 
~  LAM  is  excreted  in  the  urine of patients with  mycobacterial  disease. 
~An  indirect  ELISA  based  on  polyclonal  anti-LAM  antibodies  has  been  developed  that 
detects  nanogram  levels of  LAM  in  the  urine. 
~  Promising  preliminary  versions  of  a  "dip  stick"  test  for  LAM-detection  has  been 
developed. 
~The  specificity of the  above  tests  for the  genus  Mycobacteria appears to  be  high. 
~  A large  number  of  anti-LAP  monoclonal  antibodies  are  under  production,  and  await 
screening  for  sensitivity and  specificity,  including  species  specificity,  in  the  above  test 
systems. 
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=>  Limited clinical studies indicate that LAM  regularly (85-90o/o,  or more) is excreted in the 
urine of patients with  active tuberculosis, and that this excretion is significantly reduced 
following  antimycobacterial treatment. 
=>So far,  LAM  has only rarely (5o/o)  been found  in  the  urine of randomly selected healthy 
controls,  or in  patients hospitalised with  other infectious diseases. 
=>  Model systems for TB-infection in  mice have been established permitting i.e.  studies on 
urinary excretion  of LAM  under experimentally standardised conditions. 
=>  Further investigation is needed i.e. concerning optimal pre-assay treatment of the urine, 
choice of inert plastic tubes for storage and transportation of test material, and selection 
of an  optimal  solid phase for the dip-stick test. 
=> A  patent  application  has  been  filed,  and  further  commercial  development  of  this  test 
system will  be undertaken in  collaboration with  an  appropriate European  manufacturer. 
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IMMUNE RECOGNITION OF A NOVEL 45KDA ANTIGEN, SPECIFIC TO  MYCOBACTE-
RIUM LEPRAE, AND  EVALUATION AS A  POTENTIAL VACCINE  CANDIDATE 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1995 - December 31 , 1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
Dept. of Clinical Sciences, London, United Kingdom (H.M. DOCKRELL) 
+  To  compare T cell  recognition  of the  45kDa antigen  in  leprosy  patients,  contacts  and 
controls. 
+ To  identify immunodominant epitopes in  the  45kDa antigen  recognized  by T cells. 
+ To  investigate  whether  immune  recognition  of  the  45kDa  antigen  identifies  leprosy 
patients at  risk of  developing  reactional  complications. 
Activities 
*  To  prepare a panel  of reagents with  which  to  investigate immune  responses to  the  M. 
Jeprae  45kDa  antigen,  including  recombinant  45kDa  protein  and  overlapping  peptides 
spanning  its  sequence. 
*  To  assess  lymphocyte  transformation  and  cytokine  secretion  induced  by  the  45kDa 
antigen T cells from  leprosy patients,  contacts and  endemic controls  in  Mexico. 
*  To  identify immunodominant epitopes in the 45kDa antigen,  using synthetic peptides to 
map  the  epitopes  recognized  by  peripheral  blood  mononuclear  cells  from  leprosy 
patients and  contacts,  and  by  human T cell  clones. 
*  To  screen leprosy patients with/without a history of erythema nodosum leprosum (ENL) 
reactions  for  antibodies  to  the  45kDa  antigen,  and  monitor  a  cohort  of  lepromatous 
leprosy patients for anti-45kDa antibodies and  for development of ENL. 
Expected outcome 
=>These studies will  evaluate the specificity of the  M.  leprae 45kDa antigen as a tool for 
monitoring  M.  /eprae-specific  immune  responses. 
=>The  project  will  allow  transfer  of  cellular  immunology  methodology  to  the  National 
Medical  Centre  in  Mexico City,  with  training  of  Mexican  scientists. 
=>  Field  studies  in  Mexico will  demonstrate whether immune  recognition  of the  M.  leprae 
45kDa antigen  can  be  used  as  a predictive  marker of  ENL  reactions  in  leprosy. 
Results 
Recombinant  M.  leprae  45kDa  antigen  and  a  range  of  control  antigens  have  been 
prepared  by  the group in  Leiden,  as well  as  a panel  of overlapping synthetic peptides for 
epitope  mapping. 
A functional  cellular  immunology  laboratory  has  been  estabHshed  at  Centro  Medico  for 
work on  the cellular immunology of leprosy. 
Lymphocyte  proliferation  assays  and  cytokine  detection  by  ELISA,  as  well  as  ELISA 
assays for antibodies,  can  now be performed,  and the methodology for cytokine detection 
using  RT-PCR  and  for epitope  mapping  of antibody epitopes are  being  set up. 
In London, studies using peripheral blood from healthy BeG-vaccinated donors have shown 
that these donors can make T cell responses to the M. leprae 45kDa antigen, although these 
responses were stronger than  in  donors who had  not received  BCG  vaccination.  We  now 
aim to clone antigen-specific T cells to allow mapping of the epitopes recognized. 
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Normal  donors  showing  T cell  proliferation  to  the  M.  leprae 45kDa  antigen  also  showed 
parallel  secretion  of  the  Th1  cytokine,  interferon-gamma.  Studies  using  blood  samples 
from  leprosy patients are  now being  tested  in  London,  comparing  mANA detection  using 
RT-PCR  and  cytokine  product by ELISA. 
In  Mexico,  lymphocyte  proliferation  assays  have  been  performed  with  peripheral  blood 
samples  from  patients  with  lepromatous  leprosy,  and  their  household  contacts.  Results 
show that  58.6o/o  of the  lepromatous  leprosy patients  (n=29)  responded  to  the  M.  leprae 
45kDa  antigen,  with  higher  responses  in  donors  also  showing  a  positive  response  to  a 
sonicate  of  M.  leprae.  Additional  tuberculoid  leprosy  patients  and  endemic  controls  are 
being  recruited  to  extend  this  analysis.  The  M.  leprae  45kDa  antigen  also  induced  good 
interferon-gamma from  ±65o/o  of both  tuberculoid and  lepromatous leprosy patients,  when 
tested  in  a whole  blood  cytokine  assay. 
Overall the  results obtained to date suggest that M.  /eprae  45kDa antigen  induces strong 
Th 1 T cell responses.  However it seems that at least some epitopes may be recognized by 
T  cells  from  donors  not  exposed  to  leprosy,  suggesting  the  presence  of  some  cross-
reactive  epitopes. 
Training activities to date include visits of two members of Professor Vega-Lopez' group to 
the  London  School  of Hygiene  & Tropical  Medicine for visits  of  1 and  4 months to  learn 
methodology  for  RT-PCR  and  T  cell  cloning,  and  a  1  month  visit  of  a  member  of  Dr. 
Dockrell's laboratory to  Mexico to  help set  up  the T cell  work there. 
Partners 
London School of Hygiene and Tropical 
Medicine 
Dep. of Clinical Sciences 
Keppel Street 
WC1 E 7HT London 
United Kingdom 
Rijksuniversiteit Leiden 
Dep. of Immunohematology & Blood Bank 
Univ.  Hospital 
Building 1  E3-Q 
P.O.  Box 9600 
Lei den 
The Netherlands 
Institute Mexicano del Seguro Social 
Dept. de Dermatologia & Micologia Medical 
Ave.  Cuauhtemoc 330 
Colonia Doctores 
Mexico D.F. 
Mexico 
H.M. Cockrell 
Tel:  +44/171/927.22.56 
Fax: +44/171/637.43.14 
E-mail: h.dockrell@ lshtm.ac 
R.R.P.  De Vries 
Tel:  + 31n1/26.38.00 
Fax: +31n1/21.67.51 
E-mail: pdvries@ab.dlo.nl 
F.  Vega-Lopez 
Tel: +52/5/687.51.57 
Fax: +5215/761.74.07 
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PEPTI  DES  FOR  THE  EARLY DETECTION AND VACCINATION AGAINST 
TUBERCULOSIS AND  LEPROSY 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1995 - December 31 , 1996 
MAC CLINICAL SCIENCES CENTER, TUBERCULOSIS & REL. 
INFECT.  UNIT,  London,  United Kingdom (J.  IVANYI) 
Development of peptide  based  reagents for the early detection of disease: 
•  lmmunodiagnosis of  active tuberculosis  (TB); 
•  lmmunodiagnosis of tuberculosis  leprosy and  type  I reactions; 
•  Formulation  of peptides for skin  testing  using  liposomes. 
Design  of subunit vaccines against tuberculosis involving: 
•  Identification  and  characterization  of  genetically  permissive  petpides  recognized  by 
human  CD4  & CE8 T cells; 
•  Formulatio  n of protective forms  of antigen  delivery,  i.e.  adjuvants,  DNA plasmids; 
•  Characterisation  of the cytokine profiles of protective T cells. 
Activities 
*  Development  of  robust  in  vitro  assays  and  training  of  staff  from  India  for  testing 
anti-peptides T cell  responses  in  bulk cultures,  T cell  lines and T cell  clones. Assay of 
HLA restrictions. 
*  Testing  of  a  short-list  of  HLA  permissive  mycobacterial  peptides  for their capacity  to 
stimulate  the  proliferation  of  blood  lymphocytes  in  sensitized  healthy subjects  and  TB 
patients from  India. 
*  Identification  and  characterization  of  integral  membrane  protein  constituents  of myco-
bacteria. 
*  Construction  of  mycobacterial  peptides  containing  liposomes  and  analysis  of  their 
immunogenicity. 
*  Evaluation of cytokine profiles of peptide reactive T cells from TB patients in the course 
of chemotherapy. 
Results so far 
=>Analysis  of  variants  with  single  substitutions  in  one  epitope  core  showed  distinct 
conformations for HLA-DR1  and  BRB5*01 01  (Jurcevic et al.,  International  Immunology, 
in  press). 
=>Analysis ofT cell responses to a mixture of mycobacterial peptides with complementary 
HLA-DR  binding  profiles  showed  merely  a  weak  additive  effect  (Jurcevic  et  al.,  Clin 
Exp.  lmmunol,  in  press). 
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=>  Synthetic  peptides  non-covalently  bound  to  bacterial  hsp  70  were  shown  to  have 
enhanced T cell  immunogenicity (Roman  & Moreno,  Immunology 88:487,  1996). 
=>  Peptides overlapping the sequence of the 35 kDa protein of M.  leprae were character-
ized for binding to several HLA-DR molecules. Subsequently, immunodominant peptides 
were  identified  on  the  basis  of T cell  responses  in  leprosy patients  and  endemic  and 
non-endemic healthy subjects. 
=> Testing  of  peptides  eluted  from  HLA-DR  molecules  of  a  B.  lymphoblastoid  cell  line 
incubated with  or without a mycobacterial  extract indicated  distinct HPLC  profiles. 
Partners 
MRC Clinical Sciences Centre 
Tuberculosis & Rei.  Infect. Unit 
Hammersmith Hospital 
W12 ONN London 
United Kingdom 
Karolinska Institute 
Microbiology & Tumor Biology Centre 
Box 280 
S-171  77 Stockholm 
Sweden 
Rijksuniversiteit Leiden 
Dep. of Immunohematology & Blood Bank 
Univ.  Hospital 
Building 1  E3-Q 
P.O.  Boxe 9600 
2300 Leiden 
The Netherlands 
Central Jalma Institute for Leprosy 
Immunology Division 
282001  Agra, Taj  Ganj 
India 
National Institute of Immunology 
Microbiology Division 
Aruna Asaf Ali Marg 
110067 New Delhi 
India 
Central Drug Research Institute 
Division of Microbiology 
226001  Lucknow 
India 
J. Ivanyi 
Tel:  +44/181/740.31.61 
Fax: +44/181/743.85.36 
E-mail: j.ivanyi@ rpms.ac.uk 
R.  Kiessling 
Tel:  +46/8/728.66.88 
Fax: +46/8/30.91 .  95 
. E-mail: rolf.kiessling@mtc.kise 
T.H.M. Ottenhof 
Tel:  +31/71/26.38.00 
Fax: +31/71/21.67.51 
E-mail: ihbsecr@euronet.nl 
U. Sengupta 
Tel:  +91/56/236.11.01  - 4 
Fax: +91/56/236.00.83 
R.  Mukherjee 
Tel:  + 91/11/686.30.04 - 9 
Fax: +91/11/686.21.25 
S.K. Sinha 
Tel:  +91/52/223.24.11 
Fax: +91/52/224.34.05 
E-mail: root&cdrilk@ sirnetd.ernet.in 
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DEVELOPMENT OF A NEW VACCINE AGAINST MYCOBACTERIUM TUBERCULOSIS 
Period: 
Co-ordinator: 
Objectives 
February 1,  1995 - April 30,  1998 
STATE VETERINARY SERUMLABORATORY, BACTERIA VACCINE 
DEPT.,  Copenhagen, Denmark (P. ANDERSEN) 
The  general  objective  is  to  reduce  global  morbidity  and  mortality  from  tuberculosis  by 
vaccination.  The  immediate goals are: 
•  To  construct  an  experimental  vaccine  with  a  high  efficacy  in  animal  models  by  the 
identification  of adjuvant and  antigen  components; 
•  To  characterize and conduct detailed immunological investigations of vaccine candidate 
antigens; 
•  To  identify  antigens  frequently  recognized  by  TB  patients  during  the  first  phase  of 
disease. 
Activities 
Identification of antigen components 
Selected  proteins  purified  from  a  pool  of  secreted  mycobacterial  proteins  have  been 
identified and characterized. All the purified antigens are tested in the mouse model for the 
recognition  by  memory T cells  involved  in  the  recall  of a protective  immune  response.  A 
number of purified proteins were able to  induce IFN-y release from  memory effector cells 
tested  in  this  model  during  the  first  phase  of  a  protective  immune  response.  Three 
previously  uncharacterized  proteins  have  been  identified;  CFP-13,  CFP-29,  and  CFP-46. 
The N-terminal sequence and the amino acid composition of CFP-29 was determined and 
searches  in  protein  and  translated  nucleotide  sequence  databases  confirmed  that  this 
protein  has  not  been  characterized  before.  Work  is  in  progress  to  characterize  other 
proteins purified  by preparative 2-dimensional  electrophoresis. 
Identification of the adjuvant components 
DDA  has  proven  to  be  an  excellent  adjuvant for  a vaccine  based  on  antigens  from  the 
culture filtrate  of  M.  tuberculosis.  This  Short Term-Culture  Filtrate/DDA vaccine  is  able to 
stimulate a Th1  type of immune response as judged by the cytokine profile stimulated and it 
was able to confer protective immunity. Other adjuvants were less efficacious and,  notably, 
AI(OH)3 stimulated a Th2 type of immune response and exacerbated infection. Vaccination 
with  ST-CF and  various cytokines or modulators of cytokine expression was examined by 
antigen  specific  stimulation  of  lymphocytes  ex vivo.  IL-12  significantly  enhanced  IFN-y 
production and was able to partially protect mice from challenge with  M.  tuberculosis. 
Characterization and detailed immunological investigation of vaccine candidate antigens 
In  the  mouse  model  ESAT-6  was  recognized  by  genetically  different  strains.  Synthetic 
overlapping  peptides were  used  to  map  T cell  epitopes.  Two  T cell  epitopes  were  found 
and  one  of  these  was  recognized  by  an  exeedingly  high  frequency  of  splenic  T  cells 
indicating the  involvement of this antigen  in  the  immune  response  to  M.  tuberculosis. 
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The  gene  encoding  ESAT-6  has  been  demonstrated to  be  present  only  in  mycobacteria 
belonging  to  the  M.  tuberculosis complex  and  a  few  other mycobacterial  species tested 
whereas,  it  is  not present in  any known  M.  bovis BCG  strain. 
Identification of protective antigen targets in  human 
Human T cell screening is currently underway in the South Shoa Region of Ethiopia, 300 km 
outside Addis Ababa.  Hossana houses  a  300  bed  hospital  and  serves a  population  of  3 
milli<?n  people.  The  project  has  become  an  integrated  part  of  the  ALERT  TB/Leprosy 
programme  in  Addis Ababa.  So far blood  samples from  122 donors have  been  obtained, 
transported to Addis Ababa and frozen for later investigation. Clinical evaluation, and X-rays 
have  been  used  to  characterize  the  groups.  Twelve  donors  with  minimal  TB,  45  with 
advanced TB, and 65 healthy contacts have been identified. The donors will be followed for 
one year to monitor if any of the healthy contacts will develop TB. Laboratory analysis of the 
in  vitro  immune  responses  to  crude  antigen  preparations,  fractions  of culture  filtrate  and 
purified antigens are ongoing. Preliminary data show a heteogeneous picture but individual 
donors show a high response to ST-CF,  ESAT-6 and peptides from ESAT-6. 
Partners 
Statens Seruminstitut 
Bacteria Vaccine Dept. 
Artillerivej 5 
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Denmark 
Armauer Hansen Research Institute 
P.O.  Box 1005 
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Institute of Immunology and Rheumatology 
Group for Laboratory Medicine 
Pathology Building 
The National Hospital 
Oslo 
Norway 
National Institute of Public Health 
Vaccine Department 
Geitmyrsveien 75 
Oslo 
Norway 
University of Porto 
Centre of Experimental Cytology 
Rua do Campo Alegre 823 
Porto 
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P.  Andersen 
Tel:  +45/3/268.34.62 
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MUCOSAL  IMMUNITY  OF  LEPROSY  (MILEP2  STUDY)  DEFINITION  OF  LEPROSY 
TRANSMISSION AND PROTECTION  WITHIN  AN  ENDEMIC  LEPROSY POPULATION 
Period:  December 1  ,  1996 - November 30, 2000 
Co-ordinator:  UNIVERSITY OF ABERDEEN 
Aberdeen,  United Kingdom (WCS SMITH) 
Objectives 
•  To  establish  the  relationship  between  M.leprae  infection  and  the  development  of 
immunity in a community in which multiple drug therapy (MDT)  has been  used for more 
than  1  0 years. 
•  To  elucidate the  pathogenesis of primary nasal  infection  in  leprosy. 
•  To  develop and  test a chemotherapy-based  intervention strategy for the  interruption of 
leprosy transmission. 
Activities 
*  Whole population survey of 3 villages  in  India and one village  in Africa.  to obtain  nasal 
swabs  for  polymer  chain  reaction(PCR)  for  M.leprae  and  specimens  of  saliva  for 
measuring  lgA levels against  M.leprae. 
*  Child  contact study.  Samples will  be  obtained from  20 children  from  households with  a 
treated  leprosy patient and 20 controls at three monthly intervals over 3 years in  4 age 
groups. 
*  Assessment  of  immunity(lgA)  and  PCR  positivity  in  newly  exposed  adults,  with  3 
monthly follow  up  over 3 years. 
*  Assessment of the natural history of infection(PCR status) and immunity (Salivary lgA)in 
30  adults identified  in  the  MILEP1  study with  3 monthly follow-up. 
*  Development of simplified  PCR  and  ELISA protocols (Miraj/AHRI/London/Bergen. 
*  ENT  examination  and  nasal  biopsy  to  be  taken  by  an  ENT  surgeon  of  PCR  positive 
individuals  from  village  surveys  which  will  be  formalin  fixed  and  sent  to  London  for 
diagnosis  and  immuno-histo-chemistry  for  lymphocyte  subsets  in  collaboration  with 
Bergen.  Blood  samples  of  PCR  positive  subjects  to  be  obtained  to  determine  cell 
mediated  immunity (CMI). 
*  Double  blind  trial  of single  dose  ofloxacin,  rifampicin  and  minocycline  in  60  new  PCR 
positive subjects with  monthly follow up  for 6months and then  3 monthly measurement 
of  PCR  and  salivary  lgA to  determine the  course  of infection. 
*  Intervention  study  to  interrupt  leprosy  transmission.  'at  risk'  groups  identified  from 
activities 1-8 will  be  given a single dose of ofloxacin,  rifampicin  and  minocycline with  3 
monthly follow  up. 
88 Contract number IC18*CT960047 
Expected Outcome 
=>Assessment of PCR positivity(putative infection) and immunity to leprosy in the endemic 
community. 
=> Assessment of immunity and  PCR  positivity in  relation  to age  of first exposure. 
=>  Establish  how newly exposed  adults deal with  primary infection. 
=>  Determine the course of infection 
=>Assessment  of  methods  to  interrupt  transmission  of  M.leprae  and  the  course  of 
infection  through  administration  of single dose chemotherapy. 
=>Transfer expertise and  knowledge between the partners  in  a collaborative study. 
Partners 
University of Aberdeen 
Dept. of Public Health 
Polworth Building, Foresterhill 
Aberdeen AB9 2ZD 
United Kingdom 
University College of London 
Dept. of Ophthalmology 
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United Kingdom 
Royal Tropical Institute 
Dept. of Biomedical Research 
11 05 Az Amsterdam 
The Netherlands 
Armaeur Hansen Research Institute 
P.O.  Box 1005 
Addis Ababa 
Ethiopia 
Dept. of International Health 
P.O.  Box 1130 Blindern 
N-0317 Oslo 
Norway 
Richardson Leprosy Hospital 
Sangli Road 
Miraj 416410 
India 
W.C.S Smith 
Tel:  +44/1224/68.18.18ext53802 
Fax: +44/1224/62.994 
E-mail: w.c.smith@ abdn.ac.uk 
I. Cree 
Tel:  +44/171/6086.938 
Fax: +44/1224/629.94 
E-mail: i.cree@ucl.ac.uk 
P.  Klaster 
Tel: +31/20/5665.441 
Fax: +31/20/6971.1841 
E-mail: bo@mail.support.nl 
Sven Britton 
Tel:  +251/1n1.02.88 
Fax: +251/1n1.13.90 
E-mail: ahri@ links.se 
Gunnar Bjune 
Tel:  +47/22/85.06.43 
Fax: +47/22/85.06.72 
E-mail: g.a.bjune@ ioks.uio.no 
Vijayh Edwards 
Tel:  +91/233/21.12.13 
Fax: +91/233/21.17.08 
89 Contract number IC18*CT960060 
A MOUSE  MODEL FOR  LATENT TUBERCULOSIS AND  PREVENTION  OF  REACTIVA-
TION  OF THE  DISEASE 
Period: 
Co-ordinator: 
Objectives 
December 1  , 1996 - November 31 , 1999 
UNIVERSITY OF BERGEN, CENTRE FOR INTERNATIOAL HEALTH 
Bergen,  Norway (G.  BJUNE) 
•  To  identify the  sites where dormant bacilli  survive,  whether their metabolism  is different 
from  that of  actively growing  bacilli  and  whether they express  different antigens. 
•  To  study  the  nature  of  the  immune  response  that  maintains  the  latent  state  and 
differences  between  the  immune  response  in  men  and  mice  and  in  latent  and 
progressive tuberculosis. 
•  To  define the  immunological  and  endocrine factors  which  induce  reactivation. 
Activities 
*  Establish a mouse model for asymptomatic lifelong infection with stable bacillary counts 
to  study histopathology and  number of bacilli  throughout lungs,  spleen,  liver and  bone 
narrow. 
*  Study  antigen  expression  in  actively  dividing  bacilli  and  in  dormant  bacilli  through 
immune  response  to  specific  antigens,  purification  and  characterisation  and  identifica-
tion  of  gene  activation. 
*  Study T-cell  subsets  and  cytokines  in  various  stages  of  tuberculosis  infection  in  mice 
and  men. 
*  Follow the antigen specificity ofT-cell responses and  antibodies throughout infection in 
men  and  mice. 
*  Study  the  importance  of  hormones,  growth  factors  and  non  peptide  biological  active 
components  from  Mycobacterium  tuberculosis  in  latency  and  reactivation  of  the  dis-
ease. 
Expected outcome 
~A  relevant mouse model  for latent tuberculosis and  reactivation  of the disease in  man. 
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=>  To  strengthen  research  capability  and  training  in  two  DC  laboratories  in  tuberculosis 
high  endemic countries. 
=>  To  create a co-operative basis for tuberculosis research and new vaccine development. 
Partners 
University of Bergen Centre for International 
Health 
Armauer Hansen Building 
5021  Bergen 
Norway 
Armauer Hansen Research Institute 
P.O.  Box 1005 
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Salvador Zubiran 
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Fax: +47/55/97.49.70/22-85.06.72 
E-mail: g.a.bjune@ioks.uio.no 
S.  Britton 
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Tel:  +44/17/13.80.94.89 
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IDENTIFICATION OF  PROTECTIVE IMMUNE RESPONSES TO  PATHOGENIC 
MYCOBACTERIA 
Period: 
Co-ordinator: 
Objectives 
November 1,  1997 -April 30, 2001 
LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE, 
Department of Infectious and Tropical Diseases, 
London,  United Kingdom (H.  M.  DOCKRELL) 
To  evaluate  the  role  of  T  cell-associated  lytic  mechanisms  in  the  killing  of  intracellular 
mycobacteria,  and  the  contribution  of  these  effector  pathways  to  immunity  against 
tuberculosis and  leprosy. 
Activities 
The  function  of  various  T  cell  subsets  in  immunity  to  tuberculosis  will  be  assessed  in 
patients  with  tuberculosis,  without  or  with  co-infection  with  HIV,  and  in  normal  BeG-
vaccinated  healthy  controls.  Further  studies  will  assess  expression  of  the  P2Z  (P2X7) 
receptor in  patients with tuberculosis or leprosy,  and  in  healthy controls.  Specific areas of 
investigation are as follows: 
*  To  evaluate  whether  antigen-specific  CD4+  and  CDS+  T-cell  mediated  cytotoxicity 
reduces the survival of intracellular maycobacteria within macrophages, and the relative 
contribution of various cytolytic effector mechanisms to this T cell-induced  macrophage 
death (LSHTM,  London,  University of  Oxford,  and  MRC  Laboratories, The  Gambia) 
*  To  assess  the  role  of  the  gd  T  cell  subset  in  cytolysis  and  cytokine  secretion  in 
tuberculosis with/without  HIV co-infection  (CMDT,  Lisbon) 
*  To  investigate the mechanism(s) by which extracellular ATP-induced macrophage death 
(occurring  via the  P2Z-receptor mediated  pathway)  reduces  survival  of intracellular M. 
bovis BCG,  and to extend these studies to other pathogenic mycobacteria (University of 
Birmingham) 
*  To  investigate  the  role  of  genetic  heterogeneity  of  extracellular  ATP-induced  macro-
phage death and  intracellular mycobacterial killing in  conferring resistance to mycobac-
terial  disease,  by  comparing  P2Z  (P2X7)  receptor  expression  on  monocyte-derived 
macrophages  from  patients  with  tuberculosis  (with/without  H  IV),  lepromatous  leprosy, 
and endemic controls (University of Birmingham, CMDT Lisbon, MRC Laboratories, The 
Gambia and  IMSS  Mexico City). 
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Expected outcome 
The  study  will  obtain  scientific  data  allowing  the  relative  importance  of  these  immune 
responses  in  protection  against mycobacterial disease,  and the heterogeneity of the P2Z 
(P2X7)  receptor in  susceptibility to mycobacterial disease, to be evaluated. 
Partners 
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THE PATHOGENESIS OF TUBERCULOSIS; GROWTH RATE  REGULATION AND 
RIBOSOME SYNTHESIS 
Period: 
Co-ordinator: 
Objectives 
December 1, 1997- May 31,  2001 
MEDICAL RESEARCH COUNCIL, THE NATIONAL 
INSTITUTE FOR MEDICAL RESEARCH, 
London,  United Kingdom (M.J. COLSTON) 
To investigate the ways in which pathogenic mycobacteria are able to regulate their growth 
and  survive within  an  infected  host by: 
•  Analy  sing  the  expression  of  ribosomal  RNA  (rRNA)  genes  when  mycobacteria  are 
grown  under a variety of conditions,  including  in  host tissue. 
•  Study ing  the  role  of ribosomal  protein  S  1  0 in  the  transcription  of  mycobacterial  rRNA 
operons. 
•  Identifying  additional  transcription  factors  involved  in  expressing  genes  involved  in 
ribosome  synthesis. 
Activities 
The  expression  of  rRNA genes will  be  investigated by  identifying the  promoters  involved, 
and studying their relative levels of expression under different conditions. Comparisons will 
be  made  between  pathogenic  (M.  tuberculosis)  and  non-pathogenic  mycobacteria;  be-
tween  laboratory  and  clinical  isolates  of  M.  tuberculosis;  and  between  M.  tuberculosis 
grown  under different laboratory conditions,  including  growth  in  infected  host tissues. 
The  role  of  ribosomal  protein  S10  will  be  investigated  by  preparing  purified  recombinant 
protein  and  studying  its  interaction  with  RNA  sequences  and  with  other  proteins  of  M. 
tuberculosis. 
Addit  ional  transcription  factors  will  be  identified  by  establishing  in  vitro  transcription 
assays  using  purified  mycobacterial  RNA  polymerase.  Transcriptional  activity  will  be 
monitored  and  factors  which  affect transcriptional  efficiency  identified and characterised. 
Expected outcome 
This  study  will  identify  the  strategies  used  by  pathogenic  mycobacteria  to  regulate 
ribosome  synthesis,  and  hence  to  regulate  growth  rates.  By  identifying  specific  compo-
nents  of  the  transcriptional  machinery  of  M.  tuberculosis,  we  expect  to  identify  potential 
targets for the  development of  novel  anti  tuberculosis drugs. 
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Partners 
Medical Research Council 
The National Institute for Medical Research 
The Ridgeway 
Mill Hill 
London NW7 1  AA 
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Universidad Autonoma de Madrid 
Facultad de Medicina 
Azorbispo Morcillo s/n 
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Escue Ia Nacional de Ciencias Biologicas 
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Laboratorio de Microbiologia General 
Apartado Postal 4-870 
Mexico DF 06400 
Mexico 
M.J. Colston 
Tel:  +44/181/959.36.66 
Fax: +44/181/913.85.26 
E-mail: jcolsto@ nimr.mrc.uk 
M.J. Garcia 
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Fax: +34/1/397.53.53 
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DEVELOPMENT  OF  A  TUBERCULOSIS  VACCINE  WITH  CONSISTENT  EFFICACY IN 
DIFFERENT REGIONS OF THE  WORLD 
Period: 
Co-ordinator: 
General objective 
January 1  , 1998 - December 31 , 2000 
STATENS SERUM INSTITUT, Department of TB  Immunology, 
Copenhagen, Denmark (P. ANDERSEN) 
To  reduce  global  mortality and  morbidity from  tuberculosis  by vaccination. 
1) Objectives 
+  To identify, characterize and produce a panel of mycobacterial proteins for vaccine studies. 
+ To  investigate  the  antigens  present  in  environmental  mycobacteria  from  Karonga 
district,  Malawi. 
Activities 
Production  of  an  extensive  panel  of  recombinant  Culture  Filtrate  Proteins  (CFPs)  from 
cultures of virulent M.  tuberculosis.  Characterization of the antigens expressed by environ-
mental  mycobacteria  isolated  from  the  Karonga  District  in  Malawi.  Investigation  of  the 
recognition  of these  antigens  i)  in  vitro by cells from  memory  immune  mice  and  recently 
infected mice,  ii)  in  vitro by defined groups of TB infected,  BCG  vaccinated,  and  unimmu-
nized human donors, and iii) in vivo by guinea pigs (skintest). The protective efficacy of the 
antigens alone or in combination will finally be evaluated in mice and guinea pigs. 
Expected outcome 
An identification and recombinant production of novel immunodominant antigens. An overview 
of the  immunogenicity and  protective  efficacy of these.  An  overview of the  mycobacterial 
antigens that are relevant for protective immunity against tuberculosis in humans. 
2) Investigation of experimental vaccines in animal models 
Objectives 
+ To  construct and  investigate the  efficacy and  mode  of action  of experimental vaccines 
in  animal  models. 
+  To  study  the  interactions  between  environmental  mycobacteria  and  vaccine  induced 
protection  in  animal  models. 
Activities 
Production  of a fusion  protein  consisting  of  ESAT-6  and  Ag85B.  Testing  of  the  immuno-
genicity  of this  hybrid  molecule.  The  level  of acquired  resistance  following  immunization 
with  the  hybrid  in  the  presence  or  absence  of  various  cytokines  and  inhibitors  will  be 
studied.  The  influence  of  pre-vaccination  exposure  to  environmental  mycobacteria  on 
immune  responses  as  well  as  BCG  replication  will  be  monitored  and  the  influence  on 
subsequent protection  against tuberculosis evaluated. 
Expected outcome 
Characterization  of  the  mechanisms  underlying  the  vaccine  induced  protective  immunity. 
Information  on  the  interaction  between  immunization  and  sensitization  with  environmental 
mycobacteria. 
3) Production of ST-CF/DDA vaccine for human use 
Objectives 
+ To  produce  and  test the  new ST-CF/DDA vaccine  in  humans. 
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Activities 
When ethical clearance has been obtained from the relevant authorities, ST-CF/DDA vaccine 
will enter phase 1 clinical trial. Following a successful phase 1 trial, the experimental vaccine 
will be injected in healthy human volunteers from different geographical regions (Denmark and 
Malawi) and the responses compared with standard BCG vaccination. Cellular parameters 
such as antigen-specific proliferation, cytokine production, and antigen specific cytotoxicity in 
response to various recombinant antigens, PPD and ST-CF will be tested. 
Expected outcome 
The testing of a ST-CF/DDA vaccine in  phase 1/2 clinical trial.  Detailed information on the 
type  of human  immune  responses  induced following  vaccination  with  ST-CF/DDA. 
4) Final construction of new experimental vaccines 
Objectives 
+ To  construct an  experimental vaccine based on  immunologically relevant antigens. 
Activities 
Production  of  a  new  subunit  vaccine  based  on  a  selection  of  the  best  antigens  and 
adjuvants. 
Expected outcome 
A new subunit vaccine against tuberculosis. 
Partners 
Statens Serum lnstitut 
Department of TB Immunology 
Artillerivej 5 
2300 Copenhagen S 
Denmark 
Universidade de Porto 
Centro de Citologia Experimental 
lnst. Nacional de lnvestigacao Cientifica 
Rua do Campo Alegre 823 
4150 Porto 
Portugal 
Armauer Hansen Research Institute 
P.O.  Box 1005 
Addis Ababa 
Ethiopia 
London School of Hygiene & Trop.  Med. 
Epidemiology and Sciences department 
Keppel Street 
London WC1 E 7HT 
United Kingdom 
University of Oslo 
lnst. of Immunology and Rheumatology 
Fr.  Qvamsgate 1 
0172 Oslo 
Norway 
National Institute of Public Health 
Vaccine department 
Geitmyrsv. 75 
0462 Oslo 
Norway 
P.  Andersen 
Tel:  +45/32/68.34.62 
Fax: +45/32/68.30.35 
R.  Appelberg 
Tel:  +351/2/60.99.157 
Fax: +351/2/60.74.900 
S. Britton 
Tel:  +251/1/71.02.88 
Fax: +251/1/71.11.99 
E-mail: ahri@ alinks.se 
P.E.M. Fine 
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Fax: +47/22/20.72.87 
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F.  Oftung 
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DIAGNOSIS AND  CONTROL OF  CRIMEAN-CONGO  HEMORRHAGIC  FEVER  (CCHF) 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1993 - December 31 , 1994 
ARISTOTLE UNIVERSITY THESSALONIKI, SCHOOL OF MEDICINE, 
DEPT OF MICROBIOLOGY, Thessaloniki, Greece (A. ANTONIADIS) 
•  Production  of  new,  non-infectious diagnostic reagents  using  recombinant  DNA technol-
ogy.  These  reagents  will  be  applied  in  immunoassays  used  in  African  countries  to 
determine the  risk of CCHF zoonotic transmission. 
•  Development  of  methods  for  rapid  diagnosis  of  CCHF  virus  infections  based  on 
oligonucleotide probes  and  the  polymerase chain  reaction  (PCR). 
Activities 
*  Development of diagnostic reagents. 
*  Diagnostic  reagents  will  be  derived  from  the  S  and  M  RNA  nairovirus  genomic 
segments.  Recombinant  proteins will  be  derived  from  the  S RNA  of CCHF  virus,  and 
from  the M RNA of DUG  virus.  Laboratory animals will  be immunized with  recombinant 
antigens to  produce antibodies directed  against the  nucleoproteins or glycoproteins for 
use  in  immunoassays  and  antigen  detection  by  antibody  capture.  In  addition,  type 
specific  nucleic acid  probes  and  PCR  primers will  be  developed. 
*  Development of  diagnostic techniques. 
*  Expressed  viral  proteins  will  be  used  as  a  substrate  for  viral  antibody  detection.  A 
variety  of  standard  immunological  tests  will  be  employed  (ELISA,  Western  blot  analy-
ses,  immunoprecipitation and  immunofluorescence).  In  addition,  non-radioactive probes 
(e.g.  biotin-labelled nucleotides) will  be  used  so that the techniques can  be  adapted to 
African  laboratories. 
*  Validation  of  immunoassays. 
*  Preliminary  work  will  aim  at  establishing  a  bank  of  confirmed  positive  and  negative 
human  sera  based  on  immunofluorescent  antibody  tests  and  enzyme-linked  immu-
noassays  (ELISA)  with  antigens derived from  CCHF  10200 and  Greek viral  isolates. 
*  Identification of enzootic foci.  · 
*  Surveys  will  be  undertaken  in  the  participating  countries.  The  aim  will  be  to  identify 
endemic  areas  of  CCHF  virus  and  to  establish  a  regime  for  routine  serodiagnosis  in 
African  countries. 
Expected outcome 
=>  Development  and  productton  of  recombinant  nairovirus  proteins  and  transfer  of  tech-
nology to African  partners. 
=>  Production  of  probes  and  PCR  primers  and  their  application  for  rapid  diagnosis  of 
human  infections with  CCHF virus. 
=>  Establishm ent of immunoassays in African  laboratories using  recombinant CCHF virus 
proteins for rapid diagnosis of human infections as well as for serosurveys in  potentially 
infected  animals. 
=>  Data on the distribution and  prevalence of nairovirus infections in all  countries involved. 
=>  Publications  on  the  development  of  nairovirus  diagnostic  reagents  and  their  applica-
tions. 
Results 
The complete nucleotide sequence of the small  RNA genomic segment of Crimean-Congo 
hemorrhagic  fever  (CCHF)  virus,  Greek  isolate  AP92,  was  determined  from  cloned 
polymerase  chain  reaction  (PCR)  products. 
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The  nucleocapsid  (N)  protein  open  reading  frame  was  identified  by  homology  to  the  N 
protein  of  a  Chinese  isolate  of  CCHF  virus,  and  was  expressed  to  high  levels  in  the 
baculovirus expression system. Three N protein-derived peptides were expressed in  E.  coli 
as  fusions  to  glutathione-S-transferase,  and  the  antigenicities  of  these  proteins  and  the 
Baculovirus  expressed  protein  were  tested  in  an  enzyme-linked  immunosorbent  assay 
(ELISA).  When  tested  with  laboratory  animal  sera  representing  all  seven  serogroups  of 
nairoviruses,  the only reactive  sera were those  raised  to  CCHF virus (Greek,  Nigeria and 
Chinese  isolates)  and,  more  weakly,  Hazara  virus.  When  tested  with  a  panel  of  known 
positive  and  negative  human  sera,  the  baculovirus-expressed  N protein,  and  the  peptide 
derived from the central region of the N protein, proved to be the best for identifying CCHF 
virus-specific  lgG. 
2.440  human  sera  examined  in  Bangui  for  antibody  to  CCHF  and  Dugbe  viruses.  For 
these  viruses  variable  percentages  of  seropositives  were  detected  ranging  from  1  0°/o  to 
50o/o  in an  ELISA test with brain derived antigen. All sera reacting with CCHF virus reacted 
also  with  Dugbe  virus.  In  Senegal,  7  CCHF  strains  were  isolated  out  of  2100  ticks 
collected from  ungulates in  several  areas.  5 strains of the CCHF virus were  isolated form 
Hyalomma marginatum rufipes ticks,  1 from  Hyalomma truncatum and  1 from  Rhipicepha-
lus evertsi ticks.  1400 human  sera (430 from  Nigeria and  970 from  Greece)  examined  in 
Thessaloniki  for  antibody  to  CCHF  virus  by  IFA  and  ELISA  tests.  Results  obtained, 
revealed  5o/o  of seropositives  in  Nigeria  and  1.8°/o  in  Greece.  In  parallel,  880  ticks  were 
collected  in  Greece for virus  isolation  in  Vero  E-6  cells  as  well  as  for virus  detection  by 
PCR.  Thus far  no  virus  was  isolated from  ticks.  In  contrast by  PCR  in  one  pool  of ticks 
collected from  sheep  in  CCHF  area. 
Partners 
Aristotle University Thessaloniki 
School of Medicine 
Dept.  of Microbiology 
54006 Thessaloniki 
Greece 
Nat.  Environment Research Council 
lnst. of Virology & Environmental 
Microbiology 
Mansfield Road 
OX1  3SR Oxford 
United Kingdom 
University College lbadan 
Dept. of Virology 
lbadan Nigeria 
lnstitut Pasteur de Dakar 
Avenue Pasteur 38 
P.O.  Box 220 
Dakar Senegal 
lnstitut Pasteur de Bangui 
P.O.  Box 923 
Bangui 
Central African Republic 
A. Antoniadis 
Tel:  +30/31/99.13.48 
Fax:  +30/31/20.03.92 
P.  Nuttall 
Tel:  +44/186/551.23.61 
Fax: +44/186/55.99.62 
0. Tomori 
J-P. Digoutte 
Tel:  +221/22.51.81 
Fax: +221/22.87.72 
C. Mathiot 
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EPIDEMIOLOGY OF FILOVIRUS INFECTIONS IN THE CENTRAL AFRICAN REPUBLIC: 
A RISK FACTORS  STUDY ASSOCIATED WITH  SUBSISTENCE ACTIVITIES 
Period: 
Co-ordinator: 
January 1,  1994 - December 31,  1996 
ORSTOM,  DEPARTEMENT SANTE 
Paris,  France (J.P.  GONZALEZ) 
General long term objective 
Outside  the  devastating  epidemics  of  nosocomial  origin  or  the  contamination  events  in 
laboratories,  effects of the  Filovirus  remain  little  known  and  not well  documented. 
The  aims of this  study are: 
•  To  define the  relative frequency of anti-Filovirus antibodies for different populations. 
•  To  show the  risk factors  responsible  for infection  in  human  populations  living  in  areas 
where  the  existence  of  Filovirus is  suspected. 
•  To  define the  method(s)  of contamination  and  transmission  of  Filovirus. 
•  To  evaluate the risks of infection and  epidemics in the areas where this virus exists and 
to  propose an  information  policy for the  prevention  of epidemics. 
Specific objectives to be achieved in this contract are twofold 
•  Epidemiology and infectiology: to identify the risk factors of contamination by Filoviruses 
associated with  nutritional and  cultural  habits in  populations living  in  or on  the  edge of 
forests  in  central Africa. 
•  Anthropology:  to define the populations at risk  in  a well  described human  and  physical 
environment. 
Activities 
The  proposed  study  is  aimed  at  the  populations  living  within  or  on  the  borders  of  the 
central African  forests  and  is  dominated by two  essential  methodological  aspects: 
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*  An epidemiological study centred around the search for a link between contact with wild 
monkeys and the  presence of  anti-filovirus antibodies in  human  populations. 
*  An  ethnological  study intended to show the importance of hunting  and  consuming the 
meat of wild  monkeys in  communities of farmers and  hunter-gatherers. 
The  methodology proposed  envisages the following  activities within  the  timescale: 
*  Preparatory  phase:  Identification  of  the  environment  and  populations  to  be  targeted 
from  previously  obtained  data  from  sera-epidemiological  surveys  carried  out  in  the 
Central  African  Republic.  Based  on  this  information,  a  decision  will  be  made  on  the 
choice  of  area  (villages  and  strength  of  populations).  An  objective  questionnaire  will 
then be compiled according to populations and to which linguistic group they belong. A 
practical evaluation will  be carried out on  the materials necessary to carry out this first 
field investigation within the timescale and the location (lnstitut Pasteur de Bangui, IPB, 
Laboratoire de Langues et Civilisations Traditions Orales,  LACITO;  ORSTOM). 
*  Evaluation  of  the  questionnaire  will  be  carried  out  on  a  sample  of  the  population 
selected  (IPB;  LACITO;  ORSTOM). 
*  This will  be  followed  by the  installation  of the  logistics and  the  completion  of the first 
sera-epidemiology study,  starting  in  Bangui  (IPB;  ORSTOM;  LACITO). 
*  Packa  ging  of the  samples for  the  laboratories will  be  carried  out  in  part  in  the  field 
(decanting  of serums,  preparation  of aliquots/splitting  the  samples,  labelling,  freezing) 
and  part  in  the  laboratory (distribution,  dispatching,  IPB). 
*  Laboratory  analyses  will  be  carried  out  in  the  virology  laboratories  (IPB,  IV  Marburg, 
ORSTOMNARU). 
*  Examination of the questionnaires and the  results  of the  laboratory analyses and  data 
and  statistical  processing  (ORSTOM/LACITO). 
*  Interpretation of results,  with  reference to the field,  will  provide the information required 
for the preparation of the second visit. This will  take place one year after the first visit, 
and  during the same season. 
105 Contract number TS3*CT940286 
*  It  will  allow  follow  up  of  the  populations  (sera-conversions)  and  control  of  the  data 
acquired  (sera-prevalence),  eventual  confirmation  of  the  hypotheses  put  forward  (re-
search  on  the  homologous village  groupings),  choice  of new target  specimens  (envi-
ronmental survey in the areas of suspected cases or amongst families with a conflicting 
prevalence of antibodies)  (IPB,  ORSTOM,  LACITO). 
*  The  second  sera-epidemiological  survey  will  be  carried  out  taking  into  account  the 
results  and  interpretation of the first (IPB/ORSTOM). 
The  results  of the  second  study will  lead  to  the final  report  and  then  eventually on  to a 
statement of research  prospects I perspectives on  the epidemiology of Filovirus. 
Results 
The first analyses carried  out on  the  populations in  ten  pygmy camps and  in  two mainly 
bantu-speaking villages shows: 
=>There is  a  more  pronounced  and  higher rate  (>15o/o)  of sera-reactivity for  Ebola  and 
Marburg virus among pygmy ethnic population. 
=>The first analysis shows that risk of infection with  Ebola virus increases when there is 
more contact with  the forest,  particularly when  linked to seeking food  behaviour. 
=>The sero-positivity  for  the  Marburg  virus  is  original  and  demonstrates that  this  close 
relative of the  Ebola or a similar virus is circulating  in  this part of central Africa. 
=>Some  green  monkeys  and  one  red  monkey  (Erythrocebus  patas)  were  found  to  be 
carriers  of the  antibodies of the  Marburg virus  but  negative for the  Ebola antigens,  a 
new finding  for this region  of Africa. 
=> Transfer of technology (ELISA,  Western  Blot,  PCR)  has been  successful,  most of the 
tests  having  been  carried  in  the  Central African  Republic.  This  phase  is  about to  be 
completed with the installation of the PCR to detect the Ebola and Marburg (or similar) 
viruses in  the specimens collected on  the study site in  Lobaye in  the southern area of 
the Central African  Republic. This technology and  reagents have been supplied by the 
lnstitut  fur  Virologie  in  Marburg  (Pr  Slencka)  and  Mr  Nakoune  visited  this  institution 
twice. 
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~  The  results  obtained  so  far  have  been  object  of  several  communications  and  one 
publication  in  a highly  rated  international journal  (Journal  of Infectious Diseases).  The 
preliminary results have been presented and the first 'Colloquium on  research on  Ebola 
virus',  held  in  September 1996 at the  Prince  Leopold  Institute in  Antwerp. 
Partners 
ORSTOM, Paris 
Departement Sante 
123 rue Lafayette 
75480 Paris Cedex 1  0 
France 
lnstitut Pasteur de Bangui 
BP 923 
Bangui 
Republique Centrafricaine 
Ministere de Ia Sante, RCA 
c/o lnstitut Pasteur de Bangui 
BP 923 
Bangui 
Republique Centrafricaine 
lnstitut fuer Virologie 
Department of Virology 
Robert Koch Strasse 
Marburg/Lahn 
Germany 
J.P. Gonzalez 
Tel:  +33/1/48.03.77.77 
Fax: +33/1/48.03.08.29 
E.Nakoune 
Tel:  +236/61.45.76 
Fax: +236/61.01.09 
J-M. Diemer 
Tel:  +236/61.45.76 
Fax:  +236/61.01.09 
W. Slenczka 
Tel:  +49/6421/282.43.01 
Fax: +49/6421/280.54.82 
E-mail: Slenczka@ mailer.uni-marburg.de 
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THE  USE  OF  RECOMBINANT  PROTEINS  AND  SYNTHETIC  PEPTIDES  FOR  DIAG-
NOSTICS AND ELUCIDATION OF VIRULENCE MARKERS IN  DENGUE VIRUS INFEC-
TIONS 
Period: 
Co-ordinator: 
Objectives 
October 1,  1994 - September 30,  1997 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
DEPT.  OF MEDICAL PARASITOLOGY, 
London, United Kingdom (A.  FALCONAR) 
To  identify  dengue  viral  sequences  associated  with  protection,  virulence  and  identify 
intra-serotypic strain variations. This will  lead to the elucidation of mechanisms involved in 
haemorrhagic/shock syndromes. 
Activities 
Selected regions of dengue virus strains showing clearly demarked pathogenic capacities 
will  be  sequenced.  lntra-serotypic heterogeneity will  initially be tested  using  human  sera 
and  neutralizing  mouse  monoclonal  antibodies.  Epitopes  on  the  E  and  prM  proteins  of 
these  viruses  will  be  identified  using  computer algorithms,  synthetic  peptide  and  recom-
binant  eDNA  expression  products.  These  antigens  will  be  assessed  for  suitability  as 
diagnostic  reagents.  If  particular  sequences  are  associated  with  virulence,  PCR  will  be 
employed as a  rapid  and sensitive method for the  identification of virulent strains. 
Expected outcome 
The  data generated  in  this study will  help to design  a safe  and  suitable vaccine against 
these pathogens and may also have application to other haemorrhagic fever viruses. 
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HUMAN  PAPILLOMAVIRUS  (HPV)  INFECTIONS  IN  THE  PATHOGENESIS  OF 
OESOPHAGEAL CANCER  IN  THE  HIGH-RISK AREAS OF  CHINA 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1995 - December 31 , 1996 
UNIVERSITY OF KUOPIO,  DEPT. OF PATHOLOGY 
Kuopio,  Finland,  (K.  SYRJANEN) 
•  To  determine  the  prevalence  of  HPV  infection  in  the  oesophagus  by  multiple  DNA-
detection techniques, and evaluate the  role of HPV in the pathogenesis of oesophageal 
precancer lesions and  carcinomas  in  the  high-incidence  areas  of  China. 
•  To  study  risk  factors,  HPV  genotypes,  and  interaction  of  HPV  with  other  infectious 
agents. 
•  To analyze the frequency and type of mutations in the tumor suppressor genes p53 and 
Rb. 
•  To  derive diagnostic,  preventive  and  treatment  measures. 
Activities 
Although  a great deal of information on  OC  (oesophageal cancer)  has been  obtained, the 
causative factors of the disease remain  to  be  established.  Except for the chemical agents, 
e.g.  nitrosamines,  mycotoxins,  excessive  tobacco  use  and  alcohol  drinking,  opium  use, 
and  physical  factors,  e.g.  coarse  and  hot food  intake,  which  have  been  reported  as  risk 
factors for OC,  evidence is accumulating to suggest that infectious agents may play a role 
in  the  etiology  of  oesophageal  cancer.  Previous  studies  in  the  high-risk  area  for  this 
disease  have  suggested  that  the  ingestion  of  mouldy  foodstuffs  and  pickled  vegetables 
(contaminated  with  fungi)  is  closely  related  to  OC.  Certain viruses,  i.e.  human  papilloma-
virus  (HPV),  herpes  simplex  virus  (HSV),  cytomegalovirus  (CMV)  and  Epstein-Barr virus 
(EBV)  have  been  demonstrated  to  infect the  oesophageal  epithelium,  and  therefore  they 
should  be  considered  as  potential  etiological  agents  of  OC,  although  many  of  the  key 
issues  on  their mechanisms of action  are  unclear as  yet. 
HPV  involvement  in  human  oesophageal  benign  and  malignant  lesions  have  been 
demonstrated  by  histopathological  assessment,  immunohistochemical  studies  and  viral 
DNA-detecting  techniques.  Our  previous  studies  have  shown  a  high  prevalence  of  HPV 
infections in oesophageal samples derived from the high-risk areas for OC in China, where 
this  disease  has  been  endemic  for  generations,  with  extremely  high  incidence  rates. 
However,  since  most  of  the  previous  studies  have  only  included  small  numbers  of 
biopsies,  it is  necessary to carry out a well-organized and  extensive epidemiological study 
to assess the  prevalence of HPV infections in  this high-risk population.  It is also important 
to  clarify,  whether any differences on  the  prevalence of oesophageal  HPV  infections exist 
between  the  high- and  low-risk areas. 
114 Contract number TS3*CT940295 
During .1990-1992  our  Chinese  collaborators  in  Zhengzhou,  China  collected  a  series  of 
more  than  2,000  oesophageal  specimens  derived  from  749  patients  suffering  from  a 
variety of oesophageal squamous cell  lesions, with  pertinent clinical  data available. These 
specimens  have  been  derived from  both  the  high-incidence area for oesophageal  cancer 
in  China  and  in  Finland.  Using  multiple  histopathological  and  DNA-detecting  techniques 
which  have  been  well  established  in  the  laboratories  in  Kuopio  and  Turku  (Finland), 
Heidelberg  (Germany)  and  Sienna  (Italy),  such  as  light  microscopy,  electron  microscopy, 
immunohistochemistry,  DNA  in  situ  hybridization,  Southern  blot  hybridization,  dot  blot 
hybridization, polymerase chain reaction, single strand conformation polymorphism, as well 
as  feral  isolation,  cloning  and  DNA  sequencing  techniques,  the  contractors  have  been 
running  a systematic analysis  of  the  associations  of infectious agents  (HPV  in  particular) 
with  OC. 
Results 
==>  The  project is  progressing  on  schedule.  Technology transfer to  the  third  world  is  listed 
among the  major goals of the concerted  action. A Chinese doctor from  the  contractors 
laboratory  was  trained  in  Kuopio,  Finland.  After  having  returned  to  China,  she  has 
successfully established  a number of  DNA techniques  (e.g.  in  situ  DNA  hybridization, 
PCR,  Southern  blot  hybridization  and  gel  electrophoresis)  in  her  laboratory  in 
Zhengzhou. Additional  visits to  Sienna and  Heidelberg  will  be  realized  later. 
==>  Mapping  and  timing  of  cancer-related  genes  in  oesophageal  carcinogenesis,  not 
practiced  by  any other laboratory,  has  been  on  progress at  Henan  Medical  University. 
So  far,  more  than  40  surgically  resected  whole  oesophagi  have  been  sampled  and 
processed for detailed histopathological and  immunohistochemical analysis for different 
oncogenes  and  p53.  It  was  noticed  e.g.  that  a  transient  p53- immunostaining  from 
dysplastic  lesions  to  the  frankly  invasive  cancer  could  be  clearly  mapped  in  the 
specimen, suggesting that p53 mutations are involved in the early (precancer) stages of 
oesophageal  carcinogenesis. 
==>  To  date,  the complete series of  7  49  carcinomas  have  been  graded  by one  pathologist 
(K.S.)  and  more than 500 cases by all  four pathologists.  In  addition to  morphology,  the 
work  in  Sienna  includes  immunohistochemistry  for  cytokeratins  and  morphometric 
analysis  of  the  cancer  samples.  According  to  our  tentative  results,  the  detection  of 
HPV-suggestive  lesions  among  different  observers  appears  to  be  highly  concordant 
and  reproducible.  We  have  noticed  the  presence  of  dysplasia  in  about  20°/o  of  the 
cases,  graded  as  mild  (40o/o),  moderate  (30o/o)  and  severe  (30°/o).  Similarly  morpho-
logical changes suggestive for HPV  infection  in  non-neoplastic adjacent epithelium are 
present  in  about  25o/o  of  the  cases  and  classified  as  flat  (76o/o),  endophytic  (23°/o)  or 
exophytic  (1 o/o)  condyloma.  The complete analysis of the entire series will  take several 
months. 
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=>So far,  a total  of  1,376 oesophageal  biopsies  derived  from  483  patients  with  invasive 
squamous  cell  carcinoma  have  been  analyzed  by  in  situ  DNA  hybridization  for  the 
presence of HPV infection. Of the 483 carcinomas examined so far,  113 cases (23.4°/o) 
were  shown  to  contain  HPV  DNA sequences. 
=>  In  parallel with the  ISH screening,  more than 420 biopsies have also been  analyzed by 
the  PCR  amplification  with  the  L  1 consensus  primers  (MY09/MY11 ),  and  followed  by 
Southern  blot  hybridisation with  HPV  DNA probes. 
=>Altogether, 68 cases representing  15.6°/o of the analyzed biopsies have been  shown  to 
contain  amplified  HPV  DNA  sequences.  Combining  the  PCR  and  ISH  data,  137/422 
(32.5°/o)  seem  to  show evidence for  HPV  involvement. This forms the  largest series of 
oesophageal  samples thus far analyzed for HPV as  a potential etiological  agent in  the 
multifactorial  pathogenesis  of  oesophageal  squamous  cell  carcinoma. 
=>  Over  120  DNA  samples  have  been  screened  for  the  presence  of  p53  mutations  in 
Turku  using  the  PCR-SSCP  technique.  Among  them,  70  samples,  including  46 
oesophageal carcinomas and 24 balloon cytological samples contained enough cellular 
DNA,  from  which  the  p53  gene  sequences  were  successfully  amplified  by  the  PCR. 
P53  mutational  spectrum  in  oesophageal  cancer  shows  most  frequently  missense 
mutations  and  less  frequently,  gene  deletions.  These  data  indicate that  inactivation  of 
the p53 gene is a frequent event in oesophageal cancer and such  an  inactivation might 
be  an  important  molecular  pathway  for  the  development  of  oesophageal  carcinoma. 
The  detection  of  RB  mutations  in  these  samples  is  underway. 
=>  Detection of other potential tumor viruses,  HSV,  EBV and CMV in biopsies is completed 
using immunohistochemistry. Over 1  00 carcinoma biopsies have been analyzed for both 
CMV  and  HSV.  All  cases  remained  negative.  Recently,  more  than  1  00  cancer  speci-
mens  were  also  stained  with  EBV  antibodies,  all  cases  remaining  negative,  however. 
Part  of  these  samples  were  further  analyzed  by  PCR  with  specific  EBV  primers,  but 
again,  no  EBV  DNA  sequences  were  amplified.  These  results  strongly  implicate  that 
these viruses are  not likely to  be  involved  in  the  pathogenesis of oesophageal  cancer. 
These findings are interesting because HSV infection has been epidemiologically linked 
with  oral  cancer,  and  EBV  infection  has  been  implicated  in  the  pathogenesis  of 
nasopharyngeal  carcinomas,  particularly  in  Chinese  patients. 
=>The ongoing systematic evaluation of infectious agents in pathogenesis of oesophageal 
cancer  using  modern  DNA- and  pathobiological  techniques  should  yield  valuable 
information  on  the  etiology,  pathogenesis  and  prognosis  of  oesophageal  cancer,  and 
therefore could provide reliable data for the  prevention and treatment of this disease in 
the  future. 
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DEVELOPMENT OF HUMAN PAPILLOMAVIRUS {HPV) VACCINES  FOR  PREVENTION 
AND TREATMENT OF CERVICAL CANCER 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1997 - September 30, 2000 
CANCER INSTITUTE, CHINESE ACADEMY 
OF MEDICAL SCIENCES 
Beijing, China (Y.H. ZHANG) 
The  overall  objective  is  to  provide  scientific  background  for the  development of  efficient 
and  safe  prophylactic and therapeutic HPV-specific vaccines. 
•  To  study the prevalence and  rate  of infection of HPV 16 and  HPV58 in  high-risk areas 
for cervical  cancer in  China 
•  To develop recombinant vaccines for prevention of HPV16 and 58 infections by eliciting 
L  1-specific neutralizing antibody response 
•  To  develop recombinant therapeutic vaccines based  on  modified E6  and  E7  of HPV16 
and  58  capable  of  effectively  inducing  cytotoxic T lymphocyte  (CTL)  response  against 
HPV16 and  58-infected  pre-malignant and  malignant cells. 
Activities 
To  collect serum samples from  approximately 1  000 individuals of 15 to 35 years of age in 
a high-risk area for human cervical cancer to determine antibody titer against HPV 16 and 
58.  Serum  samples from  the  same  1  000  individuals· will  be  taken  one year later in  order 
to  estimate incidence and  prevalence  rate.  HPV  16 and  58  virus-like particles (VLPs)  will 
be  used  as  the  antigens to  develop  HPV-specific ELISA. 
Chimeric virus-like particles (CVLPs) consisting of HPV16 L  1 protein fused to mutated  E6 
or E7- will be made and used as the vaccines. The serological and CTL responses to these 
CVlPs will  be  evaluated  in  mice. 
HPV58  L  1  gene  will  be  cloned  and  inserted  into  expression  vector  in  vaccine  strain, 
replication-deficient  vaccinia virus.  Serum  lgG  antibody  response  upon  systemic  immuni-
zation  and  lgA antibody  response  upon  mucosal  immunization will  be  measured.  Efficacy 
of vaccination  will  also be  examined  by  HPV58 epithelial  infection. 
HPV58 E6,E7 genes will be cloned and modified by site-directed mutagenesis. The loss of 
their transforming  activities will  be  checked  by  in  vitro transformation  assay.  The  mutated 
HPV58  E6,E7  genes  will  be  cloned  to  vaccinia  viral  vector  serving  as  the  therapeutic 
vaccine.  CTL responses will be monitored and their activities against HPV58+ tumour cells 
grown  in  vivo  will  be  examined. 
Expected outcome 
The study will  also assess the incidence and  prevalence of HPV infection and  to  estimate 
the statistical power of future vaccination trial with the HPV L  1 vaccine in  high-risk groups 
for human  cervical  cancer. 
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THE LONG-TERM IMPACT ON MORBIDITY AND MORTALITY OF MEASLES INFECTION 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1992 - June 30,  1996 
STATENS SERUM  INSTITUT,  DEPT. OF EPIDEMIOLOGY 
RESEARCH, Copenhagen, Denmark (P. AABY) 
The  original  objectives of  the  project were: 
•  To  determine  the  magnitude  and  duration  as  well  as  the  risk  factors  for  delayed 
mortality after measles  infection through  the  use  of: 
•  existing  data on  the  long-term  impact of measles  infection; 
•  organization  of further field  research  on  the  long-term  impact of  measles infection. 
Due  to  the  unexpected  observation  of  higher  mortality  among  recipients  of  high-titre 
measles  immunization,  we  added  the  further objective: 
•  To  study  the  long-term  impact  on  survival  of  high-titre  and  standard-titre  measles 
mmunization. 
Activities 
The project has used  both  re-analyses of existing data and  organized  new  studies on  the 
short and  long-term  impact of measles  infection  and  measles immunization. The  basis of 
both types of studies have been longitudinal community studies in Bandim, Guinea-Bissau; 
Bandafassi,  Senegal;  Niakhar,  Senegal  and  Matlab,  Bangladesh,  which  have  registered 
the  incidence of measles  infection  and  measles  immunization. 
Existing  data have  been  used  from  the  urban  area  Bandim  as  well  as  a sample  of rural 
villages  in  Guinea-Bissau.  Follow-up  studies  to  determine  survival  and  immunological 
status (allergy,  anergy,  T-lymphocyte subsets)  have  been  organized  in  relation  to  children 
who  had  measles  in  major  epidemics  in  1979,  1980-83,  1988  and  1991  or  received 
different  forms  of  measles  vaccines  in  immunization  trials  of  medium- and  high-titre 
measles immunization organized in the urban community in the  1980s. Five year follow-up 
studies were organized on  children who  received  measles immunization prior to  9 months 
of  age  in  the  early  1980s.  The  impact  of  measles  as  well  as  other  vaccines  has  been 
assessed  in  a national  longitudinal  cluster-cohort study. 
In  the  rural  area  Niakhar,  Senegal,  we  have followed the  impact of  measles infection and 
measles immunization since 1983. Studies have been organized of the acute determinants 
of the  severity of measles,  the treatment of measles,  the transmission  pattern  of  measles 
and the long-term survival after measles epidemics in  1983-86,  1989-90 and  1992 as well 
as the impact of standard measles immunization. High-titre measles vaccines,  Edmonston-
Zagreb (EZ-Ht)  and  Schwarz (SW-HT),  were used  in  this area in the period  1987 to  1990 
and  we  have therefore studied the  long-term survival  impact of these vaccines compared 
with  the  standard  Schwarz  measles vaccine  (SW-STD). 
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In  1991,  an  immunological  study  measured  T-lymphocyte  subsets,  neopterin,  albumin, 
C-reactive protein,  retinol,  malaria parasitemia,  and  response to rabies  vaccine to assess 
the  possible  negative  consequences  of  high-titre  measles  vaccine.  Prospective  studies 
measuring  T-lymphocytes,  nutritional  status  and  morbidity  after  measles  infection  have 
also been  organized  in  this area. 
We  re-analyzed  data  from  Matlab  in  Bangladesh  from  the  1982-86  period  where  a 
measles surveillance was ongoing and  measles vaccine  had  only been  introduced in  half 
of the study area to determine the magnitude of post-measles mortality and the impact on 
survival  of measles vaccine. 
Due to the interest in the long-term impact of measles infection and its possible relation to 
immunosuppression,  a  simple  method  for  determination  of  T-cell  subsets  under  field 
conditions was  developed. 
Results 
Measl es infection 
Contrary to  the  initial  hypotheses,  there was  no  long-term  excess mortality after measles 
infection and no persistent immunosuppression by measles infection. The tendency is rather 
the opposite that measles cases have higher CD4 counts after infection. Secondary cases 
have higher post-measles mortality than index cases of measles. Since the tendency is the 
same in the acute phase of infection with 3-5 times higher mortality for secondary cases, the 
indication is that those who have mild acute measles also have less long-term mortality for 
secondary cases, the indication is that those who have mild acute measles also have fewer 
long-term  complications.  Index cases of measles appear to  have no  increase  in  mortality 
relative  to  community  controls  without  any  measles  infection  and  may  in  fact  have 
significantly lower mortality than controls. Long-term-follow-up in a cohort of teenagers who 
had  measles  or  measles  immunization  in  1979  in  Guinea-Bissau  indicates that  measles 
infection may be protective against allergy as measured by skin prick tests. 
Standard titre vaccine 
A number of  studies  including  data from  all  the  four  study areas  involved  in  the  present 
project  have  suggested  that  standard  measles  vaccine  may  have  non-specific  beneficial 
effects.  Standard titre measles vaccine has an  effect on  survival which  is not explained by 
protection  against acute  measles  or its  long-term  consequences.  The  data from  Niahkar 
and  Bandafassi, Senegal,  have indicated that the non-specific effect of measles vaccine is 
stronger for girls.  In  a re-analysis  of data from  the  first  measles campaigns  in  Bissau  in 
1980-83,  children  who  had  been  vaccinated  at 9-11  months of age  (RR=0.61 ). 
High-titre vaccines 
Female  recipients of high-titre  (HT}  vaccines  had  reduced  survival  compared  with  female 
recipients of standard-titre vaccines.  The mortality difference is  not  related to a difference 
in  vaccine  efficacy.  In  both  Bissau  and  Senegal,  there  was  no  indication  of  a significant 
persistent immunosuppression among the recipients of high-titre measles vaccine. There is 
no  indication  that  this  effect  is  persisting  as  we  have  not  found  differences  in  mortality 
during the  last two years of the trials. 
125 Contract number TS3*CT910002 
Conclusions 
This  research  project ended  with  the opposite conclusion to the  initial  hypothesis about a 
major excess  mortality after  infection  due  to  persistent  immunosuppression.  The  original 
hypothesis was inspired by the observation of a major reduction  in  mortality after measles 
immunization  which  could  not  be  explained  by  protection  against  acute  measles  fatality. 
Hence,  it was hypothesized that measles had severe long-term consequences which were 
also  prevented  by  immunization.  However,  the  present  project  has  shown  that  the 
explanation  is the  opposite.  Mild  measles infection  appears to  be  better than  no  infection 
as  it  is  associated with  lower mortality compared with  uninfected children.  In  this  respect,. 
the  likely explanation of the impact of measles vaccine is that it has a similar non-specific 
beneficial  effect as  the  natural  disease.  This  perspective  became  important  in  relation  to 
the  unexpected  observation  of higher mortality for girls after HT measles  immunization. 
There  is  no  data to  indicate that high-titre vaccine  in  itself has a deleterious effect.  It was 
associated  with  higher  mortality  in  areas  with  low  background  mortality.  It  was  not 
associated  with  higher  mortality  compared  with  unvaccinated  children.  There  was  no 
indication that measles is  associated with  long-term excess  mortality which  would  explain 
the  biological basis for excess mortality after HT vaccines,  much  less  is there a tendency 
that  measles  has  a  long-term  negative  effect  exclusively  for  girls.  There  is  no  data  to 
suggest  an  important persistent immunosuppression  after HT vaccines. 
Again  st this background,  the  most likely explanation  may  be that the  mortality difference 
is a question of the relative benefits of different vaccines. The difference in  mortality is only 
found in comparison with  recipients of SW-STD. Since both measles infection and measles 
immunization are associated with a beneficial effect which  is probably due to some form of 
immunostimulation,  the  differential  mortality between  high-titre and  standard  titre  measles 
vaccines  could  be  due  to  a difference  in  the  non-specific  effects.  To  a  large  extent,  the 
reduced  survival  among  recipients  of  high-titre vaccines  is  due  to  the  beneficial  effect on 
girls of  standard  measles vaccine. 
While we  have  no  indication  of specific biological  mechanisms involved  in  these  mortality 
differences,  it seems likely that dose is important. This possibility is also supported by the 
fact that we have observed long-term differences in  morality after natural measles infection 
depending on whether the person can  be assumed to be infected with a small dose (index 
case)  or a large dose of  measles virus  (secondary cases). 
The  observations  on  high-titre  vaccines  have  had  the  consequence  that  WHO  recom-
mended  the  withdrawal  of  high-titre  EZ  vaccine  at  6  months  of  age  in  developing 
countries.  The  observations on  non-specific and  sex-specific  effects of  standard  measles 
vaccine  and  measles  infection  warrant  futher  studies  as  they  may  have  important 
implications for future  control  and  immunization  strategies. 
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Partners 
Statens Serum lnstitut 
Dept. of Epidemiology Research 
Artillerivej 5 
OK - 2300 Copenhagen S 
Denmark 
Medic al  Research Council Laboratories 
P.O.  Box 273 
Banjul 
The Gambia 
ORSTOM 
BP 1386 
Dakar 
Senegal 
International Centre for Diarrhoeal Disease 
Research 
GPO Box 128 
128 Dhaka 2 
Bangladesh 
P.  Aaby 
Tel: +45/3/268.39.50 
Fax: +45/3/268.31.65 
E-mail: paa@ ssi.dk 
H. Whittle 
Tel:  +220/49.57.77 
Fax: +220/49.65.13 
F.  Simondon 
Tel:  +221/32.43.07 
A.  Bhuiya 
Tel:  +880/2/88.31.16 
Fax. +880/31/68.20.30 
E-mail: bcctg@spctnet.com 
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STUDY  OF  THE  IMMUNE  DISRUPTION  CAUSED  BY MEASLES AND  ITS  ASSOCIA-
TION  WITH  CLINICAL PROGRESS IN  DHAKA, BANGLADESH 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1995 - December 31 , 1996 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE, 
EPIDEMIOLOGY AND POPULATION SCIENCES 
London, United Kingdom  (F.  CUTTS) 
•  To  compare  changes  in  measles-specific  antibody  profile  and  cytokine  profile  after 
measles or measles vaccination,  and determine the duration  of abnormalities. 
•  To trace the expression of measles virus (MV)-specific RNAs in  different subpopulations 
of peripheral  blood  mononuclear cells  (PBMCs)  and compare the target cells of MV  in 
natural  infection versus vaccination. 
•  To  analyze  surface  molecule  changes  (including  RCA  and  LFA-1)  on  lymphocyte 
populations as  a result of viral  infection or vaccination. 
•  To compare morbidity and the immune response to challenge with  hepatitis B vaccines 
(HBV)  among  result  of viral  infection  or vaccination. 
Activities 
A prospective cohort study will  be conducted in  Dhaka,  Bangladesh. The following cohorts 
of children  will  be  recruited: 
Measles cases: 
*  A community-based  cohort of  11 0 cases of acute  measles; 
*  A hospital cohort of  11 0  cases of complicated  measles. 
Controls  (age  matched to  cases): 
*  A community-based control  group of  11 0 healthy children; 
*  A  hospital-based  control  group  of  11 0  children  attending  with  diseases  other  than 
measles. 
Measles vaccines: 
*  A  group  of  25  children  vaccinated  with  standard  titre  measles  vaccine  at  age  of  9 
months; 
*  A group of 25 children  vaccinated at ages 6 and  9 months. 
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The  research  plan  is  divided into the following  sections: 
*  Collection of  information on  morbidity among each cohort,  by weekly interviews for six 
months after recruitment.  Measurement of anthropometric status monthly.  Children with 
episodes  of  illness  will  be  referred  to  the  study  physicians  for  examination  and 
appropriate X-ray and  laboratory investigations.  Mothers will  be  invited to  bring acutely 
ill  children  to  ICDDR,  Hepatitis  B clinic at any time  during follow-up. 
*  Measurement of the serological  response to a series of 3 doses of hepatitis B vaccine 
in  each  cohort. 
*  Measuremen t of interferon-gamma (IFN-y and  interleukin-5  IL5 cytokines using whole 
blood assays in  each cohort at recruitment, six weeks and six months after recruitment. 
*  On  a subsample  of 25  children  in  each  cohort,  in  vitro  analyses of the  target cells  of 
measles virus,  surface  molecule changes,  and  indices of immune disruption. 
Expected outcome 
=> The  project  aims  to  provide  information  to  assist  in  understanding  the  basis  for  the 
immune  disruption  after  measles,  and  raise  hypotheses  for  the  mechanism  of  differ-
ences  in  persistence of immunity after measles disease or measles vaccination. 
=>  Bangladesh investigators will be trained in clinical epidemiology. The technique of whole 
blood assays for cytokines will  be  transferred to  Bangladesh. 
Partners 
London School of Hygiene and Tropical 
Medicine 
Epidemiology and Population Sciences 
Keppel Street 
London 
United Kingdom 
University of Wurzburg 
Fac. fur Virologie 
Versbacher Str.  7 
Wurzburg 
Germany 
lnternat. Center for Diarrhoeal Disease 
Research 
GPO Box 128 
Dhaka 
Bangladesh 
F.  Cutts 
Tel:  +44/171 /636.86.36 
Fax: +44/171 /436.42.30 
E-mail: fcutts@Lshtm.ac.uk 
V. Ter Meulen 
Tel:  +93/1/201.59.54 
Fax: +93/1 /201.39.54 
S.M. Akramuzzaman 
Tel: +88/0/260.01.71  - 8 
Fax: +88/0/288.31.16 
E-mail: azaman.cholera@external.ait.ac.th 
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SPECIFIC  AND  NON-TARGETED  EFFECTS  OF  A  TWO-DOSE  STRATEGY  WITH 
STANDARD  TITRE  MEASLES  VACCINE.  IMPLICATIONS  FOR  IMMUNIZATION  PRO-
GRAMMES 
Period: 
Co-ordinator: 
Objectives 
January 1,  1996 - December 31, 1999 
STATENS SERUM INSTITUT, DEPT. OF EPIDEMIOLOGY 
Copenhagen, Denmark (PETER AABY) 
The  general  objectives are: 
•  To  reduce childhood mortality in  developing countries through better control of measles 
infection  by developing a better immunization  strategy. 
•  To  investigate  the  hypothesis  that  standard  titre  measles  immunization  is  associated 
with  non-targeted  beneficial  effects  on  childhood  morbidity and  mortality  in  developing 
countries. 
The  measurable,  specific objectives are: 
•  To  examine whether a two-dose strategy for measles immunization at 6 and  9 months 
of  age  can  reduce  measles  incidence  by  50°/o  through  better  coverage  or  improved 
seroconversion. 
•  To  examine whether a two-dose strategy for measles immunization at 6 and  9 months 
of  age  can  reduce  childhood  mortality  by  20°/o  through  better  coverage,  better 
protection  against measles or non  targeted  beneficial  effects. 
•  To  determine the magnitude and duration of non-measles related changes in  morbidity 
patterns after standard titre measles immunization, in  particular to test whether measles 
immunization  is  associated with  a  15°/o  reduction  in  the  risk of diarrhoea. 
•  To determine non-measles related immunological changes among recipients of measles 
vaccine in  order to establish possible pathways for the non targeted effects of standard 
titre  measles immunization. 
Activities 
*  Conducting the trial  of two-dose standard titre  measles vaccination  in  Bissau. 
*  Conducting the  studies of  morbidity and  anthropometry. 
*  Performing the  immunological  studies  included  in  the two-dose trial. 
*  Performing data-control  and  data-analysis. 
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Expected outcome 
=>Vaccine efficacy:  vaccine  efficacy will  be  assessed both  as cumulative  incidence from 
the  time  of  entering  the  study  at  six  months  of age  and  as  protection  rate  following 
exposure from  a  measles case  in  the same house. 
=>Measles antibodies: measles antibody responses as well as decay in  measles antibod-
ies  levels  will  be  analysed for a  subgroup of individuals.  Since  previous studies  have 
shown that antibody titre below 125 miU are not protective, children with such low titres 
at 18 months of age will  be  offered  reimmunization. 
=>  Mortality: cumulative mortality will  be  analysed from entry into the study at 6 months of 
age or later to the censoring date. 
=>  Research training:  training abroad of one Guinean physician  in  research  methodology. 
Partners 
Statens Serum lnstitut 
Dept. of Epidemiology Research 
Artillerivej 5 
2300 Copenhagen S 
Denmark 
MAC Laboratories 
f'ajara 
PO Box 273 
Banjul 
The Gambia 
Ministerio de Saude Publico 
Laboratorio Nacional de Saude Publico 
CP 50, Bissau 
Guinea-Bissau 
Peter Aaby 
Tel:  +45/32/68.39.50 
Fax: +45/32/68.31.65 
E-mail: paa@ssi.dk 
H. Whittle 
Tel:  +220-49.54.42 
Fax: +220-49.65.13 
Francisco Dias 
Tel:  +245-25.24.04 
Fax: +245-25.24.04 
E-mail: lnsp@ sol.gteleco.gw 
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FACTORS  ASSOCIATED  WITH  THE  SEVERITY  OF  MEASLES  AND  OF  DELAYED 
COMPLICATIONS OF  MEASLES 
Period: 
Co-ordinator: 
Objectives 
January 1, 1997- December 31,  1998 
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE 
London,  United Kingdom  (F.  CUTTS) 
•  To  compare  levels  of  IL-5,  IL-10,  and  IFN-(,  at  recruitment,  6  weeks  and  6  months 
post-recruitment,  in  children  with  and  without  complications  within  6  weeks  of  rash 
onset,  among  those  who  had  no  complications  at  enrollment. 
•  To  determine  if  there  is  an  association  between  levels  of  IL-5,  IL-1 0,  and  IFN-(at  6 
weeks and  6 months post-measles,  delayed-type-hypersensitivity (DTH)  responses at 6 
weeks and  the development of complications  (pneumonia,  severe  pneumonia,  invasive 
diarrhoea,  or hospitalisation for other reasons)  6-24  weeks  after measles  onset. 
•  To  compare  the  risk  of  complications  among  vaccinated  vs  unvaccinated  cases. 
•  To  determine  the  association  between  cytokine  profiles  at  6  weeks  and  6  months 
post-measles onset and  early age  at  measles  infection,  sex,  and  vaccination  status. 
+  To  compare  cytokine profiles measured  by whole  blood  assays with  results of conven-
tional  assays  on  PBMCs  on  a subsample  of children. 
Activities 
This  a  nested  case-control  study  within  a  study  evaluating  long-term  morbidity  after 
measles.  Commercial  ELISA kits  will  be  used  to  measure  IL-5,  IL-10,  and  IFN-(Ievels  in 
supernatant from  whole  blood  assays at recruitment,  6 weeks  and  6 months at  ICDDR,B 
on  approximately 200 measles cases.  Cases and  controls will  be defined among  measles 
cases with  and  without complications at different times after measles onset. The following 
factors  will  be  investigated  for  a  potential  association  with  early  and  late  complications 
from  measles:  (i)  Age;  (ii)  Sex;  (iii)  Vaccination  status;  (iv)  Interval  between  onset of  rash 
and  initiating  treatment;  (v)  Primary  or  secondary  case;  (vi)  Cytokine  profile;  (vii)  DTH 
response  6 weeks  after recruitment.  We  will  have  80°/o  power to  detect  an  odds  ratio  of 
3.5  to  4.5 for different exposures of interest at  the  95o/o  significance  level. 
Expected Outcome 
~  Information  on  factors  associated  with  early and  delayed  complications from  measles. 
~Confirmation or  not  of  the  hypothesis  that  complicated  measles  cases  have  a  bias 
towards a Th2  response. 
~Establishment of the capacity to conduct whole  blood assays for cytokines at ICDDR,B 
~  A paper for  publication  in  peer-reviewed  journals. 
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Partners 
London School of Hygiene and Tropical 
Medicine 
Keppel street 
London WC1 E 7HT 
United Kingdom 
International Centre for Diarrhoeal 
Disease Research (ICDDR) 
Dhaka 1000 
Bangladesh 
University of Wurzburg 
lnst. of Virology and Immunology 
Versbacher strasse 7 
97078 Wurzburg 
Germany 
F.  Cutts 
Tel: +44/171/927.22.09 
Fax: +44/171 /436.42.30 
E-mail: fcutts@lshtm.ac.uk 
A. Akramuzzaman 
Tel:  +880/2/87.17.51 
Fax: +880/2/88.31.16 
E-mail: azaman.cholera@ external.ait.ac.th 
V. Ter Meulen 
Tel: +49/931/201.59.54 
Fax: +49/931/201.39.34 
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CONTRIBUTION TO THE  ELIMINATION  OF MEASLES FROM AFRICA 
Period:  October 1  , 1996 - September 30,  1999 
Co-ordinator:  ERASMUS UNIVERSITY 
Rotterdam, The Netherlands (ADME OSTERHAUS) 
Objectives 
•  Implementation  of  rapid,  simple  and  cheap  diagnostic  tests  for  measles  that  can  be 
used  under field  conditions. 
•  Establishment of  a  diagnostic virological  lab,  operating  according  to  WHO  standards. 
This lab may participate  in  WHO eradication  efforts for measles in  the near future. 
•  Evaluation  of the  epidemiology of  measles  in  the  Sudan,  including  vaccine  coverage 
and  efficacy. 
•  Insight  in  the  overall  health  impact  of  measles  in  the  Sudan,  including  estimation  of 
case-fatality ratios. 
•  Evaluation  of  naturally  acquired  and  vaccine-induced  measles  virus-specific  antibody 
and  T-cell  mediated  immunity. 
+ Knowledge about the mechanisms of measles-induced  immunosuppression. 
Activities 
Field work 
*  Establishment and  follow-up  of  a  cohort for the  measurement of maternal  antibodies, 
the  estimation  of  the  true  incidence  of  measles  and  the  performance  of  the  new 
diagnostic field  test. 
*  Establishment  of  a  cohort  of acute  measles  cases  for  immunological  and  virological 
studies. 
Lab work 
After  training  in  Rotterdam  and  Lyon,  immunological  and  virological  studies  will  be 
continued  in  the  Institute of Endemic  Diseases in  Khartoum,  in  which  a  new virology  lab 
will  be  established. 
Training 
A  MD  student  (epidemiological  work,  diagnostic  test  and  a  PhD  student  (immunological 
and virological  studies)  from  the  Sudan  will  be  trained  in  this project. 
Expected outcome 
=>Technology transfer from WHO reference labs to the Sudan, including the building of an 
infrastructure  and  training  of  personnel,  which  will  be  essential  in  the  planned  WHO 
global  eradication program  for measles. 
=>Knowledge about epidemiology and  health  impact of measles in  the  Sudan. 
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==>Knowledge  about the  immune  response to measles virus and  the mechanisms under-
lying  measles-induced immunosuppression. 
==>  Publication  in  peer-reviewed international  scientific journals. 
==>An  MD  and  a  PhD  thesis will  be written  by the  Sudanese students. 
Partners 
Erasmus University6 
Institute of Virology 
P.O.  Box 1738 
3000 DR Rotterdam 
The Netherlands 
lnstitut Pasteur de Lyon 
lmmunologie et Strategie Vaccinale 
Avenue Tony-Garnier 
69365 Lyon Cedex 07 
France 
University of Khartoum 
Institute of Endemic Diseases 
P.O.  Box 102 
Khartoum 
Sudan 
University of Khartoum 
Dept. of Paediatrics and Child Health 
P.O.  Box 102 
Khartoum 
Sudan 
E.E. Zijlstra/R.L. de Swart 
Tel:  +31/10/408.80.66 
Fax: +31/10/436.51.45 
E-mail:  osterhaus@viro.fgg.eur.nl, 
deswart@ vi ro. fgg.eur. nl 
F. Wild 
Tel:  +33/4n2.72.25.55 
Fax: +33/4n2.  72.25.67 
E-mail: FWIPALY imaginet.fr 
A.M. EI-Hassan 
Tel/fax: +249/1/177.54.74 
E-mail: mmukhtar@compuserve.com 
S.A. Ibrahim 
Tel:  +249/1/177.61.32 
Fax: +249/1 /178.58.79 
E-mail:mibbrahim @computo.catie.ac.cr 
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Areas of interest: 
6.  Pneumococcal vaccine development 
TS3*CT920086 
IC18*CT950025 
IC18*CT970219 
Polyvalent streptococcus polysaccharide capsular vaccine 
Evaluation of respiratory vaccines for children in South East 
Asia: streptococcus pneumoniae (and Hib) conjugate 
vaccines in prevention of childhood pneumonia in developing 
countries. 
Field studies of pneumococcal conjugate vaccines to prevent 
ARI in South East Asia - effectiveness of an  11-valent 
vaccine; safety and immunogenicity of a 4-valent vaccine 
under development 
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POLYVALENT STREPTOCOCCUS POLYSACCHARIDE CAPSULAR VACCINE 
Period: 
Co-ordinator: 
Objectives 
April  1, 1993- March 31,  1995 
NATIONAL INSTITUT OF PUBLIC HEALTH AND 
ENVIRONMENT PROTECTION 
Bilthoven, The Netherlands (W.  WITTKAMP) 
+  To  develop and  test a multivalent pneumococcal polysaccharide (PS)-protein conjugate 
vaccine containing the PS of the most prevalent pneumococcal serotypes (at least 1,  5, 
68,  14,  19F,  23F). 
+  To  ensure the implementation of the selected vaccine in  the developing world,  avoiding 
developmental  cost  implementation. 
Activities 
The  research  work can  be  separated  into a number of activities: 
*  Isolation of the capsular PS of the most invasive pneumococcal types (1,  5,  68, 14,  19F 
and  23F)  was  by  established  methods.  The  vaccine  protein  toxoid  (TT)  produced  by 
standard  methods  is  available for the  project. 
*  Coupling  of  the  PS  to  the  protein  carrier will  be  done  by  the  thioether  method.  This 
coupling  method  gives  stable  and  characterized  products.  The  PS  are  depolymerized 
by  various  methods  to  shorter  molecules  of  defined  length  (approx:  20-60  monosac-
charide  residues).  Methods  for  the  depolymerization  and  control  of  size  are  already 
established. 
*  All  conjugates and the corresponding  PS  controls will  be  tested for  immunogenicity by 
immunizing  mice  and  rabbits,  and  determining  lgM  and  lgG  antibodies in  their sera to 
the  respective  pneumococcal  PS  after 1 and  2 doses of vaccine. 
High antibody response,  lgG:IgM ratio,  and an  increased (booster) response to the second 
dose  of  vaccine  will  be  the  criteria  for  T  dependency.  Animal  infection  models  such  as 
intraperitoneal  and  intratracheal  challenge  will  be  used.  Also,  sera  selected  from  immu-
nized  children  will  be  analyzed. 
*  In the first phase, at least two alternative methods for conjugation will be tested in order 
to  choose the  best one  to  be  adopted  for the  prototype vaccine. 
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Conjugates will  be  prepared from  all  selected  PS.  They will  be  combined  in  the prototype 
vaccine. A large enough batch will  be made under GMP to allow extensive field studies for 
efficacy  (at  least  100,000 doses). 
The prototype vaccine will  be subjected to phase I and phase  II  tests in  human volunteers. 
Sera  of  immunised  volunteers  and  controls  will  be  tested  by  EIA  (lgM  and  lgG)  to  the 
pneumococcal capsular PS,  to  C-PS  (the C-PS common to all  types of pneumococci) and 
also to  the  carrier protein. 
Expected outcome 
The  expected  outcome  is  the  availability  of  the  technology  to  produce  a  multivalent 
pneumococcal  conjugate vaccine. 
Result 
=>  Durin  g  the  first  years  of  the  project,  the  laboratory  work  was  concentrated  on  the 
preparation  of  numerous  saccharide-tetanus toxoid  conjugates  of  pneumococcal  sera-
types  GB14,  19F and  23F.  For this purpose a batch  of pneumococcal  polysaccharides 
GB19F  (Pn19F),  23F  (Pn23F)  and  14  (Pn14)  and  of purified tetanus toxoid  (Tid) has 
been prepared.  Polysaccharides were decreased to an approximate molecular weight of 
either  50kD  or  350kD  by  mechanical  sheering.  A thioether  linkage  was  used  for  the 
coupling  of  saccharides  to  protein.  After  coupling,  products  were  purified  using  either 
gel  permeation  or  gel  filtration  chromatography.  Next to  the  preparation  of conjugates 
with  saccharides of 50kD,  conjugates with various saccharide:  protein ratios have been 
prepared.  The developed conjugate vaccines are  being tested  for their immunogenicity 
in  animal  experiments.  Furthermore,  assays  to  control  the  production  process  the 
quality of protein and the final saccharide-protein conjugates were set up. These assays 
include: estimation of purity of polysaccharides according to rules as established by the 
American  and  European  Pharmacopoea,  the  estimation  of  free  protein  and  free 
polysaccharide  in  saccharide-protein  conjugates,  the  estimation  of  the  thiol  (SH-
incorporated  in  the  polysaccharide)  after  spacer  introduction  and  furthermore,  the 
determination  of  the  relative  amount  of  cell  wall  polysaccharide  (CPS)  in  several 
polysaccharides. 
=> An  animal  model  for  challenge  experiments  with  pneumococci  was  developed  at  the 
Norwegian  National  Institute  of  Public  Health  Oslo.  The  LD50  for  intraperitoneal  and 
intratracheal  challenge  with  S.  pneumoniae serotypes  1,  5,  68,  14,  19F  and  23F  in 
Balb/c and  C57BU6 has  been  determined. 
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~Serological assays  for  analysis  of  anti-polysaccharides  antibodies  in  human  sera  and 
study  sites  for  field  evaluation  were  developed  at  the  Finnish  National  Public  Health 
Institute,  Helsinki.  Monoclonal  antibodies  to  various  serotype  specific  pneumococcal 
polysaccharides and to cell  wall polysaccharides were developed at the Danish Statens 
Serum  Institute,  Copenhagen. 
~  For  purpose  of  coordination  of  the  development  and  field  trial  of  a  multivalent 
pneumococcal  conjugate  vaccine,  a  coordination  group  was  established  within  the 
DNC.  The  group  consists  of  the  project  leaders  of  each  of  the  Scandinavian  Public 
Health  Institutes  and  of  RIVM,  the  Netherlands  Public  Health  Institute.  On  May  10 
(1993}  a meeting  was  held  to  discuss the  financial  and  technical  status of  the  agreed 
programme for each  of the participants. The group concluded that the joint project was 
progressing  well.  Additional  meetings for the  purpose  of coordination  of field  trial  of  a 
multivalent  pneumococcal  conjugate  vaccine  were  attended  by  members  of the  DNC. 
During  those  international  meetings discussions were  held  how to  establish  a network 
of  laboratories  in  Latin-America  which  are  able  to  carry  out  proper  diagnostic  and 
epidemiological  studies  on  pneumococcal  diseases,  future  pneumococcal  vaccines  for 
use against Acute Respiratory Infectious Diseases in developing countries, and possible 
sites  for trials  with  pneumococcal  conjugates. 
~  The efforts of the final period of the project (1995 - 1997) are focused on two matters: 
1.  The  preparation  of  a clinical  lot  of  a tetravalent  (GB,  14,  19F,  23F)  pneumococcal 
polysaccharide  vaccine  conjugated  to  tetanus  toxoid.  All  procedures  have  been 
worked  out  on  a  laboratory  scale.  A  clinical  lot  will  be  prepared  under  Good-
Manufacturing-Procedures  (GMP). 
2.  The  preparation  of  sites  in  the  Philippines  (and  Vietnam)  which  are  capable  of 
performing  human  immunogenicity studies.  The  study sites  and  the  trained  person-
nel  are  ready  for these  tests. 
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Partners 
Nat.  lnst. of Public Health and Environment 
Protection 
Lab.  of Vaccine Dev.  and Immune 
Mechanisms (LUM) 
P.O.  Box 1 
3720 BA Bilthoven 
The Netherlands 
Statens Seruminstitut 
Dep. of Bacteriology 
Artillerivej 5 
2300 Copenhagen S 
Denmark 
Research Institute for Tropical Medicine 
Dept.  Immunology 
Alabang, Muntinlupa 
Metro Manila 
Philippines 
W. Wittkamp 
Tel:  +31/30/74.27.01 
Fax: +31/3029.07.49 
E-mail: w.wittkamp@rivm.nl 
J. Henrichsen 
Tel:  +45/32/68.32.68 
Fax: +45/32/68.38.68 
R.  Capeding 
Tel:  +63/2/852.22.45 
Fax: +63/2/842.22.45 
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EVALUATION  OF  RESPIRATORY VACCINES  FOR  CHILDREN  IN  SOUTH  EAST ASIA: 
STREPTOCOCCUS  PNEUMONIAE  (AND  Hib)  CONJUGATE  VACCINES  IN  PREVEN-
TION  OF  CHILDHOOD PNEUMONIA IN  DEVELOPING  COUNTRIES 
Period: 
Co-ordinator: 
Objectives 
January 1, 1996- December,  31  1997 
NATIONAL PUBLIC HEALTH INSTITUTE 
Helsinki, Finland (PH MAKELA) 
•  To  consolidate  work  of  the  already  established  vaccine  evaluation  centre  in  the 
Philippines,  i.e.  the  Research  Institute  for  Tropical  Medicine  (RITM),  Manila  and  to 
develop  a  new  vaccine  evaluation  center  in  Vietnam  as  collaboration  between  the 
Pediatric  Hospital  No  1 (PHN1)  and  its  counterpart (RH),  Copenhagen. 
+ To obtain baseline epidemiologic information from the two centres on  natural acquisition 
of pneumococcal (Pnc) and  Haemophilus influenzae type b {Hib) antibodies and of Pnc 
and  Hib  in  the  etiology of ARI  in  children  <5  years  of age. 
•  To  monitor the  safety  and  determine  the  immunogenicity  of  candidate  vaccines  (Pnc 
and  Hib  conjugate vaccines)  in  infants  in  the  SEA region. 
Activities 
*  Collect  baseline  antibody  and  carriage  data  of  Pnc  and  Hib  in  the  Philippines  and 
Vietnam. 
*  Determine the  role and types of Pnc and  Hib  in  hospital treated  pneumonia in  children 
less than  5 years  of  age  (Philippines,  Vietnam). 
*  Vaccination  by  public  health  personnel  in  local  health  centers  within  EPI  schedule. 
Vaccine safety measured by structured parental monitoring and  home visits by a nurse. 
*  A venous  blood  sample  is  obtained  when  the  child  enters  the  study  at specified  time 
points  after vaccination.  All  antibody analyses will  be  done  at  KTL. 
*  Safety and immunogenicity of the Hib conjugate in  infancy in Vietnam will  be studied as 
above.  The  data will  also  provide  baseline  information  referred  to above. 
*  Monitoring of  the  quality of the  research,  cold  chain,  laboratory,  forms,  and  data entry 
will  be  carried  out according  to  GLP/GCP principles. 
Expected outcome 
==>There  will  be  two  experienced  vaccine  evaluation  centers  in  South-East Asia. 
==>  Safety and  immunogenicity of  pneumococcal  conjugate vaccine established. 
==>  Safety and  immunogenicity of Hib  conjugate vaccine  established  in  Vietnam. 
==>  Basal  data needed for the  planning of  Pnc  and  Hib vaccination  programs and  efficacy 
trial  will  be  available from  two  areas  in  the  South-East Asian  region. 
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Partners 
National Public Health Institute 
Dept. of Vaccines 
Mannerheimintie 166 
00300 Helsinki 
Finland 
Research Institute for Tropical Medicine 
Dept. of Health Compound 
Alabang, Muntinlupa 
Manila 
The Philippines 
Pediatric Hospital n° 1 
Dept. of Clinical Health 
N° 2 Su-Uan-Ganh 
Ho Chi Minh City 
Vietnam 
Rigshospitalet 
Pediatric Clinic II 
Julian Marie Center 
Blegdamsvej 9 
2150 Copenhagen 
Denmark 
Pasteur Merieux Serums & Vaccins 
3 avenue Pasteur 
92430 Marnes Ia Coquette 
France 
P.H. Makela 
Tel:  +358/9/474.42.35 
Fax: +358/9/474.46.75 
E-mail: Pirjo.makela@ktl.fi 
M. Lucero 
Tel:  +63/2/807.26.34 
Fax: +63/2/842.22.45 
E-mail: philari@ pworld.net.ph 
Tran-tan Tram 
Tel:  +84/8/35.11.19 
Fax: +84/8/35.60.35 
E-mail: dr tram@bvnd1.gov 
F.  Karup Pedersen 
Tel:  +45/35/45.38.64 
Fax: +45/35/45.46.73 
E-mail: rho2137@rh.dk 
0. Leroy 
Tel:  +33/1/47.95.80.50 
Fax: +33/1/47.95.80.00 
E-mail: oleroy@fr.pmc.vacc.com 
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FIELD STUDIES OF PNEUMOCOCCAL CONJUGATE VACCINES TO  PREVENT ARI IN 
SOUTH  EAST ASIA- EFFECTIVENESS OF AN  11-VALENT VACCINE;  SAFETY AND 
IMMUNOGENICITY OF A 4-VALENT VACCINE  UNDER  DEVELOPMENT 
Period: 
Co-ordinator: 
Objectives 
October 1  , 1997 - September 30,  1999 
NATIONAL PUBLIC HEALTH INSTITUTE, Dept. of Vaccines, 
Helsinki, Finland (P.H.  MAKELA) 
To  find  an  effective  primary  prevention  for  a  significant  fraction  of  acute  respiratory 
infections  (ARI),  especially  of  severe  ARI  and  related  severe  disease  in  infants  and 
children  in  developing countries. 
Specifically to: 
•  prepare,  initiate,  and  carry  out  the  first  half  of  an  effectiveness  study  with  a  new 
11-valent pneumococcal conjugate vaccine (Pnc-c) using meningococcal A,C as control, 
and  administered  within  the  national  immunization  programme  (EPI)  on  the  island  of 
Bohol,  the  Philippines 
•  assess safety and immunogenicity in both industrialized and developing country settings 
(Finland,  Vietnam)  of the 4-valent Pnc-c developed  15y  the  Dutch-Nordic consortium. 
Activities 
The preparatory activities to pave the  way for the effectiveness trial  include: 
*  enrolling infants of the target populations at 6 weeks of age in  primary health centers to 
a randomised,  controlled,  blinded  immunogenicity and safety studies of the  Pnc-c 
*  piloting the crucial  EPI  activities, randomization and record linkage procedures; upgrad-
ing  the  infrastructure  and  skills  of  personnel  to  meet the  standards  of Good  Clinical 
Practice  (GCP)  at the study sites 
*  setting  up  vaccinovigilance activities to evaluate the short and  long term  safety of the 
study vaccines 
*  maintaining  and  setting  up  surveillance  activities and  clinical  skills to  detect cases for 
the primary endpoint, i.e. pneumonia and severe pneumonia in children 4 to < 23 moths 
of age both  in  hospitals and  in  primary health  care settings 
*  identifying all  Pnc pneumonia cases both  by standard culture and  alternative methods, 
i.e.  antigen  detection,  and  measurement of pneumolysin  immune complexes 
*  within the effectiveness study,  follow up a nested cohort of infants for the impact of the 
Pncc  on  the  upper  respiratory  tract  carriage  of  Pnc,  for  establishing  serological 
correlates for protection,  and for immunogenicity of the vaccine 
*  identifying  unit costs to  measure the cost benefit of the  Pnc-c 
*  establishing  monitoring  activities to comply with  the GCP and  ICH  guidelines. 
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Expected outcome 
Demonstrate the immunogenicity and safety of the suggested  Pnc-c vaccines. The study, 
once completed, will provide evidence on the efficacy, effectiveness and cost-benefits and 
establish  serological  correlates  for protection  of the  11-valent  Pnc-c.  The  results  will  be 
directly and immediately applicable to countries of the South East Asian  region,  and more 
widely  to  developing  countries  with  a  moderate  infant  mortality  rate  of 40-60 I  1000.  In 
addition,  these  studies  will  strengthen  the  skills  of  collaborating  researchers  in  both 
developing  and  developed  countries  to  perform  small  and  large  scale  vaccine  trials 
according to the GCP requirements. 
Partners 
National Public Health Institute 
Department of Vaccines 
Mannerheimintie 166 
00300 Helsinki 
Finland 
Research Institute for Tropical Medicine 
Department of Health Compound 
Alabang, Muntinlupa 
Metro Manila 
The Philippines 
Pasteur-Merieux Serums & Vaccines 
3 Avenue Pasteur 
92430 Marnes Ia Coquette 
France 
Pediatric Hospital No 1 
Dept. of Clinical Health and Development 
No 2 Su Uan Hanh 
Ho Chi Minh City 
Vietnam 
Rigshospitalet 
Department of Pediatrics 
9 Blegdams vej 
2160 Copenhagen 
Denmark 
Statens Seruminstitut 
Artillerivejen 5 
2300 Copenhagen 
Denmark 
National Institute of Public Health 
and Environmental Protection 
P.O.  Box 1 
3729 BA Bilthoven 
The Netherlands 
P.H.  Makela 
Tel: +358/9/47.44.82.30 
Fax: +358/9/47.44.86.75 
E-mail: pirjo.makela@ ktl.fi 
M.G. Lucero 
Tel:  +63/2/807.26.34 
Fax: +63/2/842.22.45 
E-mail: dohritm@ psdn.org.ph 
0. Leroy 
Tel:  +33/1/47.95.80.15 
Fax: +33/1/47.95.80.00 
E-mail: oleroy@fr.pmc-vacc.com 
Tran-Tan Tram 
Tel:  +84/8/35.11.19 
Fax: +84/8/35.60.53 
E-mail: dr tram@ bvnd1.gov 
F.  Karup Pedersen 
Tel:  +45/32/68.36.00 
Fax: +45/32/45.46.  73 
E-mail: RH02137@rh.dk 
J. Henrichsen 
Tel: +45/32/68.36.00 
Fax: +45/32/68.81.24 
L. Van Alphen 
Tel:  +31/30/274.27.01 
Fax: +31/30/274.429 
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INTERVENTION AGAINST DIARRHOEAL DISEASES BY IMPROVING CASE MANAGEMENT 
Period: 
Co-ordinator: 
Objectives 
November 1  , 1992 - October 31,  1995 
STATENS SERUMINSTITUT, EPIDEMIOLOGY RESEARCH  UNIT, 
Copenhagen, Denmark (K.  MOELBAK) 
The  purpose  of  the  study  was  to  clarify  whether  the  incidence  of  severe  diarrhoea  and 
persistent  diarrhoea  could  be  reduced  by  improving  case  management  and  feeding 
practices,  including the  promotion  of  breast-feeding. 
Activities 
The  study  was  conducted  as  a  randomised  controlled  trial  of  a  health  education 
intervention. The intervention was  undertaken at antenatal-and child-vaccination-visits at a 
local  government health centre. These activities are among the  most popular of the health 
services  in  most. developing  countries. 
In  the  first  phase  of  the  study,  the  pre-intervention  phase,  the  optimal  form  and 
composition of the health education message was determined. This was achieved by rapid 
ethnographic  techniques:  in-depth  interviews,  group  interviews,  household  observations, 
and  focus  group  discussions. 
The  pre-intervention  phase  included  also  studies  of  management  of  sick  children  and 
feeding  practices. 
The  second  phase  of  the  study  was  the  intervention  phase.  All  the  households  in  the 
periurban  area  of  Bandim  were  clusterwise  randomised  to  an  intervention  group  or  a 
control group. The target population was the mothers with  infants born between May 1992 
and April  1993.  In  addition,  an  external control group,  of similar size was followed in  order 
to assess a possible "contamination" of the control group from the intervention- mothers 
within  Bandim.  All  children  were  followed  by weekly  morbidity  recall  interview  in  order to 
measure  incidence  of diarrhoea and  case-management practices. 
In  the  intervention  group,  a  standardized  message  was  passed  on  to  the  mother 
concerning the  following  aspects: 
*  Management of diarrhoea,  with  emphasis on  use of ORS  (Oral  Rehydration  Salts)  and 
continued  breast feeding. 
*  Encouraging lactation to the age of two years,  and preventing premature termination of 
breast-feeding. 
*  The  appropriate time  of  introducing weaning  foods  (4  to  6 months).  * In  addition,  information  on  family  planning  was  provided,  as  a large  part  of the  early 
weanings was  due  to  pregnancy of the  mother. 
The  message was  delivered to  the  mother by a social  worker on  an  individual basis.  The 
session  lasted  about  1  0  minutes,  and  included  - if  appropriate  - a discussion  of  the 
mother's own  experiences with  childhood  diarrhoea. 
Results 
A  number  of  findings  from  the  pre-intervention  phase  have  been  published.  Verbal 
autopsies were used to investigate care-seeking prior to fatal illness in young children. The 
vast majority of children  with  fatal  illness were seen  on  at least one,  but often  on  several 
occasions,  at  health. centres  or  hospitals.  There  was  no  evidence  of  mother's  delay  in 
care-seeking  as  an  important cause  of  fatal  outcome. 
The  study  suggests  that  training  of  health  workers  and  the  establishment  of  appropriate 
systems  for  triage  and  referral  may  be  more  important  than  general  public  health 
education  for an  improved  management of sick children. 
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A very detailed study of management of acute diarrhoea investigated maternal perception 
of  signs  and  causes  of  diarrhoea,  the  use  of  ORS,  and  risk  factors  for  progression  to 
persistent diarrhoea.  The  study showed  that diarrhoea perceived as caused  by ''teething" 
is  believed  to  be  normal  although  it  is  clinically  indistinguishable  from  other  types  of 
diarrhoea. This has significant consequences for management of these children. The study 
also  showed  that  though  ORS  is  commonly  used,  the  quantities  are  minute.  ORS  user 
rates  are  inadequate  measures  of  the  performance  of  programmes  for  the  control  of 
diarrhoeal diseases. 
A case-control study suggested that malaria-parasitaemia was not an  important risk factor 
for diarrhoea. 
In  an  analysis  of  945  children,  followed  from  birth  until  weaning,  only  57  (6°/o)  were 
weaned before 12 months of age.  In these cases, termination of breastfeeding was largely 
associated with illness of the mother or the child, or a new pregnancy. Thus, in  Bissau, the 
children  who  were  among  the  first  to  be  weaned  was  a  highly  selected  group,  among 
whom  a large proportion had suffered  recent illness or were vulnerable  in  other respects. 
The mothers' reasons for weaning is an  important parameter, which needs to be taken into 
account  in  both  observational  and  intervention  studies. 
The intervention  had  a significant impact on  the  introduction on  weaning food,  which  was 
delayed, and  resulted  in  a significantly increased use of intrauterine devices. The duration 
of breast-feeding was not affected by the intervention; it remained at the high median of 22 
months  in  both  groups,  as  in  earlier studies.  There  was  no  increased  rate  of  diarrhoea 
associated with early introduction of water or supplementary foods.  However, to a surprise, 
we found that late introduction of water or food was associated with an  increased mortality 
rate.  The causal  mechanism is  not clear.  However,  the finding  underscores that,  in Africa, 
emphasis  should  be  given  on  breast  feeding  promotion  rather  than  the  timing  of  the 
introduction  of  weaning  foods.  Both  the  present  and  earlier studies  form  Guinea  Bissau 
provide  evidence for the  beneficial  effects of partial  breast-feeding. 
Assessments  of the  impact of the  intervention  on  other key outcome variables,  including 
case-management practices,  child-morbidity and  mortality rates  are  under way. 
Partners 
Statens Seruminstitut 
Epidemiology Research Unit 
Artillerivej 5 
DK - 2300 Copenhagen S 
University of Aarhus 
lnst. of Social Medicine 
Hoegh Guldbergsgade 8 
DK - 8000 Aarhus C 
Ministry of Public Health, Guinea-Bissau 
CP50 
Bissau 
Guinea-Bissau 
London School of Hygiene and Tropical 
Medicine 
Maternal and Child Epidemiology Unit 
Keppel Street 
UK - WC1  E7HT London 
K.  Moelbak 
Tel: +45/3/268.31.64 
Fax: +45/3/268.31.65 
E-mail: kmolbak@ desc.ssi.dk 
M. Sodemann 
Tel:  + 45/89/42.30.75 
Fax: +45/86/13.15.80 
A.P.J. DaSilva 
S. Huttly 
Tel:  +44/171/636.86.36 
Fax: +44/171/436.53.89 
153 Contract number TS3*CT920064 
EPIDEMIOLOGICAL AND  MOLECULAR  BIOLOGICAL STUDY OF  CHOLERA TRANS-
MISSION DYNAMICS IN THE HORN OF AFRICA: A MULTIDISCIPLINARY APPROACH 
Period: 
Co-ordinator: 
Objectives 
July 1, 1993-July 31, 1997 
CENTRO INTERUNIVERSITARIO Dl  RICERCA SUI  PAESI  IN VIA Dl 
SVILUPPO, Roma,  Italy (F.  MAIMONE & T.  MERTENS) 
•  To describe the epidemiology and ecology of Vibrio cholera in the Horn of Africa for planning 
more  rational,  specific and  realistic  prevention  and  control  strategies. 
•  To  develop  identification  tools  of  complex  modes  of  transmission  and  persistence  of  the 
infection  by combining  epidemiological  methods with  molecular and  genetic techniques. 
Activities 
Epidemiological investigations 
Epidemiological  surveys  of  enteric  infections  associated  with  diarrhoeal  diseases  have  been 
conducted  in  the  critical  geographic  areas  of  Ethiopia  where  most  cholera  foci  were  active 
between  1993 and  1995 inclusive. Clinical and environmental specimens have been  screened 
for  Vibrio spp.  and  other enteric pathogens. 
Transmission dynamics 
In  order to conduct in-depth studies of transmission dynamics in a representative urban area of 
the Horn of Africa, a baseline population study of the city of Harar (capital of the Harari People 
National Regional State of Ethiopia; estimated population: 1  00,000) has been designed. The first 
phase has consisted of linking a flexible mapping software package containing the cartographic 
information on the city to an appropriate data-base programme to enter, process and disseminate 
demographic, epidemiological and behavioral data. 
Genetic and molecular studies 
Analysis  of  V.  cholera  strains  isolated  in  Somalia  and  Ethiopia  has  been  carried  ou't  on  the 
basis  of genetic  and  physical  characterization  of  plasmids,  restriction  enzyme  profiles  of the 
chromosomal  DNA,  Southern  hybridization and  polymerase chain  reaction  (PCR)  experiments 
using  DNA  probes  and  oligonucleotide  primer  pairs ,  for  specific  sequences,  and  random 
amplified polymorphic DNA techniques. 
Results 
Epidemiological patterns of cholera from 1993 to 1995 
In October 1993,  V.  cholera 01  was isolated from pattents with acute diarrhoea in Dire Dawa, the 
second largest city in  Ethiopia. In the following months clinical cases and outbreaks occurred in 
urban  and  rural  areas of numerous zones of different regions.  Systematic investigations were 
mostly conducted in  Jijiga town  (capital of Somali  National Regional State; population: 60,000) 
and for short periods in the Somali zones of Afder and Liban. 
The epidemic in  Jijiga town  started on  December 14,  1993 and  ended in  mid-June 1994. The 
final  figures were 1039 clinical cases presenting for treatment to Jijiga Karamara Hospital and 
19 deaths (case-fatality rate:  1.8°/o). Attack rates were similar in  all town districts (kebeles) and 
the  overall  rate  was  estimated to  be  15 per 1  000 population  in  the  six months of epidemic. 
The  sex- and  age-specific  patterns  of  the  cases  displayed  no  significant  differences  by  sex 
(males 50o/o)  and a mean age of 20 years (age range 3 months to 80 years);  11 o/o  of the cases 
were infants, 23o/o were 1 - 4 years of age,  16o/o were 5- 14 years of age, 38%, were adults 
15 - 44 years of age, and 12o/o were >44 years of age.  In Afder and Liban zones the epidemic 
lasted from  March  to October 1994. 
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The cases were 589  (577  in  towns)  with  38  deaths (case-fatality rate:  6.5°/o).  The  attack rate 
was  estimated to  be  2 per 1  000 population  in  the  seven  months of  the  epidemic. 
During  the  first  half  of  1995,  cases  of  suspected  cholera  were  still  reported  from  southern 
towns  and  villages  in  the  previously affected  regions.  Such  cases were  most concentrated  in 
the areas and communities where the spread of the infection had been lower or silent in  1994. 
The  major series  of outbreaks  occurred  in  the  Wollayta  area  in  the  Southern Administrative 
Region  between April  and  June  1995.  In  Ofa  District  (estimated  total  population:  135,000)  in 
the April-June period there  were  over 800 cases  (attack rate:  6 per 1  000) with  a case-fatality 
rate  of 2.2°/o. 
Development of a basic GIS infrastructure for Harar city 
A set  of  1994 stereoscopic  aerial  photographs  were  enlarged  at the  scale  of  1  :2000  to  form 
eight photo-mosaics. A detailed map was drawn from this photographic composition by plotting 
buildings,  roads  (out-lines  and  axes),  and  tree-covered  land.  The  hand-sketched  maps  were 
digitized into Geographic Information System (GIS)  layers (PC Arcinfo format) according to the 
following  specifications: 
=>  different geographical features  belong to different layers; 
=>  each  housing  unit  is  coded  according to the  numbering system  adopted; 
=>  the  basic projection  is  UTM  (Universal Transverse  Mercator); 
=>  dista nces  in  the  UTM  projection  are  in  meters  and  in  a  reference  grid  of lines  of  latitude 
and  longitude. 
An  ad hoc  data-base  package  is  being  adapted  to  the  specific  data  collection  needs  with 
particular attention to  a user-friendly approach  and  reports  print-out capacity. 
Molecular epidemiology 
The prevalence of  V.  cholerae 01 and  non-01 , the clonal analysis of the strains responsible for 
the  second  Somali  cholera  epidemic,  the  characterization  of  the  genetic  bases  for  the 
appearance of drug  resistance  phenotypes,  and  the distribution of characters of toxinogenicity 
and  drug  resistance  in  strains  of  V.  cholerae  non-01 ,  have  been  defined  for  most  Somali 
regions  of the  Horn  of Africa during  an  8-year period. 
Partners 
Centro lnteruniversitario di  Ricerca 
sui  Paesi in via di Sviluppo 
Public Health and Biomedical Sciences 
Via della Polveriera 37 
00184 Roma 
Italy 
Universidad de Cantabria 
Facultad de Medicina 
A.  Cardenal Herrera Oria 
39011  Santander 
Spain 
Region  13 Health Bureau 
Health Program Division 
P.O.  Box 894 
Harar 
Ethiopia 
Somalia National University 
Dept. of Community Health 
Mogadishu 
Somalia 
F.  Maimone 
T.  Mertens 
Tel:  +39/6/487.48.39 
Fax: +39/6/487  .48.38 
E-mail: maimone@axrma.uniromal.it 
M. Delgado-Rodrlguez 
Tel:  +34/4/220.19.70 
Fax: +34/4/220.19.03 
I. Abdulahi Ali 
Tel:  +251/5/66.03.89 I 66.17.33 
Fax: +251/5/66.20.68 
K.A. Mohamud 
Tel: +396/648.67.11 
Fax: +396/487  .48.50 
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ORAL VACCINE AGAINST CHOLERA WITH  "BUILT-IN" ADJUVANTICITV 
Period: 
Co-ordinator: 
Objectives 
October 1, 1993-September 30,  1995 
ISTITUTO RICERCHE IMMUNOBIOLOGICHE SIENA 
Siena,  Italy (S.  RAPPUOLI) 
The  aim  of  this  project  is  the  development  of  new  vaccines  against diarrhoeal  diseases 
(such  as  cholera  and  enterotoxigenic  E.  col1),  based  on  the  immunization  with  live-
attenuated strains of  \1.  cholera and  Salmonella expressing non-toxic derivatives of cholera 
and  heat-labile toxins. 
To  further  increase  the  immunogenicity  of  the  antigens  expressed,  in  vivo,  by  the 
attenuated  strains,  we  have  engineered  the  Salmonella  typhimurium  strain  to  express  a 
peptide derived from  IL-1 J3  peptide that has  been  proposed  to  be  a good  adjuvant. 
Activities 
Design, construction, purification and characterization of LT and CT mutants 
Heat-labile  toxin  (LT)  is  a  bacterial  protein  with  ADP-ribosylating  activity,  produced  by 
enterotoxigenic  E.  coli strains,  structurally  and  functionally  related  to  Cholera  toxin  (CT). 
These two toxins share  80°/o  sequence  homology and  the same  3D  structure.  LT and  CT 
are organized as AB5  hexamers,  where the homopentameric B subunit binds the  receptor 
on  the  membrane  of  eukaryotic  cells,  while  the  A  subunit  is  responsible  for  the  ADP-
ribosylation  of  the  a subunit of G5  a GTP-binding  protein. 
Using the  known  3D  structure of  LT  and  computer modelling analysis,  we  have  identified 
residues  previously  not  known  to  be  important  for  enzymatic  activity,  and  provided  the 
rationale  to  probe  their  function  by  changing  them  by  site-directed  mutagenesis.  We 
have  generated  a  number of  different  mutants  of  LT  and  CT,  expressed  them  in  E.  coli 
and  \1.  cholera strains,  respectively,  purified  and  characterized.  Some  of them  have  been 
found  to  be  completely  devoid  of  enzymatic  activity,  both,  in  vivo  and  in  vitro.  We  have 
analyzed  the  biochemical  and  immunological  properties  of  the  non  toxic  mutants  to 
define  the  influence  of  the  mutations  in  the  A  subunit  on  the  assembly,  stability  and 
immunogenicity  of  each  of  the  mutant  molecules.  We  have  obtained  mutants  in  which 
the  amino-acid  substitution  had  not  affected  the  toxicity;  mutants  in  which  aminoacid 
substitutions  had  dramatically  reduced  the  toxicity  and  mutants  in  which  the  substitution 
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had  prevented  the  formation  of  the  AlB  holotoxin.  By  the  study  of  the  biochemical  and 
immunological  properties of the  nontoxic  mutants,  we  have found  that,  single  amino-acid 
substitions in  the A subunit may affect not only the  enzymatic activity,  but  may  also  have 
profound  effects  on  the  ability to  form  the AB5  structure,  on  the  stability during  long-term 
storage,  and  on  the  trypsin  sensitivity  and  immunogenicity  of  the  assembled  mutant 
molecules. 
Among  the  non  toxic mutants tested,  the  CT-K63  and  the  analog  LT-K63  mutants,  proved 
to be non toxic, well assembled, stable to trypsin treatment, and able to induce neutralizing 
antibodies  against  both  the  A and  B subunit.  This  property  suggests  that  the  A subunit 
plays  an  important  role  in  protective  immunity  and  raises  the  possibility  of  using  these 
molecules to  improve vaccines  against  LT  and  cholera. 
Expression of CT-K63 in a Vibrio cholera attenuated strain:  IEM1 01 
The  V.  cholera IEM  101  strain  is an  attenuated  El  Tor strain  isolated  in  China. This strain 
does  not contain  the  genes  encoded by the  entire virulence  cassette.  IEM  101  has  been 
used  both  in  rabbits  and  humans to  study its  immunogenicity and  toxicity.  In  rabbits,  IEM 
101  was  able  to  induce  protection  against  the  challenge  with  a  virulent  strain  after 
immunization with  a single dose.  In humans it has been shown to be safe, able to colonize 
the  gut and  to  induce  a strong  immune  response. 
We have studied the ability of IEM  101  to produce, correctly assemble and secrete into the 
supernatant the  wild-type  CT as  well  as  the  CT-K63  mutant  protein,  and  we  have tested 
the toxicity,  in  vivo,  of the  recombinant strains. The  results showed that IEM  101  was able 
to  produce  and  secrete  into  the  supernatant,  the  wild-type  toxin,  as  well  as  the  mutant 
toxin. The results of the toxicity in  vivo,  in a Rabbit Ileal Loop assay showed that IEM  101 
expressing wild-type CT was  able to  induce fluid  accumulation,  while  IEM  101  expressing 
CT-K63,  did  not.  The  insertion  of  the  mutated  gene  into  the  chromosome  of  IEM  101  is 
underway. 
The interleukin-1 J3  peptide 
The  nonapeptide  sequence  VQGEESNDK,  corresponding  to  the  aminoacids  163-171  of 
IL-1 J3,  and  the  pentapeptide  GEESN,  has  been  reported  to  retain  the  immunoenhanc-
ing  properties  and  to  be  devoid  of  proinflammatory  activity  of  the  entire  IL-1 J3 
molecule. 
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To  increase  the  ability  of  Salmonella  strains  to  induce  immunity  against  recombinant 
antigens, we  have engineered the strain to express this peptide,  derived from  IL-1 ~' using 
as  carrier proteins the  flagellin  of  Salmonella,  LamB  and  MalE  of  E.  coli. 
The  level  of expression  of the  recombinant  proteins  and  the  immunogenicity  induced  by 
the  recombinant strains,  or by the  purified  protein,  has  been  evaluated. 
The results showed that all the recombinant proteins maintained their functionality and that 
the  amount  of  each  of  the  native  proteins  produced  were  comparable  to  that  of  the 
corresponding  chimera  proteins.  The  recombinant  strains  were  used  to  immunize  (i.p.) 
BALB/c  mice.  The  results  showed  that  the  presence  of  the  nonapeptide  in  the  flagellen 
expressed  by  Salmonella led  to an  increase  in  immunogenicity of about 2.5-fold,  confirm-
ing  previous  data  obtained  with  the  purified  protein.  In  the  case  of  LamB,  the  immune 
response  induced  in  mice  immunized  with  Salmonella  strains  carrying  the  recombinant 
LamB  gene  was  similar  to  that  induced  in  mice  immunized  with  the  strain  carrying  the 
native  LamB  gene.  In  the  case  of  malE,  the  presence  of  the  nonapeptide  had  a weak 
immunadjuvant  effect,  which  could  only  be  detected  using  low  doses  of  antigen,  and  a 
low-responder  strain  of  mice.  With  higher  doses  or  after  a  booster,  and  with  a  high-
responder mouse  strain,  no  difference could  be  seen. 
Expression of LT-K63 in attenuated Salmonella typhimurium straius 
Four attenuated  S.  typhimurium strains  of different serotypes,  three  of  them  carrying  the 
virulence plasmid and  one which does not contain the virulence plasmid,  have been  used 
for  the  expression  of  the  LT-K63  mutant  protein.  The  gene  coding  for  LT-K63  has  been 
cloned  in  different  plasmids  with  low,  moderate,  medium  and  high  copy  numbers.  The 
correlation between the copy number of the different plasmids combined with the presence 
of the virulence plasmid,  and  the  in  vitro expression  level  of LT-K63  has  been  evaluated. 
The recombinant strains have been  used for oral immunization in  mice and the immunore-
sponse  induced  has  been  assessed.  The  results  showed  that  the  different  Salmonella 
strains were able to produce, assemble and secrete the mutant protein into the periplasm. 
The  in  vitro expression  level  of  LT-K63  showed  a good  correlation  with  the  copy  number 
of  the  different plasmids  used,  so  that the  amount of  LT-K63  produced  was  higher when 
the  high  copy number plasmid  was  used. 
The  results  of the  immunogenicity experiments showed  that after a single oral  immuniza-
tion, the mice immunized with the strain carrying the virulence plasmid and expressing the 
highest level of LT-K63  mount a high  anti-LT lgG  response  in  the sera,  as well  as an  lgA 
response  in  the  mucosa,  starting from  the  second  week after immunization. 
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THE  USE  OF  CONTROLLED  RELEASE  MICROPARTICLES  AS  ORAL  AND 
PARENTERAL  VACCINES  AGAINST  VIBRIO  CHOLERA,  ESCHERICHIA  COLI AND 
BORDETELLA PERTUSSIS 
Period: 
Co-ordinator: 
Objectives 
June 1, 1993- May 31,  1997 
UNIVERSITY OF NOTTINGHAM, DEPT.  OF PHARMACEUTICAL 
SCIENCES, Nottingham, United Kingdom (S.S. DAVIS) 
•  To  assess  the  efficacy  of  microparticles  with  entrapped  antigens  as  oral  vaccines 
against two  important diarrhoeal causing  pathogens,  V.  cholera and  enterotoxigenic  E. 
coli. 
+  To  design  and  test a single dose parenteral  vaccine against  Bordetella pertussis. 
Activities 
*  The  following  antigens  were  provided  for the  project  CTB,  CFA  1  , PT  and  FHA.  The 
antigens for the studies were extracted from bacteria, CTB and CFA 1 were supplied by 
Goteborg  and  PT  and  FHA  were  supplied  by  the  National  Institute  of  Biological 
Standards,  UK. 
*  Poli  (lactide-co-glycolide)  (PLG) family of polymers were selected for use  in  production 
of vaccine containing microparticles. Two PLG  polymers were chosen,  primarily for their 
degradation properties,  PLG  75;25  (lactide:  glycol ide  ratio)  and  PLG  50;50.  PLG  75;25 
is  a slower degrading  polymer than  PLG  50;50.  This would  enable  us  to  assess  any 
long term  immunological effects of the  microparticulate vaccines. The  results  would  be 
compared  to  those  obtained for  PLG  50;50. 
*  In  vitro characterisation  of the  PLG  microparticles.  Microparticles were  produced  using 
an  established water in  oil  in  water emulsion solvent evaporation technique,  using CTB 
B.  pertussis antigens and  also tetanus toxoid  conjugated  to  LHRH.  The  microparticles 
with entrapped antigens were characterised for protein content and surface morphology. 
Microparticles with  entrapped  CTB  were  investigated for integrity of entrapped  as  well 
as  surface  associated  antigen.  This  was  carried  out  with  a  GM1  ELISA  assay.  The 
results  have  shown  that  entrapped  CTB  retains  its  GM1  binding  activity after  release 
form the microparticles.  Surface associated CTB also retains its ability to bind to GM1. 
Antibodies for the detection and for use in  determination of the integrity of  B.  pertussis 
antigens  is  still  under  progress.  Once  these  are  available  they  will  be  employed  to 
assess  integrity  of  B.  pertussis  antigens  and  also  for  quantitation  of  B.  pertussis 
antigens  released  in  vitro. 
*  lmmunogenicity in  vivo of B.  pertussis antigens PT and FHA entrapped in microparticles 
was assessed. The routes of immunisation investigated, were intra-peritoneal, subcuta-
neous,  intra-muscular and  nasal. The results so far have shown that the nasal delivery 
of entrapped  B.  pertussis antigens does not induce protective immunity,  with  low levels 
of  B.  pertussis  specific  lgG  antibody  produced.  However,  parenteral  delivery  of  B. 
pertussis  antigens  entrapped  in  microparticles  producing  high  levels  of  B.  pertussis 
antigens entrapped  in  microparticles producing  high  levels of  B.  pertussis specific  lgG 
antibodies. 
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*  The  nasal  administration  of  B.  pertussis  antigens  entrapped  in  microparticles  was 
carried  out while  the  animals were  anaesthetised.  Previously animals  have  not been 
anaesthetised and some degree of protection by soluble B.  pertussis antigens has been 
conferred. This was not seen for the studies in this project. This may be a result of the 
anaesthetic  reducing  the  cilia  motility  in  the  nasal  mucosa  and  possibly  reducing  in 
uptake of microparticles in  the  nasal  mucosa. 
*  The ability of microparticles to  function  as delivery systems for oral  vaccines  may be 
enhanced by targeting ligands designed to improve the uptake of particles into Payer's 
patches. The targeting  ligand which we have investigated in  the first instance is  CTB. 
The work so far has concentrated on the  use of novel  Dextran polymers to stabilise a 
PLG  microparticle,  followed  by addition of CTB.  Conjugation of CTB to the surface of 
the microparticles was achieved though  levels of CTB attached were found to  be  low. 
The integrity of the attached CTB was also ascertained by investigation of the ability of 
CTB to bind to its GM1  receptor.  The GM1  binding activity was found to be retained. 
This  work will  be  extended  to  include  surface  attachment of other targetting  moieties 
and also the co-entrapment of CTB with  vaccine antigens. 
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PERSISTENT DIARRHOEA IN  EARLY CHILDHOOD- A PROSPECTIVE COMMUNITY 
STUDY 
Period: 
Co-ordinator: 
Objectives 
January 1  , 1995 - December 31 , 1997 
STATENS SERUMINSTITUT, EPIDEMIOLOGY RESEARCH UNIT, 
Copenhagen, Denmark (K.  M0LBAK) 
The aim of the study is to improve community - and health-center based management of 
acute  and  persistent  diarrhoea  in  early  childhood.  Furthermore,  we  wish  to  suggest 
vaccine-based or other targeted interventions against acute and  persistent diarrhoea,  and 
explore the long term  impact of infections with  specific enteropathogens on  child  survival 
and  growth faltering. 
Finally,  the  study  will  provide  a  substantial  technology  transfer  to  the  National  Public 
Health  Laboratory in  Bissau,  and  exchange and training of scientists,  health workers and 
technicians. 
Activities 
The  core  of  the  study  is  an  ongoing  prospective  community  based  surveillance  for 
diarrhoeal  disease,  which  is  carried  out  in  a  semi-urban  area  of  Bissau,  the  capital  of 
Guinea-Bissau. All  children  below three  years  of age,  residing  in  600  randomly  selected 
houses, are followed by weekly visits. At these household interviews, we obtain information 
on  diarrhoeal diseases, other morbidity, and feeding patterns. All children have their height 
and weight measured at three-monthly intervals.  In  addition,  more detailed anthropometric 
follow-up  and  microbiological  examination  of weekly  collected  stool  samples  are  carried 
out in  cases of persistent diarrhoea and  in  the  intensive cohort (see below). 
Within this frame,  the study contains three work packages: 
*  A community-based,  randomized  controlled trial  (RCT),  comparing  standard  oral  rehy-
dration salt (ORS)  with  reduced  osmolarity ORS. 
*  The  development and  controlled  evaluation  of an  algorithm  for the  appropriate  man-
agement of persistent diarrhoea. 
*  An  intensive  cohort study with  weekly  collection  of stool  specimens  from  birth  to  the 
age of two years. 
The  aim  with  this  third  package  is  to  determine  the  microbial  etiology  of  acute  and 
persistent  diarrhoea  and  to  characterize  in  detail  persistent,  sequential  and  repeated 
infections by,  as well as disease-to-infection ratios, for major enteropathogens. These data 
will  be  used  for  the  investigation  of  the  long  term  impact  of  infection  with  specific 
enteropathogens. 
Results 
Data collection  for the  RCT of  reduced  osmolarity ORS will  be completed  by the  end  of 
1996, with a total of 600 episodes of acute diarrhoeal episodes included.  If low-osmolarity 
ORS proves to be more efficacious and/or acceptable than  standard ORS,  a strong case 
has been  made for changing the official  recommendations for the composition  of ORS. 
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For the management of persistent diarrhoea (PD),  an  algorithm was adapted during 1995. 
The  algorithm  is  primarily  based  on  dietary  therapy  with  a  frequently  offered  modified 
traditional diet, a millet gruel with an energy density of 96 kcal/100 g,  and a protein content 
of  2.3o/o.  In  addition,  children  with  PD  are  examined  at  a health  center,  and  treated  with 
antibiotics  or antimalarials  upon  scientific  indications.  Follow-up  includes  detailed  anthro-
pometry,  including  knee-heel  measurements,  in  order to  evaluate  catch-up  growth.  Chil-
dren with PD from a carefully selected control group receive the same clinical examination, 
treatment of severe  infections,  and  anthropometric follow-up  as  the algorithm  group. 
The intensive cohort,  with  approximately 150 children,  will  be assembled during 1996. The 
sampling  scheme,  with  weekly collection  of stool  specimens was  implemented from  early 
1996,  during  the  assembly  of  the  cohort.  In  1995-1996,  the  diagnostic  setup  was 
established  at  the  National  Public  Health  Laboratory  in  Bissau.  The  diagnosis  of  enter-
opathogens  is  undertaken  by  a  combination  of  conventional  and  probe-based  microbio-
logical  techniques.  For the  detection of pathogenic  E.  coli,  bacterial  lysates are screened 
by a panel  of DNA probes.  For this  purpose,  a number of different probes identifying the 
virulence factors of the  most important diarrhoeagenic types of  E.  coli as  well  as  Shigella 
spp.  have been  modified and cloned  into the same vector plasmid,  PBS,  thereby enabling 
an  effective labelling with the non-radioactive marker digoxigenin by the polymerase chain 
reaction  using  the  same  set  of  primers  for  all  the  different  probes.  Because  of  the 
substantial sample load, a system of pooling the individual probes has been developed as 
well  as  systems for the  handling and transportation of the large number of probe-positive 
strains. 
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DEVELOPMENT AND TESTING OF AN  ORAL B SUBUNIT - WHOLE CELL CHOLERA 
VACCINE:  PROTECTION AGAINST BOTH  01  AND  0139 CHOLERA 
Period: 
Co-ordinator: 
Objectives 
January 1,  1995 - December 31,  1996 
UNIVERSITY OF GOTEBORG, DEPT. OF MEDICAL MICROBIOLOGY 
AND IMMUNOLOGY, Goteborg, Sweden (J. HOLMGREN) 
•  To  test  the  safety  and  intestinal  mucosal  lgA  immunogenicity  of  a  new,  bivalent  B 
subunit-01/0139 whole  cell  (B-01/0139 WC)  oral  cholera vaccine  in  comparison  with  a 
recently  licensed  B-01-WC vaccine  in  volunteers  in  preparation  for  later phase  3 field 
trial  efficacy testing  of the  new vaccine. 
•  To undertake basic research to further define protective immunological mechanisms and 
possible  additional  vaccine  candidate antigens  in  cholera  due to  \1.  cholerae 0139. 
Activities 
*  To  assess  in  humans  the  safety  and  immunogenicity  of  the  proposed  new  bivalent 
B-01/0139 WC  vaccine  and  to  compare  the  immune  response  obtained  after vaccina-
tion  with  the  responses  in  convalescents  from  cholera  disease  caused  by  natural 
infection  with  \1.  cholerae 0139. 
*  To  develop  a  methodology  for  measuring  vaccine-specific  gut  mucosal  immune  re-
sponses by  non-invasive techniques  in  humans. 
*  To define the possible relevance of capsular antigen as a virulence factor and protective 
antigen  in  \1.  cholerae 0139. 
*  To  test  the  immunogenic  properties  of  a  new  oral  vaccine  formulation  based  on 
conjugation  of  LPS  and  putative  capsular antigens to  cholera  B subunit. 
Expected Outcome 
The  project  will  significantly  contribute  to  the  development  of  a  safe  and  protective-
immunogenic bivalent oral cholera vaccine that could be an  effective tool in  the prevention 
and  control  of cholera disease due to either  \1.  cholerae 01  or 0139 organisms/serotypes. 
Results 
A  first  phase  study  of  safety  and  immunogenicity  of  bivalent  B-01/0139  WC  vaccine 
prepared  by  S8L Vaccine,  Sweden  compared  with  the  licensed  8-01  WC  vaccine  (same 
producer)  has been completed in  Goteborg. As  with the  B-01  WC  Vaccine,  the  B-01/0139 
WC  vaccine  was found  to  be  safe  and  immunogenic.  Two  vaccine  doses given  2 weeks 
apart induced significant mucosal  lgA antibody responses  in  intestinal  lavage fluid  against 
cholera toxin  in  9 vaccinees and against both  01  and 0139 vibrios in  7 of 9 cases. A third 
dose  of vaccine  given  after 5-6  weeks  did  not  result  in  any further increased  response. 
All  of  12  vaccines  responded  with  significant  lgA and  lgG  anti-toxin  responses  in  serum. 
Such  responses are associated with  significant vibriocidal  antibody titre  rises  against 012 
vibrios in  10 cases (83°/o)  and against 0139 vibrios in  8 vaccinees (67°/o).  The frequencies 
and  magnitudes  of  the  serological  responses  to  the  8-subunit  and  01  we components 
were  similar to those  induced  by the  B-01  we vaccine. 
A similar study  is  in  progress  in  Bangladesh  by  ICCDR,  B.  The  immune  responses  after 
vaccination will also be compared with those in convalescents after clinical infection with  \1. 
cholerae 01  and  0139,  respectively. 
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Large phase II studies of consecutive lots of vaccine prepared by SBL Vaccine as compared 
with  a placebo vaccine have been  undertaken  in  700 individuals in  Germany. All  the sera 
collected will  be tested "blindly'' in  Sweden to determine the frequency and  magnitudes of 
serological immune responses to the B and different WC vaccine components. 
An  extensive basic study in  rabbits  has been  completed in  Goteborg defining the immune 
mechanisms  and  protective  antigens  of  Vibrio  cholerae  serogroup  0139  as  a  basis  for 
vaccine development. The results support the critical dependence of 0139 LPS antigen for 
inducing protection, a lesser role for antitoxic immunity than in  01  cholera but still evidence 
for clear synergy between anti-0139 antibacterial and antitoxic (anti-B subunit) immunity. A 
demonstrated  cross-reactivity  between  0139  LPS  and  capsule  makes  the  inclusion  of 
specific capsular antigen  in  the vaccine  less a priority than  at the time of application  and 
this  research  line  has  therefore not been  pursued  further. 
Studies  have  been  undertaken  in  both  Goteborg-Lyon  and  in  Helsinki  to  define  immuno-
logical  surface  markers  and  especially  so-called  homing  receptors  on  intestine-derived 
vaccine-specific  circulating  B  cells  after  cholera  (and  for  comparisons  oral  typhoid  and 
injected  tetanus)  vaccinations.  Similar  analyses  have  also  been  performed  on  B  cells 
derived  in  response  to  clinical  cholera  infection  (collaboration  between  Helsinki  and 
ICDDR,B).  The  results  clearly  indicate  that circulating  B cells  derived  from  intestine  and 
collected approximately one week after oral  vaccination  or onset of clinical  disease differ 
from  total  circulating  B cells  or specific  B cells  obtained  after parenteral  vaccination  by 
expressing  the  mucosa-homing  receptor  alpha4/beta7 integrin  (also  known  as  ACT-1). 
Based  on  this,  we  hope  to  develop  a  more  sensitive  assay  for  detection  of  specific 
gut-derived,  specific antibody-producing cells that could  be  used  also in  young  children. 
Partners 
University of Goteborg 
Dept. of Med. Microbiology and Immunology 
Guldhedsgatan 1  0 
Goteborg 
Sweden 
lnternat. Centre for Diarrhoeal Disease 
Research 
GPO Box 1 Haka-1 000 
Dhaka 
Bangladesh 
National Public Health Institute Finland 
Dept. of Special Bacterial Pathogens 
Mannerheimintie 166 
Helsinki 
Finland 
INSEAM Lab. d'lmmunologie 
Hopital E.  Herriot 
Lyon 03 
France 
Technical University Munich 
Dept. of Infectious Diseases and T.M. 
Leopoldstrasse 5 
Munchen 
Germany 
J. Holmgren 
Tel:  +46/31/60.49.11 
Fax: +46/3/182.01.60 
Q. Firdausi 
Tel:  +880/2/600.17.18 
Fax: +880/2/883.31.16 
H. Mikell 
Tel: +35/8/04. 7  4.41 
Fax: +35/8/9/47.44.86.75 
E-mail: pirjo.makela@ ktl.fi 
C. Czerkinsky 
Tel:  +33n/211.01.88 
Fax:  +33n/2.33.00.44 
T.  Loscher 
Tel:  +49/892/180.35.17 
Fax: +49/89/33.61.12 
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EARLY EVENTS IN  ROTAVIRUS INFECTION:  ROLE OF VIRAL PROTEINS ON  PARTI-
CLE INTERNALIZATION AND  MEMBRANE PERMEABILITY 
Period: 
Co-ordinator: 
Objectives 
October 1, 1996- September 30,  1998 
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE UNITE 
DE VIROLOGIE ET IMMUNOLOGIE MOLECULAIRES 
Jouy-en-Josas, France (J.  COHEN) 
•  To  identify the  domain of VP4  interacting with  sialic acids. 
•  To  characterize the  mechanism  of  membrane destabilization  and  pore formation. 
•  To  determine the viral  protein(s) and/or domain(s)  responsible for membrane destabili-
zation. 
•  To study the role of chaperones in folding and oligomerization of ET-associated proteins 
(VP7,  NSP4). 
•  To  elucidate the  role  of various genes implicated  in  early events of rotavirus infection. 
Activities 
*  Scientific  information  exchange  between  scientists  involved  in  ttie  project  in  five 
countries. 
*  Exchange  and  dissemination  of valuable  reagents  among  the  participant  laboratories. 
Exchanges of methodology by short stays of scientists in the lab of another contractant. 
*  Organizati on  of contractants meetings to produce relevant questions and  methodology 
to answer them. 
*  Common  preparation of publication  in  high  standards journals. 
Expected outcome 
=>  Insight  in  the  mechanisms  that  allow  penetration  into  the  cell  of  large  nucleoprotein 
complexes. 
=>  New strategies for prevention  of gastro-intestinal  diseases. 
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Partners 
INRA 
Unite de Virologie et lmmunologie 
Moleculaires 
Domaine de Vilvert 
78352 Jouy-en-Josas Cedex 
France 
IVIC-CBB 
Centro de Biofisica y Bioquimica 
Laboratorio de Fisiologia Gastrointestinal 
P.O.  Box 21728 
Caracas 1020 A 
Venezuela 
IVIC-CMBC 
Laboratorio Biologia de Virus 
Apartado 21827 
Caracas 1  020 A 
Venezuela 
INSERM-CFJ 9407 
5 rue Jean-Baptiste Clement 
92296 Chatenay-Malabry 
France 
IBT UNAM 
Universidad Nacional Aut6noma de Mexico 
lnstituto de Biotechnologfa 
Apartado Postal 51 0-3 
Colonia Miraval 
Cuernavaca 62250 
Mexico 
U.  Santiago 
Laboratorio de Virologfa 
Universidad de Santiago de Chile 
Facultad de Qufmica y Biologfa 
Departamento de Ciencias Biol6gicas 
Casilla 40 Correo 33 
Alameda Bernardo OHiggins 
Santiago 
Chile 
Karolinska SIIDC 
Karolinska Institute 
Dept. of Virology 
Swedish Institute for Infectious Disease 
Control (SMI) 
10521  Stockholm 
Sweden 
J. Cohen 
Tel: +33/1 /34.65.16.04 
Fax: +33/1 /34.65.26.21 
E-mail: cohen@biotec.jouy.inra.fr 
M.C. Ruiz 
Tel: +58/2/501.13.96/11.11 
Fax: +58/2/501.13.82 
E-mail: mclr@cbb.ivic.ve 
F.  Liprandi 
Tel: +58/2/501.13.77/14.89 
Fax: +58/2/501.13.82 
E-mail: Fliprandi@pasteur.ivic.ve 
F.  Alvarado 
Tel:  +33/1 /46.83.55.25 
Fax: +33/1/46.83.57.96 
E-mail: alvarado@imaginet.fr 
C.A. Arias 
Tel:  +52173/11.47.00/266 
Fax: +52173/17.23.88 
E-mail: arlas.pbr322.ceingebi.unam.mx 
E. Spencer Ossa 
Tel:  +56/2/681.25.75 
Fax: +56/2/681.21.08 
E-mail: spencer.lauca@usach.cl 
L.Svensson 
Tel:  +46/8n35.12.28 
Fax: +46/8/470.56.13 
E-mail: Lennart.Svensson@ smi.ki.se 
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PATHOGENESIS OF VIBRIO CHOLERAE INFECTION AND PERSISTENCE DYNAMICS 
IN THE HORN  OF AFRICA 
Period: 
Co-ordinator: 
Objectives 
December 1  , 1997 - May 31 , 2001 
UNIVERSITA Dl  ROMA "LA SAPIENZA", Centro lnteruniversitario di 
Ricerca sui Paesi in via di Sviluppo, Rome, Italy (F.  MAIMONE) 
•  To  yield  new,  crucial  information on  the pathogenesis of  Vibrio  cholerae infection as a 
necessary  basis  for  creating  effective  vaccines:  role  and  dual  function  of the  zonula 
occludens toxin  (ZOT)  encoded by the  V.  cholerae filamentous phage CTXF. 
•  To  design  dynamic models for persistence  of primary infection  events  and  secondary 
transmission of the infection  in  critical  geographic areas for the recurrent spreading of 
the disease. 
Activities 
The  studies  of  pathogeneis  of  V.  cholerae  infection  will  focus  on:  1)  identifying  the 
mechanisms of action  of ZOT by intracellular signalling  and cytoskeleton  rearrangement; 
2)  establishing  the  effect  of ZOT on  water and  electrolyte  transport via the  paracellular 
pathway;  3)  analysing  the  regulatory  system  and  functions  of the  zot gene  by  TnPhoA 
fusions and  site-directed  mutagenesis. 
The studies of cholera transmission will concern the screening of aquatic environments as 
possible  V.  cholerae  reservoirs  and  epidemiological  and  microbiological  investigations 
based on a Geographic Information System infrastructure (GIS). Collection of demographic 
baseline  data,  follow-up  studies  at the  household  level,  and  case-control  studies  of  risk 
factors will be conducted in  Harar (capital of Harari  Regional State of Ethiopia) and towns 
and villages  in  the  Somali  Regional  State of Ethiopia and  in  Somalia. 
To  assess genetic diversity and  relationships  in  the  V.  cholerae population  distributed  in 
humans and in  the environment, a high number of strains of  V.  cholerae (01  and non-01) 
from cases with different clinical features and from environmental sources will be analysed 
by a combination of genotypic methods. 
Expected outcome 
~  The  role  of ZOT toxin  in  modulating  biochemical  modifications of tight junctions up  to 
their disassembly in  intestinal  epithelium  will  be characterized; 
~  ZOT diarrhoegenicity in  comparison  with  cholera toxin  will  be  established; 
~Environmental factors and genetic components regulating expression of zot gene will be 
identified; 
~  The  analysis  of  the  microbiological  and  epidemiological  data  integrated  into  a  geo-
graphic and demographic information system will  identify determinants for maintenance 
of endemicity and for infection propagation. By combining these results with the pattern 
of genetic relatedness  between the  prevalent  V.  cholerae strains,  dynamic models for 
persistence  and  transmission  will  be  proposed  as practical  contributions for designing 
realistic  cholera control  strategies. 
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Partners 
Universita di Roma "La Sapienza" 
ClAPS- Centro lnteruniversitario di Ricerca 
sui Paesi in via di Sviluppo 
Via della Polveria, 37 
00184 Roma 
Italy 
Universita di Sari 
lstituto di Genetica 
Via G. Amendola, 1651A 
70126 Sari 
Italy 
lnstitut Pasteur 
Unite des Enterobacteries 
28, Rue du Dr.  Roux 
75724 Paris Cedex 15 
France 
Harari Health Bureau 
P.O.  Box 894 
Harar 
Harari People National Regional State 
Ethiopia 
Addis Ababa University 
Faculty of Medicine 
Dept. of Microbiology and Parasitology 
P.O.  Box 9086 
Addis Ababa 
Ethiopia 
Karamara Jijiga Hospital 
Clinical Laboratory 
P.O.  Box 6 
Jijiga 
Somali National Regional State 
Ethiopia 
Unit for Somalia 
Karamara Jijiga Hospital 
P.O.  Box 6 
Jijiga 
Ethiopia 
F.  Maimone 
Tel:  +3916148.67.11  I 487.48.50 
Fax: +39161487 .48.50 I 487.48.38 
E-mail: maimone@axrma.uniromal.it 
C. Pazzani 
Tel:  +391801544.33. 79 
Fax: +391801544.33.86 
E-mail: pazzani@ biologia.uniba.it 
P.A.D. Grimont 
Tel:  +3311145.68.83.40 
Fax: +3311 145.68.88.37 
E-mail: pgrimont@ pasteur.fr 
I. Abdulahi Ali 
Tel:  +25115166.03.89 I 66.17.33 
Fax: +25115166.20.68 
Y.  Mengistu 
Tel:  +25111151.89.99 ext.  11 
Fax: +251 11151.30.99 
M.T. Hassan 
Tel:  +25115199.468 
K.A. Mohamud 
Tel:  +25115199.468 
169 8.  Diphtheria and Tetanus '  ' 
·  <'Presentation of EO  st~ppo.rted ]oint ·reseamh project$, (1991~-t996r·OOntmued:  ~ 
STD3  ..  ,.  . .  .  .  .  .  . 
.  INCO.DC: 1st and 2nd Call· 
Areas of interest: 
8.  Diphtheria and Tetanus 
IC18*CT950012  Evaluation of diphtheria- and tetanus-toxin neutralizing 
antibody activity in human and animal 
Page: 
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EVALUATION  OF  DIPHTHERIA- AND  TETANUS-TOXIN  NEUTRALIZING  ANTIBODY 
ACTIVITY IN  HUMAN AND ANIMAL SERA 
Period: 
Co-ordinator: 
Objectives 
January 1, 1996- December 31, 1998 
NATIONAL INSTITUTE OF PUBLIC HEALTH AND THE 
ENVIRONMENT (RIVM) 
Bilthoven, The Netherlands (C.  HENDRIKSEN) 
+  To  investigate the  nature of the  reported  absence  of correlation  between  in  vitro toxin 
neutralization  assays  and  in  vivo  neutralization  tests  for  diphtheria  (and  to  a  lesser 
extent tetanus)  antibodies  and  to  develop a practical  solution  for this  phenomenon. 
+ To  improve research and development capacity in vaccine quality control laboratories of 
public sector vaccine  producers  in  two  developing countries  (Indonesia and  Vietnam). 
+  To  ensure  quality  in  immunization  programmes  and  local  vaccine  production  by 
developing and  making available scientifically validated test systems that can  be  used 
in  developing countries. 
Activities 
*  Establisment of anti-diphtheria serumpanels from  4 different species. 
*  Study of kinetics of neutralization test systems for diphtheria in  in  vitro tests (Vero  cell 
test,  ToBI,  Double antigen  ELISA,  DELFIA)  and  in  vivo tests  (skin  test in  guinea pigs) 
using  high,  intermediate and  low doses of toxin. 
*  Stand  ardization  of one  or two  selected  in  vitro toxin  neutralization test systems,  with 
established validity for the  in  vivo  neutralization  mechanism. 
*  Improve  horse  hyper-immunization schedules and  introduction  of plasmaphoresis. 
*  Provide  research  training to  staff at  RIVM  (two from  Vietnam  and  two from  Indonesia) 
and  implement/improve  in  vitro techniques in  Vietnam  and  in  Indonesia. 
*  Hold  two  project  meetings:  one  at  the  onset  of  the  project  and  one  at  mid-term,  to 
upgrade  research  training. 
Expected outcome 
=>  Understanding  of  the  factors  which  have  an  effect  on  the  mechanism  of  toxin 
neutralization. 
=>  Recom  mendations to  regulatory authorities  on  the  selection  and  standardization  of in 
vitro toxin  neutralization tests. 
=>  Research  training  to 2  Bio  Farma and  2  IVAC  staff workers  for  a period  of 4 months 
each. 
=>  The  organization  of  a  workshop  on  the  immunological  aspects  of  diphtheria  toxin 
neutralization  and  antiserum  production. 
=>  Improved horse immunization schedules and the introduction of plasmaphoresis for the 
production  of anti-D  serum. 
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Partners 
National Institute of Public Health and the 
Environment (RIVM) 
P.O.  Box 1 
3720 BA Bilthoven 
The Netherlands 
Statens Serum lnstitut 
Bacterial Vaccine Department 
Artillerivej 5 
2300 Copenhagen 
Denmark 
Perum Bio Farma 
Quality Control Department 
ext. 255 
Jl. Pasteur 28 
P.O.  Box 1136 
Bandung 40161 
Indonesia 
Institute of Vaccines and Biological 
Substances 
Dept. of Quality Control 
9,  Pasteur street 
Nha Trang 
Vietnam 
C. Hendriksen 
Tel:  +31/30/274.25.03 
Fax: +31/30/274.44.08 
E-mail: coenraad.hendriksen@ rivm.nl 
H. Aggerbeck 
Tel:  +45/32/68.34.86 
Fax:  +45/32/68.38.  72 
L.  Soemara 
Tel:  +62122/23.37.44 
Fax: +62/22/204.13.06 
A.  Hong 
Tel:  +84/58/82.37.05 
Fax: +84/58/82.38.15 
175 9.  Hepatitis Areas of interest: 
9.  Hepatitis 
TS3*CT930259  Epidemiological clinical and sera-virological studies of 
hepatitis C in Gabon and Brazil 
Page: 
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EPIDEMIOLOGICAL CLINICAL AND  SERO-VIROLOGICAL STUDIES OF  HEPATITIS  C 
IN  GABON AND  BRAZIL 
Period: 
Co-ordinator: 
Objectives 
February 1,  1994 - January 31,  1997 
INSTITUT DE MEDECINE ET D'EPIDEMIOLOGIE 
AFRICAINES/INSERM U13,  Paris, France (B.  LAROUZE) 
+  To  evaluate the  importance of hepatitis C virus  (HCV)  in  terms of public health  in  two 
countries with  different levels of endemicity  in  order to  design  preventive strategies. 
+ To  collect information on  the variability of HCV strains and serological patterns in  order 
to  improve diagnostic procedures and  contribute to  vaccine design. 
+ To  describe the distribution of HCV infection, to  identify its risk factors and to study its 
transmission  modes. 
+ To  investigate its  relationship  to  chronic liver diseases and  hepatocellular carcinoma. 
+ To  compare  the  structures  of  HCV  strains  circulating  in  these  countries  and  related 
serological  patterns;  to investigate serological  cross-reactions with  related viruses. 
Activities 
In  order to evaluate the importance of hepatitis C virus (HCV)  in  terms of public health  in 
two countries with  different levels of endemicity (Gabon:  high  level,  Brazil:  low  level),  we 
will  study,  in  each country,  the distribution of hepatitis C infection  in  different geographical 
settings,  in  general  and  high  risk  populations. Additional  studies will  be  dedicated  to  risk 
factors in  a community based study in  Gabon where the prevalence of antibody to HCV is 
much higher (7°/o)  than  in  Brazil  (1-2°/o).  As a complement of this last study,  a clinical and 
virological  study of  anti-HCV positive  subjects will  be  performed  in  order to  evaluate the 
clinical  impact of HCV infection.  In  addition,  case-control  studies in  Gabon  and  Brazil  will 
allow the determination of risk for cirrhosis and  HCC attributable to HCV.  From  the same 
material,  sere-virological  studies  of  HCV  will  be  designed  using  PCR  techniques  to 
compare the structures of HCV strains circulating in these countries and related serological 
patterns and to investigate serological cross-reactions with  related  viruses.  These studies 
will  provide informations to elaborate prevention strategies (including HCV blood screening 
in  blood  banks),  to  improve  serodiagnostic techniques  and  to  contribute  to  the  develop-
ment of future  HCV vaccines. 
Expected outcome 
By knowing  the  epidemiology and  clinical  impact of  HCV in  Gabon and  Brazil,  and  after 
the interpretation of the sere-virological studies,  much will  be  gained in  terms of introduc-
tion of mandatory testing in  blood banks and immunoprophylaxis when a vaccine becomes 
available. 
These  studies  will  provide  a  basis  for  decision  making  by  health  authorities  from  these 
countries and from countries with similar HCV patterns.  Insight into HCV prevention would 
complement  the  effort  developed  in  Africa  and  in  Brazil  (programme  developed  by  the 
Federal  Government) to control  HCV infection. 
The  sere-virological  studies  will  allow  the  design  of  serological  tests  adapted  to  the 
regional variability of HCV strains and taking eventually into account cross reactivities with 
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related  viral  agents.  These  tests  will  be  used  for  epidemiological  investigations,  clinical 
diagnosis and,  if the health authorities decide to screen blood donors, will  be  used for this 
purpose.  In  the  long  term,  results  of  the  sera-virological  studies  will  contribute  to  the 
design  of anti  HCV vaccines. 
The implementation of this protocol will be based on a scientific network which will 
reinforce links between participants and improve their scientific skills. 
Partners 
lnstitut de Medecine et d'Epidemiologie 
Africaines/INSERM U13 
46 rue Henri Huchard 
75018 Paris 
France 
Universita Degli Studi di  Milano 
Institute di Medicina lnterna 
Via Pace 9 
20122 Milano 
Italy 
INSEAM U.370 
CHU  NECKER 
Rue de Vaugirard 156 
75730 Paris Cedex 15 
France 
I  nnogenetics N. V. 
Viral Diseases 
lndustriepark Zwijnaarde 7/4 
9052 Gent 
Belgium 
Aristotelian University of Thessaloniki 
School of Medicine 
Dept. of Microbiology 
54006 Thessaloniki 
Greece 
Escola Paulista de Medicina 
Disc. Doencas lnfecciosas 
Rua Napoleao de Barros 715 
7 Andar 
04023 Sao Paulo 
Brazil 
Universite de Libreville 
Faculte Medecine 
Dept. de Parasitologie, Mycologie 
et Med. Trop. 
BP 794 
Libreville 
Gabon 
B. Larouze 
Tel:  +33/1/40.36.37.51 
Fax:  +33/1 /40.36.16.99 
M. Colombo 
Tel:  +39/2/55.03.54.31 
C. Brechot 
Tel:  +33/1/40.61.56.41 
Fax: +33/1/40.61.55.81 
G. Maertens 
Tel:  +3219/241.07.11 
Fax:  +3219/241.09.07 
E-mail: geertmae@mail.com 
A. Antoniadis 
Tel:  +31/991.346 
Fax: +31/200.392 
C. Granato 
Tel:  +55/11/572.63.48 
J. Perret 
Tel:  +241/77.24.17 
181 10.  Other Areas of interest: 
10. Other 
TS3*CT91 0035  Leptospirosis in the Caribbean: a study on short and long 
term pathological consequences 
Page: 
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LEPTOSPIROSIS  IN  THE  CARIBBEAN:  A  STUDY  ON  SHORT  AND  LONG  TERM 
PATHOLOGICAL CONSEQUENCES AND LEPTOSPIROSIS IN  BENIN 
Period: 
Co-ordinator: 
Objectives 
May 1992 - November 1994 
KONINKLIJK INSTITUUT VOOR DE TROPEN, DEPT OF BIOMEDICAL 
RESEARCH Amsterdam, The Netherlands (R.A. HARTSKEERL) 
The  aim  of  this  project  was  to  investigate  mortality,  pancreatic  damage  and  chronic 
infection  in  leptospirosis,  and  to further develop the  polymerase chain  reaction  (PCR)  for 
rapid  diagnosis of leptospirosis. 
The  objectives are: 
•  To  perform  post  mortem  (PM)  studies  on  humans  and  animals,  comparing  the 
capacities  of  the  methods  of  culturing,  histopathology  and  PCR  for  the  detection  of 
leptospiras. 
•  To  evaluate the  PCR  on  human  serum  for diagnosis of leptospirosis  in  the Caribbean 
region. 
•  To  explore  the  prevalence  of  leptospirosis  in  Benin  and  its  consequences  for  human 
welfare  and  animal  productivity. 
Activities 
*  Introduction  of  culturing  techniques  and  immunofluorescence  staining  by  Veterinary 
Research  Laboratory (VRL)  at the Leptospira laboratory (LL)  on  Barbados and CAREC 
on Trinidad and subsequent application on post mortem tissues from patients suspected 
to  have  died  of acute leptospirosis. 
*  Implementation of PCR on  serum and urine specimens at LL on  Barbados and CAREC 
on  Trinidad.  Development  of  a  PCR  assay  on  post  mortem  tissues  by  KIT  and 
implementation  of the assay on  Barbados  and  Trinidad. 
*  Establishment of a leptospirosis research  unit in  Benin. 
Results 
A PCR  for the  diagnosis of leptospirosis  using  two pairs of primers,  i.e.  G1/G2  amplifies 
DNA from the pathogenic species L.  interrogans',  L.  borgpetersenii, L.  wei/ii,  L.  noguchi, L. 
santarosai and  L.  inadai.  Primer set B641/B6411  amplifies DNA from the pathogenic species 
L.  kirschneri.  The  PCR  with  the  two  primer pairs  was  optimized  for application  on  blood 
and  urine samples and successfully implemented in  Barbados and Trinidad. To  adapt PCR 
for  post  mortem  tissues,  a  mechanical  disruption  of  tissue  with  a  mini-bead  beater was 
included in the protocol. Immunofluorescence staining was introduced at MRC and CAREC 
by VRL,  while culturing techniques were  introduced by both  VRL and  KIT.  The part of the 
project  entitled  "leptospirosis  in  Benin"  started  in  November  1993  by  establishment  of  a 
leptospirosis unit (LU)  in  Cotonou  during  a working  visit of staff of KIT  at Cotonou. 
Ad.  1  Post  mortem  tissues  On  Barbados  and  Trinidad,  PM  tissues  were  collected  from 
acute  16  cases  of  leptospirosis  with  a  fatal  course  as  well  as  from  12  cases  without 
leptospirosis that served as control.  Leptospiral  DNA was demonstrated by  PCR  in  tissue 
samples  from  7 of the  16  patients.  Culturing,  performed  on  tissues from  12  patients  did 
result in the isolation of pathogenic leptospiras from only one case.  IF performed on tissue 
from  3  cases  confirmed  the  results  from  PCR  in  two  cases.  Histopathological  disorders 
were  heart,  spleen  and  kidney. 
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Ad.  2  PCR  on  urine  and  serum  samples  On  Barbados  a  total  of  82  blood  and  urine 
samples from  71  patients with  proven  leptospirosis (i.e.  by seroconversion and/or culture) 
were tested by culturing and PCR were performed on first samples, consisting of 62 blood 
and 20 urine samples, mostly before seroconv~rsion occurred. Second samples were used 
to establish seroconversion. The mortality rate in  this group of patients was 16.9o/o  (12 of 
71  patients).  Samples of 16 patients without leptospirosis were used as controls.  Overall, 
PCR  demonstrated  the  presence  of leptospiras  infections  in  44  of the  72  cases  (62°/o), 
whereas  a  positive  culture  was  obtained  in  only  34 cases  (48°/o).  Positive  PCR  results 
were  obtained .in  41  blood  samples  and  33  samples  yielded  positive  cultures.  In  urine, 
PCR  was  positive  in  10  samples  whereas  culturing  was  positive  in  7  samples.  These 
results indicate that PCR,  either performed at .serum or urine, is a valuable adjuct for early 
diagnosis of k3ptospirosis. 
Ad. 3 Establishment of a leptospirosis research unit in  Benin The microscopic agglutination 
test using representative serovars from  15 serogroups applied on  numerous samples from 
inhabitants from various cities and districts in  Benin suggested a seroprevalence in  Benin 
varying from  about 24 to  35o/o. 
Partners 
Royal Tropical Institute 
Dept. of Biomedical Research 
Meibergdreef 39 
1105 AZ Amsterdam 
The Netherlands 
Ministry of Health, Barbados 
Leptospira Laboratory 
Enmore 2 
Collymore Rock 
St Michael 
Barbados 
Pan American Health Organization 
Carribbean Epidemiology Centre (CAREC) 
Jamaica Blvd, Federation Park · 
Port of Spain 
Trinidad 
Veterinary Research Laboratories 
The Queen's University of Belfast 
Dept. of_ Veterinary Science 
Stoney Road 
Stormont, BT  4 350 Belfast 
Northern Ireland 
United Kingdom 
Universite Nationale du Benin 
Faculte des Sciences de Ia Sante 
P.O.  Box 8042 
Cotonou 
Benin 
R.A. Hartskeerl 
Tel:  +31/20/566.54.41 
Fax: +31/20/697.18.41 
E-mail: bo@ mail.support.nl 
P.N.  Levett 
Tel: +80/9/427.55.86 
Fax: +80/9/429.67.38 
P.  Prabhakar 
W.A. Ellis 
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Fax: +44/232/761.662 
Th. Kounde 
Tel:  +22/9/30.1 0.37 
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11.  Non Communicable Diseases 
TS3*CT91 0024 
TS3*CT920081 
TS3*CT920142 
TS3*CT930244 
IC18*CT950024 
IC18*CT960032 
IC18*CT960132 
Bites and stings by venomous animals in  Brazil: clinical and 
laboratory investigations of envenoming and therapy 
Thalassemia intermedia syndrome: molecular 
haematological, clinical and therapeutic studies 
Nutritional influences on the emergence of high blood 
pressure and diabetes in black afro-origin populations in 
Cameroon, Jamaica, France and England 
Molecular mechanisms of genetic variability in the 
expression of major hemoglobinopathies: prognostic value of 
genetic factors and therapeutic perspectives 
Development of a vaccine against helicobacter pylori 
South American bites and stings programme 
Research on the behaviour and biology of a major African 
childhood malignancy, Burkitt's lymphoma, and its associated 
virus,  EBV 
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BITES AND STINGS BY VENOMOUS ANIMALS IN  BRAZIL: CLINICAL AND LABORA-
TORY  INVESTIGATIONS OF  ENVENOMING AND THERAPY 
Period: 
Co-ordinator: 
Objectives 
April  1, 1992- March 31, 1995 
LIVERPOOL SCHOOL OF TROPICAL MEDICINE, VENOM RESEARCH 
UNIT Liverpool, United Kingdom (R.D.G. THEAKSTON) 
The aim  of the project is to assess the problems caused by venomous bites and stings in 
Brazil. 
Activities 
*  Complete monitoring of patients with  severe envenoming will  be carried out.  The effect 
of  antivenom  in  reducing  both  the  extent  of  swelling  and  local  necrosis  will  be 
investigated,  as will  the  problem  of possible  pituitary and  adrenal  insufficiency caused 
by  pituitary infarction. 
*  The use of tourniquets in  systemic envenoming will  be  evaluated in  20 patients and 20 
controls. 
*  The  prophylactic  use  of  antimicrobial  drugs  will  be  investigated  in  patients  with 
moderate  and  severe  systemic  envenoming,  to  determine  whether  or  not  organisms 
present  in  the  oral  cavity  of venom  or on  the  gangs  of  wild  snakes  result  in  wound 
infection  in  the  bitten  patient. 
*  An  investigation  of whether  routine  prophylactic antihistamine  prevents  both  early and 
late  reactions  to  antivenom  will  be  carried  out  in  both  moderately  and  severely 
envenomed  patients  in  a randomized  double  blind  placebo-controlled trial. 
*  Thirt y patients with moderate envenoming will receive half the lowest dose of antivenom 
given earlier, and 30 will receive the same starting dose as given in the previous project. 
Recovery from clinical signs, venom clearance, circulating antivenom levels, coagulation 
and fibrinolytic, hematological and biochemical profiles will be compared. 
*  Laboratory studies will  be  carried  out to assess the  significance  of  the  ELISA method 
for detection  of functional  molecules  rather than  immune complexes. 
*  Studies  on  patients  envenomed  by  scorpions  and  spiders  will  be  carried  out  in  Sao 
Paulo  and  Belo  Horizonte to  investigate the  kinetics of envenoming  and  therapy. 
*  The  detection  of  specific venom  in  lesions  caused  by  Loxosceles spider bites  will  be 
carried  out. 
*  Investigation of the  pathogenesis of envenoming  by  Crotalus durissus terrificus in  Sao 
Paulo  and  Minas Gerais States will  be  carried  out to  improve  patient treatment. 
*  To discover the importance of snake bite, to assess the traditional methods of treatment 
and to try and improve the management of severe cases in indigenous Indian and other 
associated populations. 
*  The  latest  techniques  of  "molecular  genetics"  and  multivariate  analysis  of 
morphological/anatomical features  in  comparison to venom  composition  will  be  applied 
to  provide  practical  guidelines  for  antivenom  manufacturers  to  ensure  adequate  neu-
tralizing  efficacy of their products throughout Brazil. 
*  To  clone  Bothrops myotoxins. 
Expected outcome 
Knowledge of the  pathophysiological effects of venom  components and  the establishment 
of appropriate treatment schemes for patients with  envenoming. 
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Partners 
Liverpool School of Tropical Medicine 
Venom Research Unit 
Pembroke Place 
L3 5QA Liverpool 
United Kingdom 
I  nstituto Butantan 
Hospital Vital Brazil 
Av.  Vital Brazil 1500 
05504 Sao Paulo 
Brazil 
Universidade Federal de Minas Gerais 
Hosp. das Clinicas 
Av.  Professor Alfredo Bolena 110 
CEP 13013 Belo Horizonte 
Brazil 
University of Oxford 
J. Radcliffe Hospital 
Centre for Tropical Medicine 
OX3 9DU Headington 
Oxford OXDU 
United Kingdom 
University of Aberdeen 
Dept. of Zoology 
Tillydrone Avenue 
AB9 2TN Aberdeen 
United Kingdom 
Centre d'Etudes Nucleaires de Saclay 
Service de Biochemie des Proteines 
Gif-Sur-Yvette 
Saclay 91191 
France 
R.D.G. Theakston 
Tel:  +44/151n08.93.93 
Fax: +44/151n08.87.33 
E-mail: r.d.g.Theakston@ liverpool.ac.uk 
J.L.C. Cardoso 
Tel:  +551/1/211.83.61 
Fax: +551 /1/815.15.05 
C.F.S. Amaral 
Tel:  +553/1/239.71.00 
Fax: +553/1/226.82.77 
D.A. Warrell 
Tel:  +44/186/522.13.32 
Fax: +44/186/522.09.84 
R.S. Thorpe 
Tel:  +44/122/427.20.00 
Fax: +44/122/427.43.96 
A. Menez 
Tel:  +33/1/69.08.60.00 
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THALASSEMIA INTERMEDIA SYNDROME: MOLECULAR HEMATOLOGICAL, CLINICAL 
AND THERAPEUTIC STUDIES 
Period: 
Co-ordinator: 
Objectives 
December 1  , 1992 - November 30,  1995 
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, DEPT 
OF PED. THALASSEMIA UNIT,  ST.  SOPHIES HOSP. 
Athens, Greece (C.  KATTAMIS) 
Of the two clinical phenotypes of thalassemia (Major and lntermedia), thalassemia (Thal-1) 
is  not well  defined and studied. 
The  main  objective  of this  project  is  to  establish  precise  criteria  for  characterization  of 
Thal-l,  both  at the  molecular as well  as clinical  and  hematological  levels utilizing existing 
and  new techniques. 
Activities 
Defin  ition  of criteria for clinical  assessment in  a data base format 
*  Selection  of Thal-1  patients for study in  Athens and  Bangkok. 
*  Chara cterization  of common  hematologic phenotypes and  genotypes. 
*  Applicatio  n of a  selection  and  analysis technique of fetal  nucleated cells  in  maternal 
circulation. 
Completion  of characterization  of common  phenotypes and  genes of Thal-1 
*  Identification of rare - and  probably new - mutations. 
*  Intervention trials with  hydroxyurea (HU)  (Phases  I and  II)  in  Thal-1). 
*  Application of fetal  cell  selection  in  antenatal  diagnosis. 
*  Study of factors enhancing y-chain  production  in  selected families. 
Evaluation  of results on  common  genotypes and  phenotypes 
*  Listing and  distribution of rare  mutants in  the Greek and the Thai  population. 
*  Evaluation  of intervention trials with  HU. 
Expected outcome 
~  Stand ardized criteria for assessment of clinical  severity of Thal-l, and definition of the 
most quick,  accurate and  inexpensive methods for diagnosis. 
~Transfer and utilization of new technology by the collaborating units; this will  result in  a 
precise  evaluation  of effectiveness  and  applicability  of  the  new  techniques  in  clinical 
diagnosis. 
~  Identification  of  the  genotypes  and  hematological  phenotypes  of  Thal-1,  in  which 
treatment with  hydroxyurea may be most effective. 
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Results 
Further to  the  primary  results  summarized  in  the  first  progress  report,  the  three  centers 
have  proceeded  in  their  respective  and  collaborative  parts  of  the  project  according  to 
schedule: 
=>  On  the basis of the criteria set out in  the first 6 months, the selection of Thal-1  patients 
in  Greece and Thailand continued and the number of samples so far collected exceeds 
200. 
=> All patients have been .subjected to full clinical and hematological characterization, while 
the  molecular characterization  is  in  progress.  Of interest is the characterization of new 
mutation  (codon  29  in  the a2  globin gene)  amongst the  Greek HbH  patients. 
=>  Until  now  amongst  the  high  HbA2-B-thal  Thal-1  cases,  a  wide  range  of  previously 
defined  B-gene  mutations have  been  found. 
=>  During  this  time  the  DGGE  method  for a-gene  mutations  standardized  in  Leiden  has 
also been  set  up  and  applied  in  Athens. 
=>  Methods for effective harvesting of foetal cells from  maternal circulation continues to be 
investigated  in  Leiden. 
=> The initial results from the 6 months clinical trial were positive; the trial will be extended 
as  proposed. 
=>The  three  centres  are  all  involved  in  the  organization  of  a  wetlab  workshop  entitled 
"Recent  advances  in  the  detection  of  single-base  mutations"  took  place  in  Bangkok, 
Thailand  1 - 5 August  1994. 
Partners 
National and Kapodistrian University of 
Athens 
Dept. of Ped., Thalassemia unit, St.  Sophie's 
hosp. 
Thivon and Levadias 
11527 Athens 
Greece 
Mahid ol  University 
Fac. of Med., Thalassemia Unit 
Siriraj Hospital 
1  0700 Bangkok 66 
Thailand 
Rijksuniversiteit Leiden 
Dept. of Human Genetics 
Sylvius Laboratory 
Wassenaarseweg 72 
2333 AL Leiden 
The Netherlands 
C.  Kattamis 
Tel:  +30/1n79.40.23 
Fax: +30/1n79.57.62 
S. Fucharoen 
Tel:  +662/411.20.12 
Fax:  +662/412.97  .83 
L. Bernini 
Tel:  +31/71/27.60.00 
Fax:  +31n1/27.60.75 
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NUTRITIONAL  INFLUENCES  ON  THE  EMERGENCE  OF  HIGH  BLOOD  PRESSURE 
AND DIABETES IN  BLACK AFRO-ORIGIN  POPULATIONS IN  CAMEROON, JAMAICA, 
FRANCE AND  ENGLAND 
Period: 
Co-ordinator: 
Objectives overall 
April1,  1993 - March 31,  1995 
UNIVERSITY OF MANCHESTER MEDICAL SCHOOL, CLINICAL 
EPIDEMIOLOGY UNIT 
Manchester, United Kingdom (J.K. CRUICKSHANK) 
To  establish the  role  of nutrition  in  the  emergence of high  blood pressure and diabetes in 
African-origin  populations. 
Specific: 
+ To  establish  random  samples  of African-origin  populations  in  Cameroon,  West Africa, 
Jamaica  and  Martinique,  West  Indies  (in  both  rural  and  urban  samples),  in  Paris, 
France and  Manchester,  UK (urban  only) 
+ To  establish in  these samples average nutrient intakes by food frequency questionnaire 
(FFQ)  in  people aged 25-7  4 years,  weighted towards 40-64 years.  Using  standardised 
methods,  to  relate  these  intakes  to  the  prevalence  of  high  blood  pressure  (BP)  and 
glucose intolerance/diabetes as  major emerging  health  problems in  these  populations. 
+ To  assess  how  nutrient  intake  varies  with  other  life  style  factors  including  smoking, 
alcohol  and  exercise  habits,  social  indices and  income. 
+ To  test the  hypothesis that decreased  potassium  (based  on  24 hour urine collections) 
and  increasing  fat  intake  are  related  to  increasing  BP  and  deteriorating  glucose 
tolerance (GT)  and are associated with disordered insulin secretion and action ("insulin 
resistance"). 
+ To  assess whether a ''transition" of the distributions of BP and  GT,  as well  as of insulin 
secretion,  is detectable both within and across the four populations in  relation to energy 
and  macro-nutrient intakes. 
+  To  use these data to  plan  a later incidence and  nutritional  and  lifestyle-based primary 
prevention  programme for high  BP  and  diabetes  in  the  same  population  samples. 
Materials, Methods and Activities 
The 3 fieldwork centres were to  carry  out a closely similar programme  with  standardised 
protocols  and  procedures.  Some  local  variations  would  be  necessary  but  the  general 
format and  order was to be  the same  in  each  site,  observers  being  trained  by  the  same 
techniques. 
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1.  Population  sampling  and  Glucose Tolerance/Cardiovascular tests 
2.  Food  Frequency Questionnaires  (FFQ)  built  up  food  diaries/recalls 
3.  Analysis  by  between- and  within-centre  comparisons 
4.  Planning  the  intervention  trial  for primary prevention. 
Sampling 
A random  sample  of  adults  aged  25-79  years,  weighted  towards  40-64  years  olds,  was 
drawn  from  site  specific  population  registers,  originally to  reach  a total  of  1500  per site, 
with a response rate preferably above 70o/o  of those eligible.  Each subject received a letter 
of  personal  invitation for a "health  check"  explaining the  study and  giving an  appointment 
to  attend for their health  check,  usually at their local  health  centre.  Non-responders were 
reinvited and  then visited at home to  establish address or genuine refuser status. After an 
initial lifestyle questionnaire,  BP and  anthropometric measurements,  including one 24 hour 
urine,  subjects  either  had,  or  appointments  were  made  for,  the  2  hour  75g  GTTs  timed 
precisely  over  2  hours  and  a  second  24  hour  urine.  The  FFQ  was  administered  either 
during this 2 hour period or later at the subject's home,  having been  piloted on  a previous 
subsample. 
Phase 2 
The  FFQ  had  a standard  format  in  each  site  and  many basic questions were  the  same. 
Local  variations  were  added  in  the  same  format,  piloted  as  before.  Validation  measures 
were  developed  for  the  Manchester  sample,  including  food  diaries  recorded  by  a 
subsample of subjects after their FFQ.  Urinary nitrogen was originally to be measured from 
24  hour  urines,  but  this  was  not  done,  FFQ  repeatability  measures  were  carried  out  in 
subsamples  (Sharma  et  al,  1996). 
Quality Control 
During  both  phases  1 and  2,  an  important aspect was  quality control  of all  fieldwork,  by 
liaising  and  exchanging  data  files,  original  questionnaires  and  a  random  sample  of 
blood/serum  samples  across field  sites. 
Phase 3 Analysis 
Each  centre  was  responsible  for  their  own  data  punching,  verification  and  entry,  with 
verification by doubls entry.  Questionnaires and data were exchanged and sent to Paris for 
merging,  analysis and  age  standardisation. As  sample  sizes  and  numbers per age  group 
varied,  random  samples  totalling  400  per  site  (200  men)  for  between-site  analysis  were 
taken,  to  average  20  per age/sex  band  per  cell.  Within-site  analysis  used  full  local  data 
sets.  The  Paris  centre  acted  as  the  statistical  analysis  centre,  providing  advice  and 
integrating the  across/between  centre  comparisons.  Each  centre  handles  its  own  data as 
it  wishes,  collaborating  with  the  others for publication. 
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Results~Baseline results for anthropometry, blood pressure and glucose tolerance, as 
well as indices of social and economic  status.~Baseline nutrient intakes in each site,  in a 
subsample of age/sex groups in  Manchester from the FFQ with validation/calibration from 
further food diaries and 24 hr.  recalls. The latter have so far only been analysed in 
Cameroon and Jamaica, although programmes have been written for the FFQ analysis in 
both sites but staff were available only in Jamaica to do so. 
Conclusion 
The  project has  shown  that  nutritional  intakes,  anthropometric,  BP  and  glucose tolerance 
data can  be collected uniformly.  Here, for the first time,  results are now comparable across 
site,  indicating the  rapid transition to chronic disease in  these 3 African-origin populations. 
In our view,  environmental rather than genetic factors determine this change, as evidenced 
by  the  change  within  Cameroon.  Similarly,  mainly Jamaican-origin  Caribbean  migrants to 
the UK have higher rates than their Jamaican peers, perhaps mainly related to body mass. 
The  dietary  data,  again  unique,  show  that  while  quality  is  generally  excellent  (initial 
analyses not shown),  clearly quantity is excessive for the degree of physical  activity when 
obesity  emerges,  except  in  rural  Cameroon  where  fat  (as  palm  oil)  is  the  major energy 
source.  Obesity  is  uncommon  due  to  that  activity.  Despite  this,  it  seems  that  the 
maintaining traditional food sources (particularly complex carbohydrates) against the social 
pressure  for  high  fat  "Western"  diets  may  help  to  avoid  epidemics  of  glucose 
intolerance/diabetes  and  hypertension  emerging  in  these  developing  nations  and  their 
migrant  populations.  Intervention  and  follow-up  trials  should  indicate  what  individual  and 
public health  interventions may help prevention. 
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Partners 
Clinical Epidemiology Unit 
University of Manchester Medical School 
Oxford Road 
Manchester M  13 9PT 
United Kingdom 
Diabetes Research Laboratories 
Dept. Medicine 
Centre Universitaire des Sciences de Ia 
Sante 
Universite de Yaounde 1 
Yaounde 
Cameroon 
Tropical Metabolism Research Unit 
University of The West Indies 
Kingston 7 
Jamaica 
INSEAM Unite 21 
16 Avenue Paul Vaillant Couturier 
94807 Villejuif Cedex 
France 
J K Cruickshank 
Tel:  +44/161/275.51.99 
Fax: +44/161/275.52.19 
E-mail: clinep@fs2.scg.man.a 
J C Mbanya 
Tel:  +237/31.06.51 
Fax: +237  .22.13.20 
E-mail: Jean-Ciaude.Mbanya@ Camnet.CM 
T.  Forrester 
Tel:  +  1/809/92.71884 
Fax: +  1/809/92.73520 
E-mail: nander@ uwimona.edu.jm 
B.  Balkau 
Tel:  +33/1/45.59.51.05 
Fax: +33/1/47.26.94.54 
E-mail: balkau@sinaps.vjf.inserm.fr 
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MOLECULAR  MECHANISMS  OF  GENETIC  VARIABILITY  IN  THE  EXPRESSION  OF 
MAJOR  HEMOGLOBINOPATHIES:  PROGNOSTIC  VALUE  OF  GENETIC  FACTORS 
AND  THERAPEUTIC  PERSPECTIVES 
Period: 
Co-ordinator: 
Objectives 
July 1, 1994-April 31,  1997 
HOPITAL R.  DEBRE,  INSEAM U120, PHARMACOLOGIE DU 
DEVELOPPEMENT, Paris,  France (R.  KRISHNAMOORTHY) 
•  To  understand the  genetic and  molecular bases of the  variable phenotypic expression 
of  major hemoglobinopathies and  in  particular sickle cell  disease (SCD). 
•  To  rationalize  the  therapeutic  induction  of foetal  hemoglobin  (HbF)  in  hemoglobinopa-
thies  by  pharmacological  means. 
Activities 
*  Appreciate:  1) the feasibility of a comprehensive program on  SCD based upon neonatal 
screening,  parental  education  and  early medical follow-up  in  an African  setting,  and  2) 
the  impact of this  program  on  the  related  morbidity and  mortality (natural  history). 
*  Epidemiology of  G6PD  deficiency and  its  interaction  with  SCD. 
*  Comparison of severe form  of African sticklers with  mild  ones from  India to  assess the 
prognostic  value  of  associated  genetic  modifiers  (genetic  polymorphism  of  the  critical 
regulatory  DNA  elements  of  the  J3-globin  gene  cluster,  a-globin  gene  status,  genetic 
propensity to  express  HbF. 
*  Hydroxyurea treatment  in  pediatric SCD  patients and  follow  up. 
*  Recruitment  of  families  for  studying  genetic  modifiers  (unlinked  to  the  J3-globin  gene 
cluster),  involved  in  the  genetic control  of HbF  expression  (F-cell  genetics). 
Results (to date) 
~  In  the  social  context  of  Benin,  an  affected  newborn  with  SCD  is  rarely  retrieved  for 
regular clinical  follow-up.  We  circumvented  this  difficulty  by  focusing  our attention  on 
identifying  pregnancies  at-risk  for  giving  birth  to  a  child  with  SCD  and  by  providing 
information  and  counselling.  A  total  of  2300  pregnancies  were  followed:  5o/o  of  the 
pregnancies  with  SCD  were  managed  clinically.  1  028  newborns  were  available  for 
neonatal screenjng and  12°/o had SCD with 64°/o traits.  91  newborns entered the clinical 
surveillance  programme  (75o/o  compliance  of  the  parents)  which  included  prophylaxis 
against  infections.  Among  them  25o/o  had  an  associated  G6PD  deficiency  (G6PDA-). 
The  outcome  of these studies will  be  assessed  only  in  year/3. 
~  Contribution  to  the  culture  of  continuous  learning:  participation  to  the  first  regional 
specialized  course  of hematology on  SCD  held  at Cotonou  BENIN  (12-16  Dec.  1995) 
with  the  aim  of disseminating the  state  of  the  art of biological  and  clinical  aspects  of 
SCD  to  trainees  from  11  different  African  countries.  A  "SCD  network"  among  these 
countries has  been  created. 
~The  prevalence of G6PD deficiency by "spot test" in  Mauritius is 5.5o/o  (school and blood 
donor  screening  n  = 1435).  Molecular  analysis  (PCR  - RFLP,  SSCP,  Nucleotide 
sequencing) confirmed the phenotype data but also revealed the nature of mutant alleles 
(G6PD Orissa,  Kerala Kalyan,  Mad-Union, Hammersmith, A-)  consistent with the ances-
tral  population  input.  16  G6PD  novel  variants  await  characterization.  We  could  not 
observe SCD  in  association with  G6PD deficiency in  this population.  More  SCD  cases 
need to be screened. Transfer of knowledge and know how was extremely efficient and a 
specialized center for hemoglobinopathies was set up and now functions autonomously. 
~  Extensive comparison  of  regulatory  region  polymorphisms of the  J3-locus  in  indian  and 
different african sickle cell traits (taking into account the a globin gene status)  revealed 
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that the sickle cell gene from India has intrinsic thalassemic characteristics with resulting 
reduced expression of HbS and thus might contribute along with  elevated HbF expres-
sion to the attenuated form of the disease in India as compared to severe form in Africa. 
=>  A large three generation family consisting of 60 members with  16 presenting a J3-globin 
gene cluster dependent HPFH (moderate increase in  HbF in the basal state with further 
increase in  response to anemic stress) from Algeria is presently under investigation for 
defining the  molecular basis of such  forms of  HPFH. 
=>  Clinical trial  of hydroxyurea (HU)  treatment for the  past 2 years of the first  generation 
African  SCD  children  followed  at  Paris  (4  boys  and  3  girls,  age  range  4-16  years) 
revealed:  1)  an  excellent compliance;  2)  all  were "responders"  in  terms of  increase  in 
HbF;  3)  SCD  with  "Senegal"  haplotype  had  higher  increment  in  HbF  than  others;  4) 
absence of HU dose- dependence in HbF increase; 5) beneficial affect of HU  (in terms 
of hospitalization for vasa occlusive crisis or acute thoracic syndrome/patient/year is not 
limited to increment to HbF alone; 6) HU caused reduction in serum iron, supplementation 
of which, further increased the HbF level all  leading to the conclusion that UH treatment 
appears as an  efficient cost-effective alternative for situations where exchange transfu-
sion was the role (excepting strokes) and thus avoiding transfusion-associated risks. 
Partners 
Hopital Robert Debre, INSEAM U120 
Pharmacologia du Developpement 
48 bd Serurier 
FR - 75019 Paris 
Hopital Robert Debre 
Biochimie Genetique 
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Laboratoire d'Hematologie 
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Hammersmith Hospital 
Dept. of Haematology 
Ducanne Road 
UK- W12 ONN London 
Centre Hospitalo-Universitaire Mustapha 
Centre de Transfusion 
DZ - 16000 Alger 
Centre de Recherches Medicales SSR 
Moka 
Mauritius 
OCEAC 
Dept. d'Entomologie Medicale 
B.P.  288 
CA- Yaounde 
Centre National Hospitalo-Universitaire 
Clinique des Maladies du Sang 
B.P.  188 
BE- Cotonou 
R.  Krishnamoorthy 
Tel:  +33/1/40.03.19.01 
Fax:  +33/1/40.03.19.03 
J.Eiion 
Tel:  +33/1/40.03.23.39 
Fax: +33/1 /40.03.20.20 
R. Girot 
Tel:  +33/1/40.30.61.97 
Fax: +33/1/45.67.91.56 
L. Luzzatto 
Tel:  +44/181/740.32.34 
Fax:  +44/181/472.93.35 
K. Nafa 
Tel:  +213/2/65.36.42 
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DEVELOPMENT OF A VACCINE AGAINST HELICOBACTER PYLORI 
Period: 
Co-ordinator: 
Objectives 
January 1,  1996 - December 31,  1998 
CHIRON SPA,  IRIS RESEARCH CENTRE 
Siena,  Italy (J.L. TELFORD) 
•  To  produce a genetically detoxified  H.  pylori cytotoxin  protein  suitable for evaluation as 
a vaccine candidate. 
•  To  assess  the  genetic variability  of Chinese  isolates  of  H.  pylori,  and  to  evaluate  the 
relationship  of this variability to the  incidence of severe disease. 
•  To  test  in  the  mouse  model,  vaccine  candidates  which  show  promise  in  protecting 
against  European  strains  of  H.  pylori for  their  capacity  to  induce  protection  against 
infection  by virulent Chinese  strains. 
Activities 
*  A bank of monclonal antibodies raised  against purified native toxin  wil  be  screened for 
their ability to  neutralize  purified toxin. 
*  Sequences coding  for  potentially non-toxic VacA proteins willl  be  created  in  E.  coli by 
site  directed  mutagensis. 
Mutated  genes constructed  in  E.  coli will  be  transferred  into  H.  pylori. 
*  Mutated toxin  proteins will  be  tested for their ability to  induce gastric lesions after oral 
administration  to  mice. 
*  Sera  from  Chinese  patients  undergoing  routine  endoscopy  will  be  analysed  for  their 
ability to recognize CagA, VacA and other H.  pylori antigens to ascertain any correlation 
with  particular conditions such  as duodenal  ulcer and  gastric cancer. 
*  Strains isolated by endoscopy from  Chinese patients will  be  analysed for the presence 
of the  CagA genotype and  by  immunoblot for expression  of CagA and  VacA proteins. 
*  Selected  isolated  of  different  genotype  and  phenotype  will  be  adapted  to  mice  by 
sequential  passage. 
*  Non-toxic VacA proteins will  be tested for their ability to protect mice from  infection with 
European  and  Chinese strains of  H.  pylori adapted to colonization  of mice. 
Expected outcome 
=>  Identification  of biologically  relevant  regions  of the  VacA protein. 
=>A  genetically  detoxified  and  antigenically  intact  cytotoxin  molecule  as  a  vaccine 
candidate. 
=>  Serological data on  the association of infection with Type  I,  VacA and CagA expressing 
strains with  gastroduodenal disease  in  China. 
=>  Genotypic and  phenotypic data on  the  variation  of  H.  pylori strains  in  clinical  isolates 
form  Chinese patients and  their assocation  with  disease. 
=>  Pathogenicity in vivo and in  vitro of clinical isolates from China related to their genotype 
and  phenotype. 
=>  Evaluation of the cytotoxin toxoids in  conferring protective immunity against infection by 
European  and  Chinese strains of  H.  pylori. 
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SOUTH  AMERICAN  BITES AND STINGS  PROGRAMME 
Period: 
Co-ordinator: 
Objectives 
August 1, 1996-January 31, 2000 
LIVERPOOL SCHOOL OF TROPICAL MEDICINE, 
Liverpool, United Kingdom (R.D.G THEAKSTON) 
•  To  investigate and  improve therapy of bites and  stings  in  different areas of  Brazil  and 
Ecuador by clinical  testing  of antivenoms. 
•  To  investigate the  extent of the  problem  of bites  and  stings  in  the  above areas. 
•  To  investigate  the  efficacy  of  plant  extracts  as  possible  alternatives  to  conventional 
antivenoms. 
•  To  develop  enzymes  immunoassay as  a tool  for epidemiological  studies,  rapid  immu-
nodiagnosis and  for studying the  kinetics  of envenoming and  therapy. 
Methodology and Activities 
*  Preclinical  experimental  assessment of antivenoms  before  clinical  studies  (Liverpool). 
*  Randomized clinical trials of antivenoms using clinical  and  laboratory methods (Belem, 
Uberlandia,  Sao  Paulo-Brazil,  Shell  Pastaza-Ecuador,  Oxford-UK). 
*  Laboratory tests  on  the  pathological  effects of venoms. 
*  Isolation,  purification  and  study of venom  components. 
*  Taxonomic  evaluation  of  medically-important  snake  species  and  associated  study  of 
venoms from  these  (Sao  Paulo-Brazil,  Bangor-UK). 
*  Epidemiological  survey studies  in  Amazonian  Ecuador and  Brazil  to  establish  the  true 
extent  of  bites  and  stings  in  these  areas  (Sao  Paulo  and  Belem-Brazil,  Pastaza, 
Shell-Ecuador). 
*  Enzyme-linked immunosorbent assay is being used as a tool for examining the kinetics 
of  envenoming  and  therapy (Liverpool,  Paris). 
*  Isolates from  various  plants are  being  prepared  in  Hannover and  tested for antivenom 
activity in  Liverpool. 
*  Affinity purification  of specific venom  antigens  is  being  used to  increase the  specificity 
and  decrease the  time taken  for immunodiagnosis  (Liverpool,  Paris). 
Expected outcome 
~  The  optimum  antivenoms and  antivenom doses will  be  determined following preclinical 
tests and possibly clinical trials for use in  central and Amazonian Brazil and Amazonian 
Ecuador. 
~  Epidemiological  studies  will  result  in  clarification  of the  extent  of the  health  problems 
caused  by  bites  and  stings  in  Brazil  and  Ecuador. 
~The  purification and testing of venom components will help in the possible development 
of novel  drugs. 
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RESEARCH  ON  THE  BEHAVIOUR  AND  BIOLOGY  OF  A  MAJOR  AFRICAN  CHILD-
HOOD  MALIGNANCY,  BURKITT'S LYMPHOMA, AND ITS ASSOCIATED VIRUS,  EBV. 
Period: 
Co-ordinator: 
Objectives 
February 1, 1997-January 31, 2000 
IMPERIAL COLLEGE SCHOOL OF MEDICINE 
London,  United Kingdom (B.E.  GRIFFIN) 
+ To  seek a better prognosis for BL,  based on  clinical  re-evaluation and  reassessment of 
treatment,  particularly for  patients with  non-responsive tumors,  correlating  patient data 
with  molecular exploration  of tumor tissue,  and/or sera or whole  blood  analyses. 
+  To  establish  new assays for diagnosis,  some of which  will  be  designed for use  on  site 
in  Malawi,  and  analyzing  viral  (and  cellular)  gene  expression,  correlating  data  with 
clinical  information. 
+  To  generate  useful  questionnaires  regarding  patient  and  family  histories,  as  they  may 
relate  to  onset  of  the  disease,  or  the  different  individual  clinical  patterns  observed, 
looking for possible  genetic and/or environmental  links to  disease. 
+ To  explore  viral  markers  that  may  have  bearing  on  treatment  of  disease,  aimed  at 
correlation  with  clinical  behavior.  To  build  up  a  profile  of  EBV  gene  expression 
alongside  patients  data. 
+ To train local personnel to  help in  management of the BL programme,  both  with  regard 
to  data collection,  analysis,  patient management and  laboratory work. 
Activities 
*  To  establish an  effective communications system among the partners,  both  with  regard 
to  exchange  of data and  of  materials. 
*  To  train  local  personnel  with  respect  to  sample  and  data collection  and  interpretation, 
also  with  regard  to  laboratory diagnoses. 
*  To set up serum, blood and tissue banks on patients, and suitable controls, for assaying 
with  regard  to  EB  viral  (and  cellular)  gene  expression. 
*  To  re-evaluate treatment protocols,  particularly with  regard  to  patients with  tumors that 
do  not  respond  to  conventional  chemotherapy,  hunting  for  patterns  between  EB  viral 
gene  expression  and  tumor response. 
*  To  explore the establishment of BL in  an  animal model to  provide continuing sources of 
tumor material for analyzing gene expression within  a single tumor population;  alterna-
tively,  using molecular approaches to generate gene expression libraries for evaluation. 
Expected outcome 
==>  Data  that  lead  to  the  re-evaluation  of  BL,  and  improved  methodologies  for correlating 
gene  expression  with  patient prognosis. 
==>  New  assays  relevant  to  diagnosis  and  treatment  of  BL,  and  an  overall  better  under-
standing  of this  major childhood  tumor in  sub-Saharan Africa. 
==>  Trained  local  personnel to  work on  BL  projects  in  longer term. 
==>  Distribution of findings to  other African  countries where  BL is a major childhood tumor, 
and  publication  of data as  a means of distributing  information  further afield. 
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PAFTTNFRSF{IP BETWEEN EUHOPE AND DHVffiLOPING COUNTHIH$
IN HEALTH RESEARCF{ 
1
The Eurt)pean Ccrnrnission has been sr"rpporting joint researchi activities relerrant
to Cevelcprnent.  including health related research, sil'ice X983, ancJ has i-eceltly
issued tl're seccnd call for scientific proposals within the programme of Interna-
tiorral Ccoperation with Develclping Countries {INCO-DC; which lras hecorne  a
Lrrcader programrne thalt its predecessor. Health research remains a pliority area,
together with research on agriculture  ancJ the sustainable use of riatural resoLtrces.
Tl'ie Comrnission's International Scientific Cooperation  Programme is an integral
part of the [uropearr Union's Fourth Framework Frograrnme on Researcl'r. lt
serve$ Europe's research policy but it does even rnore. lt is alsc an instrument  to
support other Iuropean policies, such as devek:pment cooperation, erternai
relations or econornic cooperation with third countries.
A guiding principle of the European Union is a desire to contribute to workJwicle
sustainable development.  A desire which stems from a sense of co-responsibility
for tl"ie prcbiems faced by third countries. This responsibility must be shared by
every citizen but a special role, undervalued in the past, must be reserved for the
scientists who have chosen to address problems of developing countries.
most important cornmodity for sustainable developnrent is kngwledge and knowl-
ecige wili be the nurnber one production factor in the 21st century. lts importance
will far outweigh that of capital and labor,rr in the present century, an6 if one wishes
to safeguard the furture and to increase knowledge, more needs to be invested in
research now. Research is increasingly  perceived as a basis for welfare within the
Eu. Research must therefore be just as important for the welfare of third countries.
This assurnption has received too little attention. Knowledge is an invaluable
commodity and to acquire knowledge one has to help develop a culture of
questioning.
Responsibility  and Mandates
The develcpment of a culture of science and research is the responsibility of
everyone. Scientists within the individual member states of the European Union
are already involved at personal, institutional, regional, or national level in a variety
of programmes with a variety of goals related to Health ln tropical areas or
developlng ccuntries. A wealth of research activities are, or can also be, performed
or developed on a bilateral basis by each of the European l\4ember States. The
commission strongly encourages all these efforts.
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and whenever possible to  be  in  synergy with them,  but the Commission's strength 
lies in  its ability to harness expertise at a supra-national level within  Europe,  in the 
context  of  its  relations  with  third  countries.  Adding  a  European  dimension, 
complementing the  existing  bilateral  regional  and  national  interactions. 
The  European  Commission  will  not  replace  any  of  the  inputs  from  others.  The 
more support scientists in  Europe or Developing Countries receive or acquire from 
national or other sources,  the  more European programmes will  be  meaningful and 
give room  for substantial cost efficient added value.  The Commission functions on 
the  basis of subsidiarity,  a concept which  has been  a matter of debate in  the  EU. 
At the  European  level,  the Commission does what can  be  done only at this level, 
and  most  importantly,  done  better  at  this  level.  The  Commission  builds  on  the 
valuable  contributions  to  health  research  of the  individual  Member  States  of the 
European Union. Many agencies like the Institutions of the United Nations, such as 
WHO,  have  an  alternative  agenda focused  on  different  roles  and  responsibilities, 
although  often  in  support of common  goals. 
It is critical that each  has their own  clearly defined goals and  modes of operation. 
It is  also important that all  operations are transparent so that what is  being  done, 
and  where,  can  be  precisely  established,  thus  avoiding  wasted  efforts  and 
unnecessary duplication.  What it boils down  to,  is  the  need  to  establish  equitable 
partnerships which will facilitate the sharing of knowledge. Clearly with the financial 
and  human  resources  which  can  be  harnessed  from  within  the  European  Union 
the  opportunity can  be  provided  for partnerships  to  be  established  within  Europe 
and  with  third  countries.  These  resources  are  not  an  objective  or  a  solution  in 
themselves.  They  simply  provide  the  appropriate  environment  and  the  means  to 
progress. 
For  too  long  it  was  considered  that  ideas  and  practices  in  health  research  were 
"for''  Developing  Countries,  and  that  they  could  be  exported  from  Europe  to 
Developing Countries for direct application. While that attitude was not exceptional 
in  times  gone  by,  it  is  now  certainly  no  longer acceptable.  The  European  Union 
encourages  health  research  "with"  Developing  Countries. 
In  establishing  partnerships  in  health  research  with  Developing  Countries,  the 
criteria considered to  be  most important can  be  divided  in  three  parts. The  first is 
the scientific aspect.  It is essential that the process of science is of a high  quality, 
indeed of international status,  and  respected on  its own  merits and  rules.  There is 
only  one  science,  whether it  is  classified  as  basic,  fundamental,  strategic,  opera-
tional  or  action  research.  What  matters  is  that  science  flourishes  in  a variety  of 
socio-economic and  cultural  environments. 
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the  EU  policy  of  scientific  cooperation  in  health  research.  It  would  be  naive  to 
consider that any scientific interaction can  take  place  in  a vacuum,  insulated from 
other aspects  of  life.  There  must  be  consideration  of the  societal  aspects  of the 
science.  In  other words  there  must be  an  expectation  that the  scientific work will, 
at  one  time,  bring  tangible  benefits  for  society  as  a whole.  Therefore,  the  work 
supported  by  the  Commission  is  aimed  at  addressing  the  major health  problems 
faced  by  developing  countries.  New  practices  and  technologies  have  to  take 
account  of  the  context  in  which  they  may  be  applied  and  the  health  benefits  of 
their  application  have  to  be  clearly  established.  Public  health  concepts  are  a 
common  platform  for all  health  research. 
The third important point to consider is that health research partnerships cannot be 
established  unless  there  are  partners  to  establish  them  with.  Partners  within 
Europe  are  easier  to  find,  but  research  capacity  in  Developing  Countries  is 
relatively  scarce  and  cannot  be  created  overnight.  Although  the  inputs  from 
national or international  research  programmes can  help,  they  are not the  solution 
in  themselves. 
What  is  needed  is  a prolonged  intensive  investment and  other support to  ensure 
capacity  and  capability  strengthening.  This  will  only  be  achieved  through  the 
political  will  and  the  economic  commitment  of  the  countries  themselves  together 
with support from other. national and international sources.  Fortunately the need for 
this  support  has  been  recognised  by  the  European  Union  through  its  economic 
and development cooperation policy which  is mainly the responsibility of DGIB and 
DGVIII  within  the  Commission. 
Science  should  not  suffer from  any  unproductive  rivalry,  as  was  the  case  in  the 
early  years  of  this  century,  when  scientists  argued  over  whether  resistance  to 
disease was  dependent upon  cells  or serum.  Scientists  allied  them~elves on  one 
side  or  the  other  on  the  basis  of.  their  nationality.  In  the  initial  stages  of  the 
European  Union's  Research  Programmes  even  the  prospect of  uniting  two  Euro-
pean  research  institutions  or  laboratories  from  different  member  states  seemed 
daunting  to  less  receptive  scientists,  and  brought  some  opposition.  Scientists 
assumed,  falsely,  that their efficiency or competitiveness  would  be  diminished  by 
having  to  participate  in  what  was  considered  by  some  to  be  a  cumbersome 
interaction.  But the imposition of this requirement of joint research  for eligibility for 
European  Union  support  has  stood  the  test of time  and  is  helping  to  change  the 
paradigm  for international  cooperation  to  one  of equitable  partnerships. 
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European  cooperation  with  many  examples  of  the  EU  programme  providing  the 
initial contacts between labs which have blossomed and been extended to address 
many problems outside the current programme.  Competition  between  laboratories 
remains a driving force for advances, but this has ensured that scientists tended to 
become  better specialists  in  their own  particular area.  There  is  now  an  apprecia-
tion that the complexity of the problems and challenges being faced, can be solved 
only through  cooperation  among  scientists with  expertise  in  complementary  disci-
plines. 
If  establishing  links  between  scientists  in  Europe  needed  some  persuasion, 
European  scientists found  establishing  links  with  developing  countries  even  more 
difficult  to  accept.  The  EC  is  not  interested  in  providing  strictly  pre-conceived 
"European"  solutions  to  problems  of  development.  There  is  an  acute  awareness 
that the complex problems of development cannot be  contained within  national or 
regional  boundaries, they affect all  societies. The aim  is to find  a common  path to 
achieving  improvements  in  development,  bringing  together  scientists  from  North 
and  South who will address the problems as an integrated unit, each bringing their 
own expertise and experience to bear on the problem at hand.  If this is done in the 
right  way,  the  goal  of  learning  to  learn  will  be  achieved.  A culture  of  learning,  in 
which  scientific  methodology  becomes  an  intrinsic  part  of  society  will  be  estab-
lished.  Hypotheses  will  be  tested  and  development  programmes  modified  -in  the 
light  of  the  results,  things  will  not  be  left  to  chance.  The  interactions  of  the 
scientists  in  the  Commission's programme leads to the establishment of a culture 
of learning  across the  globe. 
The  Commission  continues  to  encourage  interactions  among  scientists.  Links 
between  European  laboratories are  stronger now than  they have  ever been.  The 
same  can  be  said  for  links  between  European  scientists  and  their colleagues  in 
Developing  countries. 
But  ttiere  is  an  additional  benefit  from  the  requirements  of  the  programme, 
South-South cooperation,  and the sharing of knowledge among the third countries 
anxious  to  involve  their  regional  neighbours  in  their  quest  for  knowledge  of 
common  problems which  are  best addressed  in  partnership.  Of course this  is  not 
a  unique  achievement  but  it  is  clear  that  the  Programme  has  done  much  to 
facilitate  additional  steps  in  this direction. 
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THE EUROPEAN  UNION (EU) FOURTH FRAMEWORK PROGRAMME
FOR RESEARCH AND TECHNOLOGTCAL  DEVELOPMENT  (RTD)
Collaborative research with developing countries is carried out against the back-
ground of the Commission's Fourth Framework Programme for Research (Fp4).
The basic aim of FP4 is: To support inter-Member State scientific collaboration,
networking and concertation  on issues of common concern. To reach this goal FP4
supports multi-centre research projects, concerted actions and accompanying
measures which help to improve quality of life and increase European competi-
tiveness, in a global context. More than this, FP4 serves to support other EU
policies, such as economic and development cooperation.
The total budget of FP4 (1994-1998) is 12.31 billion ECU and is divided over four
main activities:
l. Research, Technological Development and Demonstration  within the EU Member
States
(10686 Million ECU (MECU)),
ll. Cooperation  with Third Countries and International Organisations (540 MECU),
lll. Dissemination  and optimization of results (330 MECU) and
lV. Training and Mobility of researchers within the EU (74O MECU).
Activity ll, Cooperation  with Third Countries and International  Organisations has a
pivotal role, linking EU policies in science, economic cooperation and development
through coherent collaborative research activities with third countries.
Health-related research can take place in activity land in activity ll.programmes.
The BIOMED and the BIOTECH programmes of Activity I have a budgbt of 552
MECU and 336 MECU respectively. Many aspects of heafth research which are
trans-disease, can be covered by these programmes and might also be of great
importance for collaboration with Developing Countries for example, malaria
vaccine development.  Within the activity  f l INCO programme (540 MECU) there is
also a health component. In the specific Programme for developing countries a
total budget of 63 MECU will be available for health between 1994-1998 and in the
component  geared towards Eastern and central Europe, health-related research is
also covered (INCO-Copernicus).
'ln 1996, budgets of specific programmes  were increased to the new total of 13.1MECU.
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Although  they may differ in  detail the  Commission's research  programmes  in  FP4 
have  the  following  modes  of  implementation: 
I  Multilateral joint research  projects, 
II  Concerted  Actions,  covering  the  actual  costs  of  concertation,  such  as  the 
search  for partners,  meetings,  common  publications 
Ill  Accompanying  Measures,  such  as  contract holders meetings,  networks,  stud-
ies,  targeted  research  training  and  mobility  and  the  dissemination  of  results 
and 
IV  Concertation through  consultation  with  the  Member states and  in  the  case  of 
the  INCO-DC  programme consultation  with  developing countries. 
These  are  set  out  in  the  detailed  Work  Programme  together  with  the  main 
objectives  of  the  programme.  For  INCO-DC  these  are,  to  promote  the  role  of 
relevant  high  quality  RTD  in  development in  economic cooperation,  to  encourage 
scientific collaboration between Europe and DCs,  between DCs and within Europe, 
to  help reinforce and  maintain  RTD capacities,  including human capital,  in  DCs,  to 
contribute  to  maintaining  a competence  in  Europe  in  scientific  sectors  of  mutual 
interest and  in those pertinent to problems of DCs,  to capitalise on  the experience 
gained  during  the  implementation  of  previous  Commission  S& T  co-operation 
activities  and  to  take  into  consideration  the  political  obligations  of the  Union  and 
the  recommendations of international fora such  as  the  Rio  conference concerning 
research  in  DCs. 
The  Work  Programme  is  implemented  through  Calls  for  Proposals  which  are 
updated from  year to year.  Details of research  themes which  are to  be  supported 
are  provided  in  these  Calls for  Proposals. 
The Call for Proposals 
The Call for Proposals (Anon  1996) contains detailed information on  criteria which 
have  to  be  fulfilled  by  applicants,  for  example  partnerships,  and  also  on  the 
specific  topic  areas  for  which  research  proposals  are  invited.  The  Call  for 
Proposals  is  updated  for  each  call  and  permits  the  Commission  to  direct  the 
research  programme on  the  basis of the consultation  processes with  the  Member 
States,  developing countries and  on  the  Commission's existing  research  portfolio. 
In  general the Call  for Proposals  is  issued six months in  advance of the  deadline 
for  submission  of  proposals.  On  arrival  at the  Commission,  proposals  undergo  a 
stringent review  procedure. 
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In  addition to  scientific quality each  proposal  is  evaluated on  a variety of aspects, 
which  include: 
Is  the  health  problem  relevant to developing countries? 
Is  the  problem  of national,  regional  or global  relevance? 
Is  the  problem  of known,  documented  magnitude? 
Is  the  problem  vulnerable  (are  there  opportunities for cost-effective  impact)? 
Is  there  political  will  to  overcome the  problem? 
Will  the  research  be  induce  changes  in  approach  or political  awareness? 
Does  the  research  build  on  existing  and  matching capacities? 
Does the  research  partnership  have  a comparative  advantage  (including  DC) 
Is  there  a demonstration value  (spin-off  in  financial  or scientific terms)? 
Is  there  a likelihood  of leverage for complementary funding  in  European  Member 
States  and/or DCs? 
Is there  likelihood  of sustainability of the  proposed  approaches? 
What  is  the  research  capability strengthening  aspect of the  proposal? 
What  is  the  training  and  mobility aspect of the  proposal? 
How is  the  integration  of the  DC  partner(s)  in  the  national  setting? 
How does the  project fit  in  the  international  funding  picture? 
The  evaluation  of proposals  is  effectively done  in  four tranches: 
I.  Decision on eligibility by the Commission's Services based on  partnership and 
documentation of the  innovation  and  relevance  of the  project. 
II.  Scientific evaluation  by  selected  experts. 
Ill.  Evaluation of the highly-rated proposals from the second tranche by a regional 
panel  from  developing countries 
IV.  Prioritisation  of  the  highly-rated  proposals  based  on  coherence  and  comple-
mentarity with the Commission's existing research  portfolio, partnership value, 
research  capacity  strengthening  and  training  value  and  regional  versus 
national  relevance. 
Following  these  procedures  the  Programme  Committee  consisting  of  the  repre-
sentatives of the  Member States and  associated countries,  give an  opinion on  the 
proposals.  Finally the Commission decides to implement the selected projects and 
activities. 
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